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SUMMARY
Rabbit antibodies to oestrogen receptor of human origin were 
utilized for investigating oestrogen receptor distribution, quanti­
fication and translocation in oestradiol target cells. The purifi­
cation of oestrogen receptor to homogeneity has been achieved. A 
single protein band was obtained at 65,000 molecular weight under 
denaturing conditions. The purified oestrogen receptor also had a 
sedimentation value in the region of 4S. The antibodies to the 
affinity purified oestrogen receptor had been produced in rabbit and 
a significant titre was found 3 months after primary immunization. 
The antibodies obtained had been shown to contain specific 
antibodies to the receptor protein by four criteria:
1. precipitation of the radioactive steroid after the addition of 
goat anti-rabbit antibody to a mixture of the [^H] 
oestradiol-receptor complex and the immunoglobulin. Using the 
double antibody precipitation technique, the titre of the 
antibodies was also determined,
2. adsorption of the oestradiol-receptor complex by immunoglobulin 
linked to Sepharose,
3. the ability of the immunoglobulin to increase the sedimentation 
coefficient of the oestradiol-receptor complex. Using [^H] 
oestradiol as the marker for oestradiol-receptor complex, it is 
possible to observe shifts in the sedimentation coefficients of 
oestrogen receptor in the absence and the presence of the 
antibody under both low and high salt conditions,
4. the demonstration of translocation of receptor in ZR-75-1 
cells.
The immunofluorescent method, using anti-oestrogen receptor 
antibodies as primary and goat anti-rabbit fluorescein isothiocya- 
nate conjugated as secondary antibody, was employed for immuno- 
histochemical localization of oestrogen receptor. The frozen 
sections from rat and human uterine tissues, oestrogen receptor 
positive human breast cancer and the ZR-75-1 cell line all showed 
cross-reaction. No immunoreaction was observed in tissues from rat
Vlll
spleen and oestrogen negative human breast tissues. In vitro 
translocation sudies were also carried out on ZR-75-1 cells and 
human myométrial tissues when they were incubated with diethyl- 
stiboestrol at 37®C. The in vitro translocation was then quantitated 
using an MPV compact linked to a fluorescence microscope. These 
results revealed the suitability of anti-receptor antibodies for 
investigating the intra-cellular dynamics of oestrogen receptor in 
target cells responding to oestrogen. This technique was then 
applied to 50 fine needle aspirates (FNAs). The quantitation of 
100-150 cells was compared with the standard biochemical assay of 
cytosol and nuclear oestrogen receptor. FNA antibody staining 
correctly predicted the presence of oestrogen receptor in 20 of 21 
ERc+/ERn+ tumours. There were 2 false positive results in 26 
ERc-/ERn- tumours though both these tumours were heterogenous by 
antibody staining, in keeping with the tendency for such tumours to 
be hormone independent in long-term response to endocrine therapy.
The immunochemical similarity of mammalian oestrogen receptor 
has been demonstrated by the ability of the antibodies to 
cross-react with the oestrogen responsive cells and tissues. 
Antibodies were shown to cross-react with receptor from rat uterus 
as well as human uterus but did not react with either dihydro- 
testosterone-receptor complexes from rat prostate or with proges- 
terone-receptor complex. These findings indicate an immunochemical 
similarity among oestrogen receptor from different sources, but not 
among receptor proteins for different steroid hormones.
IX
INTRODUCTION
1.1 STEROID HORMONES AND RECEPTORS
Hormones are chemical signals released from the endocrine 
glands directly into the blood stream. There are two classes of 
hormones: peptide hormones and steroid hormones. Once in the blood
stream the steroid hormones will bind to sex hormone binding 
globulin (SHBG) and albumin (Clark and Peck, 1979). Recently, 
Strel'chyonok et al. (1984) proposed that in plasma membranes of the 
oestradiol-1^6 (E^) target cells, there is a recognition system for 
the SHBG-E2 complex which may allow these cells to take up not only 
free E2 but also E2 complexed with binding protein from the blood. 
The entry of the steroid into the cell initiates responses which 
include changes in enzyme activities, transport activities and 
modulation of gene expression, growth and cell division.
Target cells are characterised by the presence of specific, 
high affinity binding proteins. These proteins are called 
receptors. The structure of each receptor allows it to be recognised 
only by the particular hormone. Receptors for the peptide hormones 
are located in the plasma membrane while those for the steroids are 
internal though their precise location is still under much debate 
(see section 1.1.2).
The six classes of steroid hormones are the oestrogens, 
progestins, androgens, mineralocorticoids, glucocorticoids and 
vitamin D3 metabolites (cholecalciferol) (Pike, 1982). Three of 
these hormones: oestrogen, progestins and androgens act principally 
on the reproductive tissues.
1.1.1 Structure and Biosynthesis of Steroid Hormones
The steroid hormones are derived from a parent structure - 
cholesterol. The fundamental structure of all steroids is 
phenanthrene to which is fused a five-membered ring structure. This
complete structure is called the cyclopentanoperhydrophenantrene 
nucleus. In cholesterol, a side-chain eight carbon atoms long is 
attached at the position of C-17. The numbering sequence is shown in 
Figure 1.
The Oestrogens
The female sex steroids are oestrogens and the progestins. 
Together they control the oestrous or menstrual cycles through 
feedback regulation of the hypothalamus - pituitary axis.
Oestrogens are responsible for the development of the breast 
and reproductive tissues. During the proliferative phase of the 
menstrual cycle, oestrogens promote growth and development of the 
uterine endometrium (see section 1.3.2). In pre-menopausal woman, 
they oppose the osteoporotic (calcium resorption from bone) effects 
of corticosteroids. The principal form of oestrogen in these women 
is oestradiol-1^  which is synthesized from cholesterol in the ova­
ry as a result of stimulation by gonadotrophins.
Biosynthesis of Oestrogens
Oestrogen are synthesised in the theca cells of the follicular 
tissue and corpora lutea of the ovaries. The parent compound, 
cholesterol, is converted to pregnenolone and this gives rise to 4- 
androstenedione and testosterone. Through various enzymes, 
conversion of these androgens to oestrogen takes place after 
spontaneous arrangement of the aromatic ring A, the final product being 
oestradiol-1^ from testosterone and oestrone from 4-androste- 
nedione. All enzymes involved in oestrogen biosynthesis require 
NADPH and oxygen for activity and are cytochrome P-450-dependent.
Other organs that produce oestrogens are the adrenals, testes 
and peripheral tissue. In post - menopausal women, most of the 
oestrogen produced comes from peripheral aromatisation of adrenal 
4-androstenedione. The pathways involved in oestradiol and oestrone 
synthesis are shown in Figure 2.
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1.1.2 Steroid Entry Into the Cell
Steroids are relatively small hydrophobic molecules and this is 
thought to assist in the diffusion of steroids across the cell 
membrane. It is generally said that the steroid enters target cells 
by passive diffusion (Higgins and Gehring, 1978) which explains 
steroid entry into both target and non-target cells (Jensen and 
Jacobson, 1962).
In the intact cell in vivo unfilled receptor may be attached 
loosely to the inside of the plasma membrane (Leake, 1976). Pietras 
and Szego (1977), using affinity chromatography, have demonstrated 
the existence of oestrogen binding sites on the surface of 
endometrial and liver cells. Similar studies had been reported by 
several groups (O'Malley and Means, 1974; Wittliff, 1975). Also 
Mueller et al. (1978) and Pietras and Szego (1979) demonstrated the 
presence of specific ER associated with uterine plasma membranes.
Terayama et al. (1976) demonstrated that some plasma membrane 
steroid binding sites are lost during malignant transformation of 
cells and Zanker et al. (1981) have demonstrated a similar loss of 
binding sites from the plasma membrane of neoplastic tissue 
compared with normal tissue. They further suggested that normal 
cell receptor at the plasma membrane may be serving as the 
modulator of intracellular hormone levels, protecting the cells from 
excess exposure to hormone.
Nenci et al. (1980, 1981) demonstrated that plasma membrane is 
involved in the steroid uptake. However Chamness et al. (1980) 
point out that these plasma membrane sites are type 2 binding 
proteins and not oestrogen receptor (which is known as Type 1)
1.1.3 Properties of Steroid Receptors
All the receptors for steroid hormones (oestrogens, androgens, 
progestins, glucocorticoids, mineralocorticoids, vitamin D) do have 
certain common characteristics. The molecular weight is in the
region of 50,000 to 110,000 with an affinity in the range 10"^^ to 
10"9 M for its respective ligand. They also have a tendency to
aggregate in vitro at low ionic strength. The steroid-binding site 
is relatively heat labile, and they have a domain in the molecule 
that is able to interact with DNA and/or with the nuclear chromatin.
The physicochemical characteristics of the receptor are also 
similar. Weigel et al. (1981) and Dougherty et al. (1982)
demonstrated that progesterone receptor from chick oviduct is a 
phosphoprotein. The same report was given about the glucocorticoid 
receptor from mouse fibroblasts (Housley and Pratt, 1983) and 
oestrogen receptor from the calf uterus (Migliaccio et al., 1982). 
Phosphorylation was found to modulate the activity of the 
steroid-binding site in oestrogen receptor from the calf uterus 
(Migliaccio et al., 1982) and from glucocorticoid receptor (Sando et 
al., 1979). Most of these studies utilised the property of a
steroid-binding site on the receptor protein. Oestrogen receptors, 
at least, are substrate for tyrosine kinases (Auricchio-et al., 1984).
1.1.3.1 Oestrogen Receptor
The oestrogen receptor is known to exist in two states. One
form predominates in animals that have been treated with oestrogen
or an oestrogenic compound and can be isolated from the nuclear 
fraction of the target tissue. A cytosolic or soluble form of 
receptor (ER^) is found in cell-free preparations in the absence of 
steroid (Jensen et al., 1968; Shyamala and Gorski, 1969). This form 
of receptor can be transformed to the nuclear form (ER^) when 
treated with oestrogen. The degree of transformation depends on 
exposure period temperature and ionic strength of the buffer. 
After transformation, the receptor is believed to have properties 
differing from the nontransformed receptor in several ways including 
its chromatographic behaviour (Molinari et al., 1981), and an 
increased affinity both for ligand (Weichman and Notides, 1977), DNA 
(Yamamoto, 1974), and for chromatin (Gschwendt and Hamilton, 1972; 
Jensen et al., 1972). A change in the sedimentation value from 4S 
to 5S was also observed in receptor from immature rat uterus and 
calf uterus (Jensen et al., 1971; Gschwendt and Hamilton, 1972).
This change has also recently been shown in human tumour tissue 
(Hyder and Leake 1982), The 4S form of the cytosolic receptor is 
said to be a monomer in high salt extract and has the tendency to 
aggregate to 8S in low salt buffer.
Notides et al. (1981) and Sasson and Notides (1983), suggested 
that at sufficiently high receptor concentration, the affinity for 
ligand is due to the presence of site-site interaction within the
dimer after its formation, while Puca et al. (1977) suggested that
the transformation event is mediated by other proteins present in 
the cytosol in the form of enzymes or even through direct formation 
of a complex with receptor (Thrower et al., 1976; Thampan and Clark,
1981).
However, Sakai and Gorski (1984a) tested the role of the 
subunit-subunit interactions and nonreceptor proteins in 
transformation. They dissociated the oestrogen receptor into 
monomers by treatment with high-salt buffers and then bound these 
monomers to hydroxylapatite. They did not find any cooperative 
ligand-binding behaviour showing that adsorbed monomers cannot 
dimerize or interact with other adsorbed cytosol proteins. This 
report which suggests that dimerization does not occur for
transfomation to take place, is in disaggreement with that of 
Weichman and Notides (1977) who postulated that dimerization is 
essential for the transformation of receptor to the high affinity 
ligand state. Other studies (Sato et al., 1979; Bailly et al.,
1980; Gschwendt and Kittstein, 1980 and Muller et al., 1983, 1985)
which showed the ability of monomeric 45 oestradiol-receptor 
complexes to bind to nuclei and DNA also suggest that
transformation may occur without the process of dimerization.
Oestrogen receptor from the liver has been purified to 80% 
purity and has a molecular weight of 55,000 (Gschwendt et al., 
1983). The sedimentation value is also in the region of 4S. It 
occurs in both sexes in equal concentration (Tamulevicius et al.,
1982). The DNA binding site is affected by protease activity and by 
molybdate (Petterson et al., 1982) and is probably on the same
domain as the E 2 binding site. However, the mechanism by which 
molybdate acts is still unclear. Molybdate may bind directly to the 
DNA binding site as suggested by Lukola and Punnonen (1983), or 
inhibit the activity of phosphatase which is required for the 
binding to DNA to occur.
1.1.3.2 Progesterone Receptor
Most of the work on progesterone receptor has used chick 
oviduct. The protein has been found to contain two polypeptides: A
and B which are dissimilar in molecular weight, 79,000 and 108,000 
respectively (Sherman et al., 1970; Schader et al., 1972; Schrader 
et al., 1977; Schrader and O'Malley 1980). Dissociation of the 
subunits by pyridoxal phosphate leaves A able to bind to DNA (Hughes 
et al., 1981) while B appears to be the acceptor protein binding 
site. However, both subunits are required for receptor function. 
The loss of either subunit prevents the ability of the progesterone 
to alter RNA synthesis in vivo. Purification and antibody production 
on this protein had also been reported (Case et al., 1984; Renoir 
and Mester,1984; Tuohimaa et al., 1984).
1.1.3.3 Glucocorticoid Receptor
The glucocorticoid receptor has been purified by taking 
advantage of its DNA-binding property (Wrange et al., 1979; Westphal 
and Beato, 1980), or by affinity chromatography (Govindan and 
Sekeris, 1978; Lustenburger et al., 1981; Grandies et al., 1982). 
Polyclonal antibodies (Carlstedt-Duke et al., 1982) and monoclonal 
antibodies (Grandies et al., 1982; Westphal et al., 1982) had 
allowed one to distinguished at least three distinct domains on the 
receptor molecule i.e. steroid-binding domain, DNA-binding domain 
and immunoactive domain. The steroid-binding domain comprises at 
most one quarter (called meroreceptor) of the monomeric receptor. 
Thermodynamic studies suggest that the steroid molecule is 'buried' 
into its binding sites (Wolff et al., 1978). Inhibition of steroid 
binding to the receptor by pyridoxal 5'-phosphate and 1,2-cyclohexa- 
nedione (Disorbo et al., 1980) may indicate that lysine and arginine
residues are involved in steroid binding. DNA-binding domain 
comprises a portion of the receptor which is about the same size as 
steroid-binding domain. Experiments with chemical probes of amino 
acid residues, using crude receptor preparations suggest that 
histidine, arginine and lysine residues are important for 
DNA-binding activity (Disorbo et al., 1980). Immunoreactive domain 
consists of an immunoreactive fragment of about 3nm, which is roughly 
half the size of the holoreceptor (Rousseau, 1984). This domain is 
required for glucocorticoid activity and has been called the 
'specifier' domain (Vedeckris, 1983). Loss of this domain by 
mutation leads to an abnormal increase in DNA binding and steroid 
insensitivity (Gehring and Hotz, 1983; Okret et al., 1983). Most of 
these receptor studies are on liver from rats and involved the use 
of molybdate. Molybdate is said to inhibit protease activity 
(Sherman et al., 1981, 1983; Sherman and Steven, 1984) and may also 
inhibit dephosphorylation. Activation of the receptor also involves 
the removal of a phosphate group (Sekula et al., 1981).
1.1.4 Mechanism of Action of Oestrogen
In spite of a large number of studies using different approaches 
by different investigators, the mechanism of action of steroid 
hormones is still not completely understood.
1.1.4.1 The Two-step Model
In earlier studies most of the work was based on the use of 
radiolabelled steroid hormone as a marker. Jensen and Jacobson
(1960) demonstrated that target tissues for the hormone could retain 
physiological amounts of radiolabelled oestrogens. Then, it was 
found that the oestrogen was retained both in the nucleus as well as 
in the cytosol (Jensen et al., 1968). When Toft and Gorski (1966) 
introduced the sucrose density gradient technique for receptor 
studies, the homogenised immature rat uterus extract contained 
almost all of the oestrogen binding protein in the soluble fraction. 
This protein sedimented at 4S in high salt. When the immature rats
recieved E2 prior to death, the receptor was found mainly in the 
nucleus and, after extraction in high salt, sedimented at 5S (Gorski 
et al., 1968; Jensen et al., 1968). As a result of their experiments 
they proposed a general pathway for the mechanism of action of 
oestrogen in target cells as shown in the Figure 3.
Steroid enters the cell, probably by passive diffusion, and 
rapidly binds to its receptor protein forming an oestrogen-receptor 
complex in the soluble region of the cell. Notides et al. (1975) 
believed that the complex might undergo activation. This was then 
followed by dimerization. The dimerized-form complex was then 
translocated to the nucleus where interaction with a certain 
acceptor site was followed by subsequent initiation of nucleic acid 
synthesis leading to the synthesis of protein, growth and cellular 
responses that are characteristic of the hormone response. This 
model is known as the classical two-step model.
The supposed translocation from the cytoplasm to the nucleus 
occurred after activation had taken place. This evidence for 
activation of the steroid-receptor complex is (1) a change in the 
sedimentation coefficient of the complex from 4S to 5S (in the 
presence of a high ionic strength buffer) when filled receptor is 
incubated with E2 at 37°C and (2) the ability to bind to isolated 
nuclei and DNA is confined to the 5S. Hyder and Leake, (1982) could 
also demonstrate a similar change in sedimentation constant in human 
breast tumour under specific conditions. While oestrogen receptor 
shows a change in sedimentation value on activation, other steroid 
receptors do not. Progesterone receptor complexes from hamster (Chen 
and Leavitt, 1979), guinea pig and rabbit uterus (Saffron et al.,
1976) exhibit a decrease in sedimentation value, while no change was 
observed in chick oviduct (Buller et al., 1975). Liao (1975) showed 
that activation of dihydrotestosterone complex of rat prostate also 
shows a decrease in sedimentation value from 3.85 to 3S.
Whether activation is a real phenomenon is debatable. A number of 
reports have appeared which claim to have difficulty in reconciling
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practical data with the two-step model. Important amongst these is 
the observation that empty receptors do in fact exist in the nucleus 
of both normal (Jungblut et al., 1978; Carlson and Gorski, 1980; 
Clark et al., 1982) and other oestrogen target tissues (Sonnenschein 
et al., 1976; Edwards et al., 1980).
Consistent with this is the failure to observe activation in 
cytosol in the absence of a nuclear component. Linkie and Siiteri 
(1978) showed that the conversion of 4S to 5S takes place in the 
nucleus. They used immature rat uterus, sucrose gradient analysis 
and biochemical extraction using high salt buffer for nuclear 
receptor. After 2h incubation of the receptor extract with E2, the 
4S conversion to 5S was detected and the ratio was quantified. What 
they observed as the 5S was always in the nuclear pellet, while the 
ratio of the 5S to 4S rose from 0 to 6.41. Pietras and Szego (1979) 
using hypotonic saline and 0.25M sucrose buffer found that the use 
of these buffers led to the recovery of cytosolic (4S) empty 
receptor from the particulate fraction. Thus the origin of these 
unfilled sites is still not very clear.
1.1.4.2 The Equilibrium Model
Using autoradiography of the rat uterus, Sheridan et al. (1979) 
showed that nuclear uptake of tritiated oestradiol-1^6 ([^H]E2)occurs 
even after short periods of in vitro incubation at low temperatures. 
These conditions are said to reduce translocation from the 
cytoplasm to the nucleus to a minimum. In another experiment
Martin and Sheridan (1980) prepared the nuclei in different
buffers. The first buffer contained 100% glycerol in which a frozen
and freeze dried cell pellet was homogenised. The other buffer 
contained 10% glycerol in Tris or phosphate buffer. They found that 
with 100% glycerol significantly more nuclear receptor was recovered 
compared to 10% glycerol in phosphate buffer. The use of 10%
glycerol showed that the proportion of receptor found in the cytosol, 
depended on the volume of buffer used in the homogenisation.
Sheridan et al. (1981), also did experiments involving
12
progesterone receptor. By using a thaw-mount. autoradiograph 
technique, with [^H] progesterone and [^H] R5020, they concluded 
that the steroid was localised in or over the nucleus. But when the 
progesterone receptor was analysed biochemically, the receptor was 
mainly in the soluble fraction. Thus, after these studies Martin 
and Sheridan (1982) proposed that, in the steroid responsive cell, 
empty steroid receptors are in equilibrium between the available 
water space of cytoplasm and the nucleus, the equilibrium being 
shifted in favour of the 'cytoplasm' by tissue homogenization 
(Figure A).
Based on this model, empty nuclear receptor assayed using 
conventional techniques may only represent a small fraction of the 
total of the cellular content of unfilled sites actually present 
with the bulk of unfilled sites being soluble in the cytosol during 
the preparation.
1.1.4.3 A New Model of Steroid Action
Given the concept that some cytosol receptor may be present due 
to the breaking down of the nucleus during extraction, Welsholns et 
al. (1984) recently described a novel procedure involving the use of 
cytochalasin B-induced enucleation in the preparation of cytoplast 
and nucleoplast fractions from receptor-rich GH^ cells derived from 
rat pituitary tumour. The cytoplast fraction was found to contain 
little oestrogen receptor, about 5-10% of the whole cells, while 
most of the empty receptor resided within the nuclear fraction. 
Scatchard plot revealed that the Kj was about 0.3nM and there were 
20,000-30,000 binding sites per cell. The total number of receptors 
per cell was retained when the whole cells were incubated in the 
enucleation medium. This finding supports the idea that empty 
receptors reside within or in association with the nucleus of 
oestrogen responsive cells.
Another important and equally convincing study was carried out 
independently by King and Greene (1984). They used monoclonal 
antibodies which are specific to oestrogen receptor. Five different
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monoclonal antibodies were used individually to localise the 
oestrogen receptor from different tissues including fixed sections 
of human breast tumours, human uterus, rabbit uterus and other 
mammalian reproductive tissues, as well as fixed MCF-7 cultured 
cells. They observed that, using the immunoperoxidase technique, 
the specific staining was confined to the nucleus of all oestrogen 
sensitive tissues while staining was limited to a few cells in 
receptor-poor breast cancer tissues. Non-responsive tissue such as 
colon epithelium was negative. King and Greene incubated some of 
the target tissues or cells in Eg for various times prior to 
staining. No increase in nuclear intensity was observed with time 
of exposure to Eg. From this, they concluded that both the cytosol 
and nuclear forms of the receptor reside in the nuclear compartment 
and no translocation was taking place after the formation of the 
oestrogen receptor complex. The distribution of oestrogen receptors 
as predicted from the studies of Welshons et al. (1984) and King and 
Greene (1984) could be viewed as only an alteration in the position 
of the activation and translocation step from that established in 
the two-step model. According to Leake (1985) the two-step 
mechanism of action is not totally abolished and it is only the 
"site of action" that must be changed. That is, steroid still 
diffuses into the cell down a concentration gradient, then comes in 
contact with the empty receptor which is loosely attached to the 
nucleus. This is followed by the activation of the complex which 
has a high affinity for a specific nucleotide sequences, located in, 
or close to, the AT-rich sequences whose binding of steroid-receptor 
complex may be helped by the non-histone chromosomal proteins. Thus, 
activation is merely a nuclear event, as the study of Linkie and 
Siiteri (1978) suggested. However, much work needs to be done 
before the precise cellular location of each event can be described.
1.1.5 Binding of the Steroid-receptor Complex to the Nucleus
1.1.5.1 Acceptor Site
An acceptor site is a site in the nucleus where the steroid 
receptor binds specifically to the chromatin to induce a biological
15
response (Leake, 1976). Evidence regarding the participation of 
non-histone chromosomal proteins in localising the sites of 
interaction of the activated complex with the chromatin, comes 
mostly from Spelsberg’s group. Several groups believe that the 
receptor may have two independent binding sites, one for hormone and 
the other for interaction with chromatin (Milgrom et al., 1973; Khan 
et al., 1980; Myatt et al., 1982a,b)
Spelsberg and his colleagues, working on the progesterone 
receptor complex derived from the avian oviduct, found that a 
specific component of the chromosomal non-histone protein fraction 
is the essential protein component of the nuclear acceptor site. 
The acceptor protein, bound to DNA, may act as the appropriate 
chromosomal signal to rapidly pull the activated receptor to the 
general region of the DNA containing the specific polynucleotide 
receptor binding sequence (Leake, 1981). A similar observation has 
been reported for acceptor proteins of activated oestrogen receptor 
(Ruh and Spelsberg, 1983). Using differential extraction of 
chromosomal proteins, Spelsberg determined the fractions which
contained the specific acceptor protein. Extraction using 3M NaCl at 
pH 6.0 extracts all the histones plus 10% non-histone protein. A 
solution of 4M GuHCl removed 80% of the non-histone and 7M GuHCl 
removed another 10%. None of the three fractions isolated showed any 
ability to bind to the receptor-protein complex. However, in complex 
with DNA, the last fraction retained the majority of the receptor, 
whilst the other two fractions still had minimal binding
activity. When an undamaged, protein-free DNA preparation was used, 
and the condition of incubation controlled to be very close to 
physiological, minimal binding of activated progesterone-receptor 
complex occurred (Thrall and Spelsberg, 1980).
However, conflicting observations on this property of the
acceptor site have also been reported. While Buller et al. (1975)
and Spelsberg (1976) observed saturation in the binding of oestrogen 
receptor to the nuclear sites, Chamness et al. (1974) did not. This 
conflicting result could be due to the different experimental 
conditions whereby a physiological ionic strength buffer was not
16
used by the latter group.
The involvement of non-histone proteins in receptor-chromatin 
interaction has been agreed in many laboratories besides Spelsberg's 
(King and Gordon, 1972; Puca et al., 1974, 1975; Mainwaring et al.,
1976). The role of DNA in the acceptor activity has also been 
concluded from several studies. Treatment with DNAase destroyed the 
acceptor activity (Shyamala-Harris, 1971; King and Gordon, 1972)
while preheating the nuclei or treating them with RNAase did not 
change the acceptor activity. An agreement was reached from three 
different groups that both DNA and chromatin were involved in 
acceptor activity of the steroid-receptor complex in the nucleus 
(King and Gordon, 1972; Spelsberg, 1974; Leake, 1976). Activated 
semipurified glucocorticoid receptors have been found to bind to a 
DNA fragment which contains about half the sequences present in 
intact murine mammary tumour virus (MMTV) DNA. One sub-fragment was 
found to bind to the glucocorticoid-receptor with enhanced activity 
(Payvar et al., 1981; Govindan et al., 1982; Payvar et al., 1982).
Other important studies were carried out by Mulvihill et al.
(1982). Competitive binding assays were done in which oviduct
progesterone-receptor complex was incubated with DNA-cellulose. By 
competing with purified cloned fragments of genomic DNA from 
hormonally responsive genes coding for the egg white protein and 
comparing the homology of the various sequences in their 
experiments, the authors concluded that a highly AT-rich sequence is 
the appropriate binding region for the progesterone-receptor 
complex.
The confirmation of the involvement of non-histone protein-DNA 
complexes is important in the field of recombinant technology. The 
isolation and molecular cloning of certain steroid modulated genes 
has successfully been carried out (Dugaiczyk et al., 1978; Gannon et 
al., 1979; Payvar et al., 1981). For example subunit A of the
progesterone receptor has been shown to bind selectively to the
ovalbumin gene fragment (Compton et al., 1982). This further 
supports the involvement of a specific DNA sequence in the genomic
17
binding of steroid receptor.
Yamamoto and Alberts (1975), after observing the presence of 
low affinity binding of oestrogen-receptor complex to the DNA, 
suggested that, since the low affinity binding exists to a far 
greater extent than the high affinity binding, there is a 
possiblity of a masking effect.
1.1.6 Oestrogen Receptor Replenishment
After being translocated, the oestrogen receptor undergoes 
restoration or replenishment and disappearance from the nucleus. How 
these processes are achieved in the system has been investigated by 
many laboratories.
When oestrogen is injected into the oestrogen responsive 
system, there is a depletion of cytosolic receptor with a 
concomitant increase of the nuclear receptor. This phenomenon is 
then followed by a gradual rise in the cytosolic unfilled receptor. 
This is termed replenishment. Anderson et al. (1974) suggested that 
the replenishment was important before the tissue can respond to 
further administration of oestrogen.
1.1.6.1 Mechanism of Receptor Replenishment
The use of the protein synthesis inhibitor, cycloheximide, has 
provided information on receptor replenishment. However, the use of 
this inhibitor is time dependent. It is only effective (at 
inhibiting replenishment of receptor) when given 0-2h after the 
injection of £2* When given at 6h later no effect was detected 
(Sarff and Gorski, 1971). Cidlowski and Muldoon (1976) observed a 
similar result when working with castrated rats. Kassis and Gorski
(1983) interpreted the result to mean that the synthesis of receptor 
does take place but that the new receptor is the inactive form.
Contradictory results have been also reported by other
groups. Using a higher dose of E2 (Ipg) Mester and Baulieu
(1975) found 90% depletion of cytosolic receptors and replenishment
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(50% of control value) obtained after about 6h. Replenishment of 
receptors was completed in llh.
Many factors need to be considered when using this approach. 
Firstly the use of an inhibitor of protein synthesis which could kill 
the animal before the study is completed. The study of receptor 
replenishment is a slow process and the toxicity of the inhibitors 
of protein synthesis could kill the animal in 12h exposure. Secondly 
the stability of the receptor is still under debate. Uterine 
oestrogen receptor was found to be stable for up to 8h in the 
presence of this drug by Sarff and Gorski (1971) while Cidlowski 
and Muldoon (1976) noticed a conspicuous drop at this time.
Further evidence comes from the work of Horwitz and McGuire
(1976) and Sica et al. (1981) who studied the effects of protein 
and RNA synthesis inhibitors (cycloheximide and actinomycin D) on 
the loss of nuclear receptor. It has been found that both the 
compounds inhibit nuclear receptor loss in some system. This implies 
that, the drugs might stabilize the receptor in the nucleus rather 
than inhibiting the synthesis of a new protein.
1.1.6.2 Evidence of Recycling
To shorten the time for the observation of receptor 
replenishment, Kassis and Gorski (1983) used a 'short acting' 
oestrogen (oestradiol-16*) rather than the 'long-acting' E^. The 
physiological difference between the two oestrogens is: 'short-
acting' oestrogen induces very early responses (water imbibition, 
induced protein synthesis etc.) but not DNA synthesis which is a 
long-term response. Injection of oestradiol-16KS shows complete 
replenishment of receptor after 4h, whereas DES or Eg gave no 
replenishment in that time. Since replenishment could be observed 
in such a short time, they could rule out the weaknesses of the use 
of the drug. They also used cycloheximide in their studies. They 
could not observe any reduction in cytosolic receptor replenishment. 
Thus they concluded that receptor recycling, rather than 
resynthesis, occurs after induction of, at least, the short-term
19
responses.
The effect of progesterone on oestrogen receptor replenishment 
had also been looked at. Experiments done by Hsueh et al. (1975) 
showed that progesterone could reduce the concentration of cytosolic 
oestrogen receptor. In 1976, the same group reported that 
progesterone inhibits synthesis of receptor but does permit 
re-cycling of waiting receptor.
1.1.6.3 Receptor Processing
If receptor is simply recycled, then the total receptor 
concentration in the system should always remain constant. However, 
this is only true for rats treated with oestradiol-16w (Kassis and 
Gorski, 1983) and not those treated with other oestrogen, (Mester and 
Baulieu, 1975; Zava et al., 1976; Baudendistel et al., 1977; Kassis 
and Gorski, 1981; Sica et al., 1981). This loss of receptor is 
termed processing, which means the loss of detectable binding of 
steroid. This might mean that there is a change in the binding 
activity of the receptor.
Thus processing may also be a modification of the oestrogen 
receptor to a form which is not able to recognise steroid. If this 
is the case, it will not be detected by the normal steroid binding 
assay. Using inhibitor studies, Horwitz and McGuire, (1978c, 1980) 
showed the possibility of inhibiting processing. Actinomycin D and 
chromomycin A, both G-C specific DNA intercalators, were very
effective in inhibiting processing in MCF-7 cells. This could be due 
to the direct disruption of the DNA structure.
Further evidence that processing is due to inactivation of 
receptor comes from the work on Swiss mice. The loss of oestrogen 
binding in the nuclei of cells from these mice can be inhibited by 
molybdate, thus a phosphatase might be involved in this process 
(Auricchio et al., 1981). Futher, when the depleted 
oestrogen-binding cytosol is treated with ATP, an active binding 
component was recovered (Migliaccio and Auricchio, 1981). From these
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studies, Auricchio et al. (1981) suggested that the receptor is 
processed or inactivated by dephosphorylation in the cytoplasm.
However, there is no clear indication that processing is 
involved in the oestrogen response pathway.
1.2 CARCINOMA OF THE BREAST
1.2.1 Oestrogens in Breast Cancer
Oestrogens have long been recognised as trophic factors for 
normal and neoplastic breast growth. In 1896 Beatson first observed 
tumour regression following oophorectomy, in premenopausal patients 
with advanced breast cancer. Huggins and Bertgenstal (1952) 
reported the same observation following adrenalectomy on 
postmenopausal breast cancer patients.
The first evidence that the interaction of oestrogen with the 
tumour could be of diagnostic value was given by Folca et al.
(1961), who reported that the lesions of the patients who later 
responded to adrenalectomy took up more of the administered 
oestrogen (hexoestrol) than did the lesions of the patients who did 
not respond.
The administration of pharmacological doses of oestrogens will 
also cause tumour regressions in some patients (Stoll, 1972). It is 
reported that the regression in response to either of these 
therapies is correlated with the presence of oestrogen receptor in 
tumour biopsies (Englesman et al., 1973; Byar et al.,1979; Hawkins 
et al., 1975; Leake et al., 1981)
1.2.2 Oestrogen Receptors in Human Breast Tumours
Steroid hormone receptors occur late in the differentiation 
pathway of breast epithelial precursor cells. For this reason they 
are, in normal cells, a direct index of the highly differentiated 
state (Leake, 1981), Thus receptor positive tumours might be
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expected to reflect slow and controlled growth with minimum invasive 
potential.
Another phenomenon which is said to have a role in neoplastic 
mammary tissues is increased androgen metabolism, leading to 
synthesis not only of oestrogens but also of a spectrum of C19 
steroids (Couch et al., 1973) which are released into the immediate 
micro-environment of the oestrogen receptor in mammary cells and 
which may modulate Eg binding and receptor translocation (Poortman 
et al., 1975; Nicholson et al., 1978; Zava and McGuire, 1978).
Refinements in laboratory technique have enabled steroid 
receptors to be quantitatively assayed in individual tissues. These 
refinements have also led to the discovery of receptors in mouse 
and rat mammary glands (Shyamala and Nandi, 1972; Bohnet et al.,
1977), normal mammary gland at low levels (Sander, 1968; Block et 
al., 1975) and in malignant tissue (Jensen and DeSombre, 1972; Leake 
et al., 1981a)
Normal mammary cells contain specific receptors for each of the 
hormones known to influence growth and function of the mammary 
gland. These receptor sites are responsible for the initial
interaction between the hormone and the cell, and trigger the 
biochemical events characteristic for that particular hormone. When 
malignancy occurs, the mammary gland epithelial cells could escape 
the influence of oestrogen, and could lose the capacity to
synthesize oestrogen receptor. Alternatively receptor sites may be 
retained by only a proportion of the cells (Wittliff et al., 1972; 
Jensen, 1975). In the later case, the growth and function of a tumour 
may still be governed and controlled by the hormones as in normal 
cells and such tumours may be responsive to endocrine therapy, at
least initially. If the receptors are lost from the tumour cells,
the cells would be endocrine resistant and would not be responsive 
to hormone manipulation, except by some indirect mechanism.
In breast cancer, the first receptors to be identified were 
oestrogen receptors. There are extensive data that the growth promoting
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effect of oestrogen is receptor-mediated (Wittliff, 1979). The 
properties of the oestrogen receptor have been demonstrated in 
induced hormone-dependent rat mammary tumours and in human mammary 
tumour cytosols (McGuire and De La Garza, 1973). The principal 
properties are the high affinity binding of (^HjEg (K^<lnM) and the 
sedimentation values of the oestrogen receptor i.e. 8S in low salt 
and AS in high salt sucrose gradients. Parallel gradients are always 
run with a 100-fold excess of unlabelled diethylstilboestrol to 
measure any nonspecific binding component.
An indirect role of prolactin in governing the tumour growth in 
rat mammary tumour had been reported (Sinha et al., 1973). 
Prolactin had been demonstrated to be able to increase the level of 
oestrogen receptor in both rat mammary gland and uterus and in 
mammary tumours of intact ovariectomised and ovariectomized- 
hyphophysectomised rats (Sasaki and Leung, 1974; Vignon and 
Rochefort, 1976; Asselin et al., 1977). There is considerable 
indirect evidence for a role for prolactin in human breast cancer 
(Sinha et al., 1973; Henderson et al., 1975; Pearson and Monni,
1978).
Very little is known about the inhibition of oestrogen receptor 
synthesis. Experiments showed that prostaglandins could inhibit 
oestrogen receptor synthesis (Jacobson, 1974). Progesterone is 
recognised as a physiological inhibitor of oestrogen receptor 
synthesis (Bohnet et al., 1977; McGuire, 1978; Clark and Peck,
1979).
The use of oestrogen receptor as an index of hormonal 
involvement in growth and development of tumours has been studied by 
various groups (Feherty et al., 1971; Maass et al., 1975; Englesman 
et al., 1973). Other studies showed that 40-60% of patients with 
oestrogen receptor positive tumour biopsies show regression after 
receiving hormone therapy (Byar et al., 1979; Hawkins et al., 1980; 
Leake, 1981) and after taking the receptor concentration into 
account the possibility of response is increased (Jensen, 1975; 
Leclerq and Hueson, 1977) but only in premenopausal patients
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(Hawkins et al., 1979).
It has been suggested that patients with receptor in both 
cytosol and the nuclear fractions have a much better chance of 
responding to hormone therapy than those with receptor in the 
cytosol alone (Leake et al., 1981a).
Receptor negative tumours were thought to be more aggressive 
(Knight et al., 1977) and growing at a faster rate (Meyer et al.,
1977). Various reports showed that patients w i t h r e c e p t o r  negative 
had earlier recurrance rates and shorter survival times compared to 
patients with receptor positive tumours (Kiang et al., 1978; Bishop 
et al., 1979; Cooke et al., 1979; Kinne et al., 1981).
Oestrogen receptors have been the most extensively studied, the 
following statements summarise the present knowledge of receptors in 
breast cancer.
1. 60 to 70% of primary breast cancers are oestrogen receptor
positive. This is lower in advanced disease.
2. Premenopausal women have a lower incidence of oestrogen recep­
tor positive tumours than postmenopausal women.
3. Receptor status may change with the natural history of the
disease. Thus a primary oestrogen receptor positive lesion 
may recur with oestrogen receptor negative métastasés, and 
vice versa (though this latter is unusual).
4. Individual tumours are probably heterogenous with regard to
receptor concentrations, some clones of cells being receptor 
positive, others receptor negative.
5. Following from (4) it has been suggested that the higher the
concentration of oestrogen receptor, the greater the chance of 
a response to endocrine therapy. A number of clinical studies 
support this theory (DeSombre and Jensen, 1980).
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6. The risks of breast cancer are thought to increase in
women with no ovulation due to an inadequate level of 
progesterone (Lilienfeld et al., 1975). Sherman and Korenman 
(1974) also reported that oestrogenic stimulation of breast 
cell growth in the absence of sufficient progesterone 
secretion could provide a favourable environment for the 
development of breast cancer. Thus, progesterone receptor 
levels are found to be important.
7. Androgen receptors are found in about 50% of breast cancers,
and glucocorticoid receptors in about 30%. The therapeutic 
significance of these receptors remains to be assessed.
8. About 50% of ER+ and 70% of ER(./ERjj+ or ER+/PR+ tumours will
respond to endocrine therapy, whereas only 5-10% of receptor
negative tumours seems to be hormonally sensitive. It has
been suggested that receptor positive patients are less likely 
to respond to cytotoxic therapy, but this remains 
controversial (Lippman et al., 1978; Kiang et al., 1978).
The relationship between oestrogen receptor content of primary 
breast cancer and subsequent prognosis was examined with regard to 
nodal status (Leake et al., 1981b). They found that, within a 
particular nodal group, patients with tumours containing fully 
functional oestrogen receptor had a longer disease-free interval 
than those with receptor negative tumours. Also that receptor
negative primary disease gave rise to distant métastasés as first 
site of recurrence more frequently than did receptor positive
patients.
The discovery of steroid receptors does not automatically 
explain all aspects of endocrine therapy in breast cancer, but it 
does offer a starting point for putting that explanation on a 
rational basis. Furthermore, as oestrogen receptor assays become 
more widely available, they offer an important guide for selecting 
appropriate treatments for women with breast cancer.
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1.2.3 Treatment of Breast Cancer
Beatson's observation that, after . oophorectomy two 
premenopausal patients with advanced breast cancer experienced 
regression of disease laid the foundation for the development of 
endocrine therapy, in breast cancer. Endocrine therapy was 
originally ablation (castration, adrenalectomy, hypophysectomy). 
Later additive therapy, (pharmacological doses of oestrogens, 
androgens and glucocorticoid) was preferred and, more recently, use 
of synthetic antioestrogens anti-prolactins and LHRH analogues have 
all been tried. In premenopausal women oophorectomy is still 
common whereas postmenopausal patients usually receive tamoxifen - 
an anti-oestrogen with minimal side effects.
Another important factor in the endocrine therapy of breast 
cancer is the withdrawal response. Of those women who gain a 
remission on oestrogen or antioestrogen therapy, about 30% will 
achieve a second remission merely by stopping therapy (Patterson et 
al., 1982).
Tamoxifen, probably acts in the long-term, through inhibition 
of replenishment of available, functional receptor. Biopsies taken 
from patients, prior to treatment with tamoxifen, have yielded 
significant quantities of functional receptor, but biopsies taken 
during treatment show no detectable receptor and receptor does not 
reappear until some weeks after treatment is ceased (Leake et al 
1980b).
Because anti-oestrogens act initially through the receptor 
system, they appear to be oestrogenic in the short term. Tamoxifen, 
for example, will induce the first round of DNA synthesis and the 
characteristic oestrogenic increase in wet weight at 24h after 
injection. However after a longer time course, the anti-oestrogenic 
activity becomes apparent, presumably due to, either the loss of 
available receptor or to the blocking of the relevant nuclear 
binding sites (Leake et al., 1980b).
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Thus, the current choice of endocrine therapy for patients with 
advanced disease is tamoxifen initially for receptor positive 
patients and combination chemotherapy in receptor negative patients. 
A similar approach has been made to adjuvant therapy for primary 
disease with node involvement (Bonadonna et al., 1982). It seems 
reasonable in theory but recent evidence suggests that adjuvant 
chemotherapy may be only of general value to pre-menopausal patients 
(Rouesse, 1984)
These findings of receptor assays and response to endocrine 
therapy have led to the classification of hormone dependent and 
hormone resistant tumours (McGuire et al., 1975).
1.2.4 Alternative Indices of Hormone Dependence
Alternative indices of hormonal-dependence have been tried, and 
perhaps the most successful is measurement of soluble progesterone 
receptor, a product of oestrogen action in normal target tissues. 
However the presence of progesterone receptor is not always 
associated with an improved clinical response. It is usually 
associated with the presence of fully functional oestrogen receptor 
and so yields a similar success rate in the identification of 
responders to hormone therapy (Barnes et al., 1979; Thorsen and 
Stoa, 1979).
1.3 UTERUS AND STEROID HORMONES
1.3.1 The Uterus
The uterine wall is mainly made up of bundles of smooth muscle 
fibres supported by vascular connective tissue. This is called the 
myometrium. The uterine cavity is lined by a mucous membrane termed 
the endometrium which consists of a mixture of simple columnar 
ciliated and secretory epithelium supported by a broad, highly 
cellular, connective tissue stroma. The endometrium experiences 
monthly cyclic changes in structure. This is in response to 
rhythmical variations in the secretions of steroid hormones from the
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ovary.
The endometrial surface epithelium is invaginated to form 
numerous tubular glands called uterine glands. These glands extend 
into a thick lamina propia, which is referred to as endometrial 
stroma. It contains stellate cells embedded in a copious ground 
substance. The epithelium lining the glands is continuous with that 
of the surface and contains fewer ciliated cells. The glands 
subdivide in the deeper layer of the endometrium and vary in size 
and shape during the monthly cycle.
The uterus is supplied by a highly coiled uterine artery which 
arises from the internal iliac artery. Large branches pass 
transversely across the surface of the organ to anastomose with the 
vessels from the opposite side. The deepest portion of the 
endometrium, the stratum basale, is supplied by the basal arteries. 
Continuing upwards into the endometrium, the spiral arteries reach 
the innermost endometrial zone, where they break up into a rich 
network of capillaries. The region of the endometrium which the 
spiral arteries course is called the stratum functionalis.
1.3.2 Uterine Cycle
Hormones secreted by the ovary during the ovarian cycle result 
in changes involving principally the epithelium and supporting 
connective stroma tissue of the endometrium. This is termed the 
uterine cycle.
In women, the uterine cycle can be divided into three phases. 
The proliferative phase coincides with the growth of the ovarian 
follicles and their secretion of oestrogenic hormones. The 
proliferative phase lasts for 10-11 days. In this phase, the 
endometrium initially consists solely of the stratum basale, which 
represents only a few stumps of uterine glands embedded in a dense 
endometrial stroma. The surface epithelium rapidly generates from 
these glands and lines the uterine cavity.
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In the ovary, if ovulation is to occur, the Graafian follicle 
(and the egg within it) must undergo further changes that can only 
take place under precisely controlled hormonal conditions. The level 
of circulating FSH remains elevated for only a short time at the 
beginning of the growth phase, after which the quantity of 
circulating gonadotrophin (FSH and LH) remains fairly constant. The 
onset of pre-ovulatory maturation is marked by a sudden and dramatic 
rise in gonadotrophins from the pituitary, especially of LH (the 
so-called *LH surge'). In reality, both the FSH and LH levels rise. 
The LH surge (or the increase in oestrogen which causes it) is said 
to induce a final 'wave' of mitosis in granulosa cells so that their 
number reaches an optimum size for the ovulatory Graafian follicle. 
The oocyte is shed from the Graafian follicle by the process of 
ovulation at a precise time after the onset of the LH surge.
The secretory phase coincides with the period when the corpus 
luteum is functionally active and secreting progesterone. This 
phase lasts about 14 days. Under the influence of the steroid 
hormones the cells of the endometrial stroma enlarge. The glands 
dilate and finally the endometrium forms a thick, edematous, highly 
vascular lining. When the secretions from the ovary decline the 
endometrium breaks down. This gives way to the third phase of the 
menstrual cycle. Towards the end of' the menstruation, the 
endometrium is reduced to about half a millimetre in thickness which 
is approximately a tenth of its maximum thickness.
In other mammals, changes in plasma levels of steroid hormones 
give rise to the oestrous cycle. A duration of 4-5 days is common 
in rats and mice (Johnson and Everitt, 1980). The cyclic changes 
are somewhat similar to those described in humans, except for the 
absence of bleeding at the end of the secretory phase.
1.3.3 The Effect of Oestradiol on Uterine Cells
Oestradiol-1^ stimulates uterine growth by inducing cellular 
hypertropy and hyperplasia. The magnitude of the hyperplastic 
growth response is dependent upon the species and strain of animal
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and its hormonal status (Martin et al., 1973; Martin, 1980; Kirkland 
et al., 1981).
Morphological changes in the hamster uterus during the oestrous 
cycle include proliferation of the luminal epithelium prior to 
ovulation (Ward, 1948). Similar cyclic changes occur during the 
oestrous cycle of the rat and mouse (Allen, 1922). In these species, 
proliferation occurs in response to oestrogen and is blocked by 
progesterone (See Sandow et al., 1979).
West et al. (1978) correlated the serum oestrogen and 
progesterone levels and uterine oestrogen receptor levels with the 
morphology of the uterine luminal epithelium in cycling and 
hormonally altered hamsters. Proliferation of the uterine luminal 
epithelium occured from dioestrus day 2 through pro-oestrous, when 
oestrogen was elevated and serum progesterone was low. Uterine 
nuclear oestrogen receptor levels were found to be elevated. 
Degenerative changes in the epithelium occurred during oestrous when 
serum oestrogen was low and serum progesterone was high. Uterine 
nuclear oestrogen receptor levels were depressed. The degenerative 
changes were symptoms of oestrogen withdrawal because they occurred 
within 24h after ovariectomy on the morning of pro-oestrous and 
could be prevented by oestrogen treatment (West et al., 1978).
Sandow et al. (1979) reported ultrastructural evidence for the 
degenerative process in the hamster uterus including the death of 
numerous epithelial cells by apoptosis, a type of cell death 
characterized by extensive nuclear and cytoplasmic fragmentation 
(Kerr et al., 1972). The ultrastructural alterations in such cells 
include condensation and margination of the chromatin, cytoplasmic 
condensation, amoeboid changes in cell shape with formation of 
pseudopodial extensions and nuclear and cytoplasmic fragmentation. 
The cell fragments, or apoptotic bodies, accumulate near the basal 
lamina, and are then phagocytosed by macrophages and possibly by 
neutrophils as well. Apoptosis appears to be a sensitive 
morphological end-point of oestrogen withdrawal in the hamster 
uterine luminal epithelium (Sandow et al., 1979).
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Work on determination of oestrogen receptors in human uterus 
suggests that functional binding sites in human tissue have a 
Kj=10 (Soutter et al., 1979) and the same was reported by
Zachariah and Chakmakjian (1983). The stability of the uterine 
receptor was checked using cytosol prepared from tissues and then 
immediately frozen in liquid nitrogen compared and with tissues kept 
for various lengths of time up to 20 months at -70°C. They found 
that the oestrogen receptor from cytosol prepared from frozen 
tissues were more stable. Soutter et al. (1979) found that the 
dissociation constant of the E2 receptor of human endometrium was 
similar in both cytoplasmic and nuclear fractions which was in 
common with other workers using rat uterus and human breast tumour 
cell lines. They also found that inhibition of oestrogen receptor 
by progesterone takes place in human endometrium at late follicular 
phase (Soutter et al., 1979).
1.3.3.1 The Oestrogen Effect in Mature and Immature Animals
Uteri from immature and mature rodents are used extensively 
as model systems to evaluate oestrogen-receptor interactions and 
tissue responsiveness to oestrogen stimulations. However there 
exist important differences between the cellular responses seen in 
uteri of immature and mature rats. For example, in the immature rat, 
high doses of oestrogens stimulate cell division in all uterine 
component tissues: epithelia, stroma and myometria (Kaye et al.,
1972; Kirkland et al., 1979). In contrast, in the adult castrated 
rat, this does not happen. Only the uterine epithelial cells 
respond to oestrogen stimulation through DNA synthesis and cell 
division (Clark, 1971; Tachi et al., 1972).
1.3.3.2 Effect of Oestrogen on the Mouse Uterus
The uterus of adult ovariectomized mice show two peaks of DNA 
synthesis occurring after oestrogen stimulation (Kerach, 1981). This 
raises the possibility that in the mouse uterus, DNA synthesis and 
cell division might be occurring in two different cell types at two 
different times after oestrogen treatment.
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Quarmby and Korach (1984) reported that uteri from immature 
(21-day-old) and adult mice show different patterns of cell division 
in response to a physiological dose of £2» In the immature mouse 
uterus, oestrogen increased the stromal and epithelial cell 
proliferation by shortening the cell generation time. In the adult 
mouse uterus, oestrogen stimulated epithelial but not stromal cell 
proliferation. They discovered that oestrogen stimulated uterine 
hyperplasia by selectively decreasing the G1 phase of the cell cycle 
in specific cell populations. In their developmental study, they 
found that the stromal cell population gradually lost its ability to 
divide in response to oestrogen stimulation during day 22-52 after 
birth. In prepubertally ovariectomised mice, the stromal cell 
population showed a very low mitotic response to oestrogen 
stimulation at all ages. Thus an ovarian mechanism may regulate the 
change in stromal responsiveness to oestrogen stimulation.
1.4 ANTIBODIES TO OESTROGEN RECEPTOR
Biochemical assays of oestrogen receptor require relatively 
large amounts of tissue. Both for investigation of oestrogen 
receptor in primary cell cultures and to determine oestrogen 
receptor in small clinical samples such as a fine needle aspirate 
(FNA), an antibody to oestrogen receptor would be most valuable.
1.4.1 Polyclonal Antibodies
As soon as the oestrogen receptor was accepted as the main 
molecular component for the mechanism of action of oestrogens, 
attempts at purification began in several laboratories (Jungblut et 
al., 1965, 1967; De Sombre and Gorell, 1975; Puca et al., 1970, 
1972, 1975; Sica et al., 1973; Bresciani et al., 1978). The aim was
to produce purified receptor suitable for biochemical, chemical or 
physical characterization. It was also hoped that the molecule would 
have sufficient antigenicity for antibody production. The presence 
of receptor protein in the cell is very low i.e. only between 
10^ and 5x10^ copies/cell (Moncharmont and Parikh, 1984). Therefore 
the difficulties lie in the preparation of homogeneous receptor
32
protein in amounts sufficient to immunize the animals and to produce 
antibodies in quantities adequate for characterization of the 
antigen. DeSombre and Gorell (1975) and Bresciani et al. (1979) have 
used kilogram quantities of calf uterine tissue to recover l-2mg of 
receptor protein.
The first report of the production of a rabbit antiserum to 
oestrogen receptor dates back to 1969 (Soloff and Szego, 1969). They 
used a semipurified oestrogen receptor and the presence of the 
antibody was checked by looking at the shifted peak on sucrose 
gradients in the presence of such an antibody. Then, in 1976, Fox et 
al. published another report on the production of rabbit antiserum 
against oestrogen receptor. They suggested that the receptor be 
injected into the rabbit in its aggregated form in order to increase 
its antigenicity. They used gel filtration chromatography and 
immunoprécipitation as specificity tests for the antibody.
In 1977, Greene et al. prepared the antigen from calf uterus 
after translocating the cytosolic receptor to the nucleus and 
subsequent extraction in high salt. The purified antigen was
Injected into rabbits. For specificity tests of the antibodies they 
used immunoabsorbants, immunoprécipitation and sucrose density 
gradient analysis methods. These antibodies were found to react 
with cytosolic and nuclear oestrogen receptor complexes from calf 
uterus as well as oestrogen receptor from other mammals and also
from chick oviduct. They also found that the binding of the
antibodies to the antigen did not affect the hormone binding site. A
similar procedure was applied to raise antibodies in goat (Greene et 
al., 1979). The properties of the antiserum were similar to the 
previous rabbit antiserum except that the affinity of the receptor 
for ligand was reduced if the goat antibodies were allowed to react 
with naked receptor protein prior to incubation with oestrogen. They 
demonstrated the immnochemical similarity of mammalian oestrogen 
receptor, since the immunoglobulin obtained from both species 
cross-reacted with all radioactive oestradiol-receptor complexes 
from several mammalian species. The immunoglobulin showed no 
affinity for the receptor proteins for other steroid hormones. These
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antibodies recognise the oestrogen receptor when associated with 
antioestrogen (Garcia et al., 1982). Radanyi et al. (1979) did not 
use purified, translocated receptor but rather used purified 
cytosolic receptor from calf uterus as antigen and reported that 
they raised satisfactory antibodies in rabbit.
In 1973, Sica et al. introduced the affinity chromatography 
method in the production of highly purified oestrogen receptor from 
calf uterus. Since then, the application of affinity chromatography 
in the purification process had been widely applied. Coffer et al. 
(1980) and Coffer and King (1981) reported the use of human uterine 
oestrogen receptor, purified through affinity chromatography and by 
electrofocusing. Their antibodies were raised in sheep. Besides 
having reactivity with human oestrogen receptor, the antibodies are 
also reported to cross-react with other mammalian oestrogen 
receptor. Other antisera to oestrogen receptor have been reported by 
Raam et al. (1981) using gels as a means of purification. The 
sections of the gels, containing oestrogen receptor from human 
breast cancer, were sliced, pooled, and ground to a fine powder 
before being injected into rabbits. This group reported that the 
antiserum which they raised decreased the affinity of the receptor 
for its ligand. Al-Nuaimi et al. (1979) also used oestrogen receptor 
from tumour tissue but from rat mammary tumour induced by Dimethyl- 
•benzanthracene.
Antibodies against the chick oviduct progesterone receptor have 
also been raised in goat, and in rabbit. Glycerol gradient 
sedimentation profiles showed that several immnoglobulin molecules 
can bind to the chick oviduct progesterone receptor, since several 
types of antigen-antibody complex were detected (Renoir et al.,
1982). Logeât et al. (1981) immunised a goat with a semipurified 
preparation of progesterone receptor extracted from rabbit uterus. 
The antiserum obtained reacted with both cytosolic and nuclear 
rabbit progesterone receptor and also with progesterone receptor 
from other tissues. A cross-reactivity was also observed with 
progesterone from cytosolic receptor of rat and guinea pig uterus, 
human breast cancer tissue, and nuclear receptor from human 
endometrium. On the otherhand, no interaction with nonmammalian
receptor (chick oviduct progesterone receptor) was observed. Also 
no cross-reactivity with nonreceptor progestrone-binding proteins 
(transcortin from plasma and uteroglobin from uterine fluid) was 
seen.
Tuohimaa et al. (1984) injected a rabbit with the highly 
purified B-subunit of the chick oviduct progesterone receptor. The 
specificity of the antibodies obtain were tested using 
immunoprécipitation, immunoblotting, density gradient ultracentrifu­
gation and Protein A-Sepharose assay methods. They found that the 
antibodies not only recognised the B-subunit, but also the 
A-subunit. Besides that, cross-reactivity also occurred with the 
nuclear progesterone receptor, the meroreceptor (proteolytic 
cleavage product) and the "non-activated" molybdate stablized "8S" 
receptor.
Polyclonal antibodies, though heterogeneous, may become an 
important diagnostic tool in small specimens or smears 
for the detection of the heterogeneity and localization of receptors 
in the tissues and cells. As far as structure and function are 
concerned, monoclonal antibodies are more useful and reliable.
1.4.2 Monoclonal Antibodies to the Hormone Receptor
With the development of hybridoma technology by Kohler and 
Milstein (1975, 1976), the production of monoclonal antibodies
against the oestrogen receptor was made possible. Greene and Jensen 
(1982a) produced monoclonal antibodies against different sites on 
oestrogen receptor and used them to build a library of monoclonal 
antibodies for the location of determinants on the molecule of the 
protein (Greene et al., 1984). Monoclonal antibodies have been used 
to study the molecular structure of acetylcholine receptor 
(Lindstrom et al., 1980; Tzartos and Lindstrom, 1980; Gullick et 
al., 1981; Conti-Tronconi et al., 1981). Lennon et al. (1980) used 
monoclonal antibodies for the purification of the cholinergic 
receptor. The B-adrenergic receptor (Frazer and Venter, 1980), and 
structure and function of thyrotrophin receptor (Yavin et al., 1981)
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have been similarly studied.
1.4.2.1 Monoclonal Antibodies to the Oestrogen Receptor
Monoclonal antibodies to oestrogen receptors were obtained for 
the first time by Jensen and co-workers (Greene et al., 1980). They 
immunized rats with oestrogen receptor protein purified from calf 
uterus. The hybridization of Lewis rat spleen cells with a mouse 
mutant myeloma cell line gave hybridoma cell lines which secrete 
anti-oestrogen receptor immunoglobulin of classes G and M. All 
their clones showed cross-reactivity with receptor only from calf 
uterus. The IgM has affinity for the nuclear receptor, while the 
IgG had affinity for soluble as well as nuclear receptor. The 
Kjj for binding was O.lnM.
Using a human breast cancer cell line, MCF-7, the same group 
(Greene et al., 1980) after purification of the cytosol through 
affinity chromatography, produced monoclonal antibodies. The 
production of large numbers of MCF-7 cells was necessary for this 
experiment. Using two mouse myeloma cell lines, fusion with the 
spleen cells of the immunized Lewis rat, followed by cloning from 
limiting dilution, gave rise to three hybridoma cell lines, two IgG2A 
and one IgM. One of the antibodies recognized the oestrogen 
receptor from human and primates only, while the others recognized 
calf and rat uterine receptors as well. There seems to be evidence 
that these three antibodies recognise three different epitopes on 
the human receptor molecule. Moncharmont et al. (1982) also obtained 
monoclonal antibodies to the native cytoplasmic oestrogen receptor 
from calf uterus. The fusion of spleen cells from an immunized 
mouse with a non-secreting mouse myeloma cell line give them fivq 
hybridoma lines, all IgG's of subclass 1 and 2A. Four of the clones 
showed cross-reactivity with the receptor of other mammalian and 
avian species, while one does not recognize human oestrogen recep­
tor. These monoclonal antibodies show a high affinity (K^=0.5nM) 
for the oestrogen receptor. They also found that even though these 
antibodies show differences in subclasses and cross-reactivity, they 
have no ability to bind simultaneously to the antigen molecule i.e.
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they must all be directed against closely related sites on the 
receptor molecule.
1.4.2.2 Monoclonal Antibodies to the Progesterone Receptor
Monoclonal antibodies to progesterone receptor have been 
produced from partially purified molybdate-stabilized progesterone 
receptor from chick oviduct (Radanyi et al., 1983). They reported
one clone which secretes IgG2B and is able to recognise progesterone 
receptor. This antibody, which has a high affinity for 
progesterone receptor from chick oviduct with Kj=lnM, does not 
cross-react with progesterone receptors originating from mammalian
species but instead, does cross-react with other chick steroid
receptors (Joab et al., 1984). Logeât et al. (1983) also reported 
the production of monoclonal antibodies to progesterone receptor 
purified from rabbit uterus. Eleven clones were obtained. Five of 
the clones show an affinity towards the antigen in the range of 0.1 
to 0.4nM. Three of the clones secrete IgG and all the antibodies 
cross-reacted with mammalian receptors but not avian. No report was 
made on the cross-reactivity with other steroid receptors.
1.4.2.3 Monoclonal Antibodies to the Glucocorticoid Receptor
Monoclonal antibodies against the 90,000 molecular weight 
species of the activated rat liver glucocorticoid receptor were
reported by Westphal et al. (1982). Using an immunoprécipitation 
assay of labelled liver cytosol receptor for screening, eight of the 
clones were found to react with the receptor molecule. One of the 
positive clones secreted IgG while the rest secreted IgM. Seven of 
the clones tested reacted with the 90,000 molecular weight form of 
the receptor which contained both the steroid and DNA binding 
domain. Other reports on glucocorticoid receptor monoclonal 
antibodies came from Grandies et al. (1982) and Gametchu and 
Harrison (1984). The latter group confirmed the specificity of the 
antibodies by sucrose density gradient analysis and Western blot 
analysis which showed that the antibody detected a single band with 
a mobility (molecular weight about 95,000) identical to that of the
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[3h ] dexamethasone 21-mesylate-labelled rat glucocorticoid receptor.
So far, no reports have been made of the presence of common 
antigenic determinants between steroid receptors and other 
steroid-binding proteins, showing that there is no immediate genetic 
relationship between these proteins. However, the existence of a 
common site in all steroid receptors needs to be further explored. 
Radanyi et al. (1983), produced monoclonal antibodies to chick 
oviduct progesterone receptor, which could recognise not only 
progesterone receptor from the same tissue, but also the oestrogen, 
glucocorticoid and the androgen receptors (Jaob et al., 1984), all 
in their native forms (8S). These receptors, if present in high 
salt (4S), are not recognised by the antibody. This finding might 
suggest that the antibody may be directed towards a protein that 
forms a common subunit to the aggregated form of all steroid 
receptors in this particular tissue. The validity of such a 
hypothesis needs to be further investigated and also the application 
to the different tissues of different species has to be tested. The 
physiological significance of such an observation has yet to be 
established.
1.4.2.4 Monoclonal Antibodies and the Structure of the Steroid 
Receptor
Most of the antibodies to steroid receptors so far obtained 
have no effect on the interaction of the receptor protein with its 
steroid hormone. Only some of the antibodies, such as the polyclonal 
from goat antiserum (Greene et al., (1979) in rabbit (Raam et al.,
1981) reduce the affinity of the receptor for oestrogen. 
Grandies et al. (1982) found a monoclonal antibody to the 
glucocorticoid receptor which inhibited hormone binding. Several 
groups have used monoclonal antibodies to investigate the subunit 
structure of a receptor protein. Each antibody has specificity for 
only one antigenic determinant, and forms stoichiometric complexes 
with its antigen, thus information on the number of antigenic 
determinants present on the molecule can be determined. Moncharmont 
et al. (1982) and Moncharmont and Parikh (1983) have investigated
38
various molecular forms of the calf uterine oestrogen receptor using 
these criteria. They found that the native 8S oestrogen receptor 
has two antigenic determinants per molecule, while the AS high salt 
molecule has only one. They found that agents that induce the 
dissociation of the 8S form to smaller forms also dissociate the two 
antigenic determinants. This suggests that the homodimer of the AS 
subunit is associated with another protein molecule(s) to form the 
large 8S form of the native receptor. Moncharmont et al. (1984)
also concluded that the 4S form was the smallest form of the
molecule and did not contain repetitive structures associated with 
the steroid binding site. The 5S nuclear receptor, which was said 
to be a homodimer of the AS subunit by Notides and coworkers
(Notides and Neilsen, 1974; Neilsen and Notides, 1975; Notides et 
al, 1975, 1981), was shown to possess two antigenic determinants for 
the monoclonal antibody (Moncharmont et al., 1984).
In 1984, Greene et al. collected a library of monoclonal 
antibodies reacting with different regions of the human oestrogen 
receptor molecule. Using this collection, they were able to locate 
roughly the position of various determinants on the molecule. They 
could locate an epitope on the DNA binding domain from one
monoclonal antibody and found that six of the monoclonal 
antibodies recognized the steroid binding domain. They then 
realised that all these seven antibodies recognised receptor from 
all species while two other monoclonal antibodies, each showing 
specificity for mammalian or primate oestrogen receptors bind in the 
region between the steroid binding domain and the DNA binding 
domain. They used mercuripapain, chymotrypsin and trypsin which had 
the ability to remove selectively from receptor the determinants for 
each antibody. However they discovered that their results are in 
contrast to the findings of Carlstedt-Duke et al. (1982) who 
reported that the glucocorticoid receptor can be cleaved into three 
separate domains by limited proteolysis: a domain for binding to 
DNA, one for binding steroid and the third is the immunoactive site 
which recognises all the antibodies to glucocorticoid receptor.
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1.5 DETECTION OF OESTROGEN RECEPTORS
The first essential criterion of any assay is that it should 
measure the biologically functional receptor in the target tissue. 
The assay should also be accurate, relatively simple and inexpensive 
to perform.
1.5.1 Biochemical Assays
Classical assays of intracellular steroid receptors require 
homogenization of tissues and titration of binding sites with 
labelled hormones. The unfilled oestrogen receptor is a soluble 
protein characterised by a limited binding capacity, high binding 
affinity and strong specificity for oestrogenic hormones. The assay 
should have minimal background contamination due to binding of the 
hormone to non-specific sites. Binding to the cellular receptor 
should be a saturable phenomenon reflecting a single class of 
binding site.
It is essential that the measured affinity of the receptor for 
the hormone should be in the physiological concentration of that 
hormone. It is also important that the receptor measured should be 
that which distinguishes biologically active hormone from chemically 
similar, but biologically inactive molecules, e.g. the oestrogen 
receptor will bind diethylstilboestrol (DES) (a non-steroid) and E2 
with about the same affinity, whereas its affinity for 
oestradiol-13Xis very low (Leake, 1981).
An ideal assay should, therefore, accurately quantitate a 
specific receptor, determine a single binding affinity, be able to 
eliminate non-biological binding, and be both inexpensive and easily 
reproducible (Leake, 1981).
The biochemical method should separate receptor-bound hormone 
from both unbound steroid and that bound by plasma carrier proteins. 
Plasma proteins are a common contaminant of human tumour biopsies 
(Maass et al., 1975) and have been suggested as the most likely
source of "false-positive" identification of receptor in some biopsy 
materials (Leake et al., 1980). Elimination of non-specific and 
lower affinity binding is usually done by running parallel 
incubations containing radiolabelled steroid alone and radiolabelled 
steroid plus 100-fold excess of unlabelled competitor. In the case 
of oestrogen, the competitor is usually diethylstilbestrol (DES) 
since this oestrogenic compound binds the cellular receptor with an 
affinity at least equal to that of E2 but has a much weaker affinity 
for sex hormone binding globulin (SHB6). The use of an 
anti-oestrogen as competitor has also been tried with apparent 
success, although critics suggest that an anti-oestrogen may bind to 
a separate site on the receptor (Rochefort and Capony, 1977).
The assays measure unoccupied receptor sites. This was a 
reasonable approach since only a maximum of 30% of the receptors in 
the cytosol fraction of breast tumour biopsies have been found to be 
filled (Sakai and Saez, 1976) and no correlation has been found 
between high plasma oestrogen levels and reduced cytosol receptor 
content (Fishman et al., 1977). However, the measurement of nuclear 
receptor levels have been suggested as a better index of hormone 
dependence (i.e. translocation to the nucleus being an indication 
of functional receptor) (Laing et al., 1976). Exchange assays have 
therefore been developed and investigators have observed an 
increased correlation between receptor positive tumours and response 
to endocrine therapy (Barnes et al., 1979; Macfarlane et al., 1980; 
Leake et al., 1981a,b).
At the moment the two biochemical methods most widely used to 
measure levels of oestrogen receptor are sucrose density gradient 
centrifugation (SGA) and dextran-coated charcoal (DCC) analysis.
1.5.1.1 Sucrose Gradient Assay (SGA)
The SGA can be used to quantitate receptor by demonstrating the 
specificity of 8S and AS binding to [%]E2 (Chamness and McGuire,
1972). They stated that the 6S form is the physiological soluble 
receptor form and that the 8S and AS forms are artifacts of
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preparation in low or high salt. The 6S form associates to yield 8S 
molecules in low salt (0.15M KCl). The dissociation of 8S back to 6S 
is slow at 2*C, leaving a significant amount of 8S material on the 
gradient. This shows that a slight variation in conditions can 
affect oestrogen receptor forms considerably. The polyanion effect 
in particular allows production of almost any sedimentation 
artifact. Nevertheless this method is very popular and shows direct 
measurement of oestrogen receptor.
1.5.1.2 Dextran-Coated Charcoal Assay (DCC)
This method depends on the concept that DCC will bind free and 
loosely bound steroid but will not strip steroid from receptor. The 
assay yields data that can be plotted by the method of Scatchard to 
determine both the affinity and the number of oestrogen-binding 
sites. This method was first developed by Korenman and Duke (1970). 
After that several modifications has been proposed (Hawkins et al., 
1975; Koenders et al., 1978; Chamness and McGuire, 1980). McGuire 
and De La Garza (1973) observed the importance of temperature and 
thiol reagent during incubation of labelled steroid with the 
receptor, as well as during tissue fractionation. To get good 
competition data for the Scatchard plot, DES is usually added at a 
hundred-fold concentration above that of oestradiol. It will 
effectively compete for all the high affinity receptors but will not 
displace labelled Eg from low affinity sites (Leake, 1980). Even 
though there are several modifications of this method, the 
procedures are relatively similar. The advantage of this assay is 
that it enables the determination of total binding sites and 
affinity of steroid for receptor.
The data of the specific binding needs to be analysed. Most 
authors use the well-established Scatchard plot (Hahnel and Twaddle,
1973). However, such data can be easily misinterpreted (Chamness 
and McGuire, 1975; Braunsberg and Hammond, 1979) and these plots are 
frequently non-linear. Several alternatives to the Scatchard plot 
have been proposed (Braunsberg and Hammond, 1980), the Woolf plot is 
perhaps least subject to error of the graphical methods (Keightley
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and Cressie, 1980).
These biochemical methods have the weakness that the receptor 
has to be prepared in homogenates. Since the procedure includes 
homogenization and fractionation, the specimen and its cellular 
components are totally disrupted. Thus this procedure does not 
allow the detection of receptors at their native sites in the intact 
cells. In addition, a relatively large amount of tissue is 
necessary to perform the assay which is a problem in small tumour 
samples and biopsies. The fact that it uses radioactive materials 
and expensive equipment makes its application limited to larger 
medical centers and commercial laboratories which obtain a 
sufficient number of specimens. Individual tumour cell receptor 
heterogeneity as well as the original sources of Veceptor protein, 
cannot be identified. This is important since benign as well as 
malignant tissue may contribute to total receptor content. De 
Sombre et al., (1978) suggested that the variable levels of 
oestrogen receptor in breast carcinomas may reflect varying 
proportions of oestrogen receptor positive (ER+) and oestrogen 
receptor negative (ER-) cells. If the proportion of the latter is 
large, then the effect of endocrine therapy may be masked by the 
continuous growth of autonomous cells.
The recognition of these factors and other limitations of 
current biochemical methods has led several groups to investigate 
other techniques for the identification of oestrogen receptor, using 
other techniques.
1.5.2 Assay for Oestrogen Receptor Using Immobilized Oestradiol
Antiserum
Fishman and Fishman (1974), Fishman et al. (1975) and Castaneda 
and Liao (1975) used antioestradiol antibody as a probe in 
determining the quantity and binding characteristics of materials 
which compete with the antibody for the same ligand. Fishman and 
Fishman (1979) used immobilized antibody on a polymer film. This 
complex is used in competition for (^H]E2 with oestrogen receptor
43
or antioestradiol antibody in solution. Through this method 
evaluation of association constant and quantification of the 
oestradiol-complexing species in solution is possible. Using the 
immobilised antibody method at 4°C, 0.8-0.12x10^^ was the 
association constant for oestradiol receptor in rat uterine cytosol, 
and 2.6x10^^ M  ^ was the association constant found for
antioestradiol antibody raised in a rabbit. The antigen is E2
linked to bovine serum albumin via a C—6 carboxymethyloxime. Rochi 
et al. (1979) worked on the same antibody but using £2 
17-hemisuccinate as antigen. The antioestradiol antiserum was
reacted with a protein-A-bearing strain of Staphylococcus aureus. 
This bacterial immunoabsorbant was then used to estimate the
oestrogen receptor concentration in several breast cancer specimens. 
Using this method they calculated the affinity constant of the 
immobilized absorbent for the E2 to be 10 M which for the breast 
oestrogen receptor complex are about 10^-10^^“ .^ Through this 
method it is possible to remove the free steroid from a reaction 
mixture containing cytosol, radiolabelled E^, and the antioestradiol 
bacterial adsorbent by pelleting the bacteria by low speed
centrifugation. The radiolabelled oestradiol receptor complex 
remains in the supernatant and can be easily counted in the 
scintillation counter. The data can then be analysed using the
saturation curve of the specific binding.
1.5.3 Analysis of Oestrogen Receptor by Isoelectric Focussing
Several authors had reported on the use of isoelectric 
focussing in oestrogen receptor studies (Coffer and King, 1976; Boyd 
and Spelsberg, 1979; Gustafsson et al., 1979). However this 
technique had been found inadequate due to large sample 
requirements, low recoveries, long focussing times and poor 
resolution. Later, Thibodeau et al. (1980) reported the use of 1% 
agarose as supporting medium and ( I]E2 as labelled ligand for 
oestrogen receptor. After completing the focussing procedure, the 
gel is frozen at -70°C and subjected to fluorography. Using 
diisopropylfluorophosphate (DFP) and molybdate (Mo) as stabilising
agents they showed the presence of at least six distinct species of
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the human oestrogen receptor. Of these, four appear to be products 
of proteolysis. Their isoelectric points are 6.9, 6.8, 6.4, and 6.3, 
with a combined sedimentation coefficient of approximately 3.2S. The 
non-activated form of the receptor, prepared in the presence of 
serine ^protease inhibitor diisopropyl fluorophosphate (DFP) 
(Hartley, 1960) and molybdate, a proposed inhibitor of oestrogen 
receptor activation (Nielsen et al., 1977; Leach et al., 1979; Toft 
and Nishigori, 1979; McBlain and Shyamala, 1980), focused at pH 4.8 
and had a sedimentation coefficient of approximately 9.5S. The 
activated form detected in the presence of DFP sedimented at 8.OS 
and had an apparent pi of 5.4 (Thibodeau et al., 1983)
1.5.4 Gel Filtration Technique
The gel filtration technique was adapted by Godefroi and 
Brooks (1973). They used either Sephadex G-25 or G-lOO columns. 
Gore-Langton et al. (1973) proposed a thin layer gel filtration 
procedure using Sephadex G-150 to avoid complexity. Although this 
approach was rapid and separated 8S and 4S forms of receptor it did 
not always produce results comparable with conventional techniques 
and therefore, it is not popular. Ginsberg et al. (1974) used a 
small LH-20 Sephadex column and produced results comparable with 
those obtained by DCC (Barnes et al., 1977).
1.5.5 Visualisation of Oestrogen Receptor Using Fluorescent Ligand
Martin et al. (1983) used four fluorescent ligands as agents 
for visualisation of oestrogen receptor in MCF-7 cells: coumestrol
(Figure 5) and 12-oxoestradiol which are fluorescent compounds; and 
tamoxifen and 4-hydroxytamoxifen which become maximally fluorescent 
only after ultraviolet irradiation. Using photon-counting 
spectrofluorometry, coumestrol and 12-oxoestradiol can be detected 
in protein solutions down to 0.5nM. Three of these compounds have 
good affinity for the oestrogen receptor: coumestrol (20%),
12-oxoestradiol (12%) and 4-hydroxytamoxifen (37%), relative to E2 
(100%). Under conditions where autoradiographic experiments showed 
the nuclear localisation of oestrogen receptor, they could
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demonstrate the nuclear fluorescence using nM concentrations of 
coumestrol, 12-oxoestradiol, and 4-hydroxytamoxifen. Using excess 
concentrations of DES, the fluorescence could be abolished.
Tobin et al. (1980) used coumestrol to detect oestrogen 
receptor in whole cells grown in tissue culture. To the cells,
lxlO~^M coumestrol was added for 2-180 min and the cells were then 
immersed in ice cold PBS and immediately examined by ultraviolet 
microscopy.
Coumestrol, a naturally fluorescent probe, has been shown to 
bind to oestrogen receptor with high affinity and specificity
(Bickoff et al., 1957; Folman and Pope 1969; Perel and Lindner 1970;
Shemesh et al., 1972; Shutt and Cox, 1972). Martin et al. (1978),
demonstrated the coumestrol-receptor binding in MCF-7 cells by 
biochemical means. Pertschuk et al. (1978) showed histochemical 
analysis with direct visualization of nuclear translocation. They 
also showed the specificity of coumestrol-receptor fluorescence by 
the marked inhibition with DES and £2» while progesterone, testosterone 
and corticosterone had no effect. They also found the 
coumestrol-receptor assay in breast cancer correlates closely with 
results of DCC.
1.5.6 Cytochemistry and Immunochemistry
The visualization of steroid binding sites at the microscopic 
level can, in theory, be approached either by labelling the 
receptor protein itself, or by labelling the steroid which binds to 
the receptor protein. With respect to the latter approach two 
methods are available: cytochemistry and immunochemistry i.e. there 
are two methods of labelling the steroid. The first one involves 
conjugating the steroid with enzymes (peroxidase, alkaline 
phosphatase) or with fluorescent probes (fluorescein 
isothiocyanate (FITC)). The other means of locating oestrogen 
receptor is by detecting the presence of E2 through the use of an 
antibody to the steroid. The bound antibody is directly or 
indirectly labelled with peroxidase or fluorescein.
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Different investigators have used several types of ligands for 
histochemical receptor assays. Dandliker et al. (1978) showed that 
labelling E2 with FITC at the position 17 resulted in a compound 
with a higher affinity for oestrogen receptor than labelling at 
position 16. Barrows et al. (1980) also employed E2 labelled at 
position 17. Pertschuk et al. (1978, 1979) and Lee (1979) used a 
BSA-FITC E^ conjugate labelled at position 6, whereas Walker et al.
(1980) used a similar molecule with peroxidase as the marker. 
Antibodies to E2 have also been widely investigated in several 
laboratories (Kopp et al., 1979; Nenci et al., 1979).
Walker et al. (1980) demonstrated that histological techniques 
gave similar qualitative results to the dextran-coated charcoal 
assay. They noted that the only differences that they obtained in 
the results of both techniques was due to sampling procedures or the 
variation in the number of binding sites per cell. They also found 
that the immunocytochemical method was less satisfactory due to the 
small number of positive cells detected compared to the cytochemical 
methods. This could be due to the use of unpolymerised oestradiol
whereas Pertschuk et al. (1978) used polymerised ligand which
provides a larger antigen target for the antibody. Moreover they
used fluorescent labelled ligand, while Walker et al. (1980) and 
Walker (1981) used peroxidase labelled-ligand to oestrogen 
receptor.
1.5.6.1 Fluorescent Ligand
In this method, the steroid is linked directly to a fluorescein 
moiety. For example l-(N)-fluoresceinylestrone thiosemicarbazone is 
an oestrogen derivative, which binds specifically to cytoplasmic 
oestrogen receptor at 4°C, and to nuclear oestrogen receptor at 37°C 
(Nenci et al., 1980). Another conjugate which is more widely used 
is the l^-oestradiol-6-carboxymethyloxime-bovine serum albumin 
fluorescein isothiocyanate (E-BSA-FITC); (Lee, 1979). The former 
can be used on intact cells while the latter is a macromolecular 
analogue whose size hinders it from permeating the plasma 
membrane. Therefore E-BSA-FITC must be used on cryostat sections.
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in which almost every cell has been cut open (lee, 1981).
1.5.6.2 Fluorescent Labelled Antibody to Oestrogen
1.5.6.2.1 Direct Method
The direct method does not require a second antibody. The 
primary antibody is conjugated to FITC (Coons and Kaplan, 1950). 
Then the conjugated antiserum is allowed to react with oestrogen 
receptor in the intact cells or frozen sections and the unbound 
antibody is then washed off. Ultraviolet (uv) microscopy is used to 
observe the site of attachment of the antibody which is apple green 
in colour.
1.5.6.2.2 Indirect Method
This method requires a secondary antibody as well as a primary 
antibody. The secondary antibody is labelled with FITC. It should be 
an antibody, raised in another species, (e.g. goat) to the 
Ç-globulin of the animal (e.g. rabbit) which donated the primary 
antibody. It is called Goat anti-rabbit-IgG-FITC conjugated 
secondary antibody.
The primary antibody is incubated first with the cells or 
frozen sections, the excess washed off, and then incubated with 
secondary antibody. The first antibody, which is already bound to 
the antigenic sites, acts as a %-globulin antigen for the 
secondary-FITC antibody. Again viewed under uv, an apple green colour 
will show positive staining.
There are several advantages in using indirect methods compared 
to the direct methods. The sensitivity of the reaction increases 
since two of the secondary antibody molecules can bind to each 
primary antibody molecule. It is also economical since one 
fluorescent second-layer antibody can be used to stain any type of 
primary antibody to a different antigen, as long as the primary 
antibody is raised in the same species as that which donated the IgG
49
for the secondary antibody.
The indirect method for detecting bound oestrogen was 
originally developed by Pertschuk et al. (1978). Polyoestradiol 
phosphate (PEP) was incubated with the frozen section. This is then 
followed by incubation with anti oestradiol-antiserum (Alonso and 
Brownlee, 1981). After 30 min, the washed tissue was then covered 
with a 1:10 dilution of fluorescein sheep anti-rabbit serum and 
washed with phosphate buffer saline (PBS) for 60 min. All dilutions 
were made in PBS containing 4% bovine serum albumin. Competitive 
binding was checked with antioestrogen, by .incubating the sections 
with tamoxifen (1.0 mg/ml) in phosphate buffered saline for 60 min 
following exposure to PEP. Parallel sections of each tumour were 
incubated in PBS instead of PEP to allow for detection of E^, bound 
in vivo.
1.5.6.3 Peroxidase Labelled Technique
This technique does not require an antibody. Horseradish 
peroxidase was coupled to l^-oestradiol-6-O-carboxymethyloxime- 
bovine serum albumin, by the periodate method of Nakane and Kawooi 
(1974) or the two stage glutaraldelyde conjugation method of 
Avrameas and Ternynek (1971). These peroxidase labelled oestrogens 
were applied to the frozen sections and incubated for 2h at room 
temperature. Peroxidase was localised using the diaminobenzidine- 
hydrogen peroxide reaction (Graham and Karnnowsky, 1966).
1.5.6.4 Immunoenzyme Method
Nakane and Pierce (1966) first introduced the peroxidase 
technique. The tissues or cells are first immersed in a solution of 
hydrogen peroxide in buffer or methanol to 'exhaust' the endogenous 
peroxidase of the tissue. Alternatively, periodate and borohydride 
(Heyderman, 1979), sodium nitroferricyanide, or phenylhydrazine can 
be used (Straus, 1971, 1972). This is followed by the application 
of primary antibody, then by the secondary antibody which is 
IgG-peroxidase conjugated. Finally, the substrate for the
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peroxidase is then applied.
The advantages of this method over the fluorescence method is 
the permanent staining, visible with an ordinary microscope and 
therefore easily photographed. However there are several 
disadvantages since it has extra steps. The slides need to be incubated 
with hydrogen peroxide because peroxidase might be present (Duffy 
and Duffy, 1977). Therefore extra washings are required, which may 
result in tissue being detached from the slides. Also the component 
of the substrate, diaminobenzidine, or 3-amino-9-ethyl carbazole is 
said to be carcinogenic. Extra precautions are required.
1.5.6.5 The Peroxidase Anti-peroxidase Method (PAP)
This is a further modification of the above indirect method, 
and has been found to be more sensitive. It has a first layer of 
primary rabbit antibody, a second or another antibody (but not 
labelled) to |^-globulin in rabbit, and a third layer which is a
rabbit antibody to peroxidase coupled with peroxidase. Thus it
forms a stable PAP complex. There are also several advantages to 
this technique. There is an increase in sensitivity of about
100-1000 times over the first indirect method. This is because the 
peroxidase is bound immunologically to the antibody rather than 
chemically conjugated. Therefore there is no loss in its enzyme 
activity. Due to the higher sensitivity, more dilute antibody can 
be used. This results in greater specificity. The PAP complex is 
highly specific since it will react only with the anti-rabbit
^globulin of the second layer. It will not attach to tissue, so 
background staining is minimal. The only disadvantage it has is that 
it requires an extra reagent.
1.5.6.6 Technical Conditions of Tissue Preparation
1.5.6.6.1 Management of Tissue Samples
The management of tissue samples has played an important role
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in the success of the application of this technique. Most authors 
do not fixed their cryostat sections but use them immediately after 
cutting or storage. Lee (1978) reported that tissue kept in PBS at 
2-5®C for up to 24h did not significantly loose its binding capacity 
to the steroid. However, tissue blocks frozen at -20°C were not 
suitable for this kind of study.
Other authors reported that freezing techniques could affect 
the ability of the ligand to be stained. Van Marie et al. (1982) 
demonstrated that only freezing the tissues rapidly in liquid 
nitrogen-chilled isopentane showed the presence of nuclear 
fluorescence. They pointed out that only storage in liquid nitrogen 
maintains a satisfactory level of staining while storage over short 
periods at -70*C decreases the level of staining intensity quite 
considerably. However, this finding is in contrast with Curtin et 
al. (1982) who reported they had successfully stored their 
specimens at -70°C. They stated that freezing allows the 
histochemical detection of oestrogen binding. The same was reported 
by Walker (1981) for her specimens of breast cancer tissues.
1.5.6.6.2 Fixation
After the preparation of the cryostat sections, the next step 
is to consider whether fixation is necessary. Again different 
authors have different opinions. According to Lee (1978, 1979,
1981) sections must be air-dried (60 min at 4*C). Hanna et al. 
(1982) allowed the sections to air-dry only for 15-20 min at 4*C. 
Tominaga et al. (1981) centrifuged the sections first before 
staining. Curtin et al. (1982) let their preparations 
(aspiration-biopsy smears) dry before freezing.
Others (Nenci, et al., 1980; Danguy et al., 1981; Panko et al.,
1982) apparently did not use any type of fixation. Lee (1978) 
reported that cold acetone, 3.7% buffered formaldehyde and 1% 
glutaraldehyde completely abolished staining.
Raara et al. (1982) stated that acetone, formaldehyde, 75%
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ethanol and Bonin's fixative destroyed the antigenicity and 
oestrogen-binding capacity of oestrogen receptor to an appreciable 
degree. In contrast, oestrogen binding proteins have been displayed 
on routinely fixed embedded tissue by immunocytochemistry (Kurzon 
and Sternberger 1978; Taylor et al., 1981) using antibody against 
E2» However, these may detect only Type II sites.
Thawing of the sections mounted on glass slides is also 
reported to influence the result. Curtins et al. (1982) emphasized 
that exposure to ambient temperatures after thawing, reduces the 
affinity for the ligand-conjugates. Nenci et al. (1980) briefly 
discussed the problem of temperature. They stated that thawing of 
frozen sections involves nonspecific diffusion of cytoplasmic 
oestrogen receptor complexes which could then appear in the nuclear 
compartment. Walker (1981) also reported that, if tissues thawed 
during cutting, this led to poor staining. The same results were 
obtained with tissue initially frozen in solid carbon dioxide, 
rather than liquid nitrogen (Walker, 1981).
Must the sections be rehydrated before incubation? Raam et al. 
(1982) used frozen unfixed sections which were first dehydrated 
gradually by 10 min exposures in graded ethanol (30, 50, 75, 90% in 
physiological saline) and rehydrated by reversing the dehydration 
steps. The authors stated that this procedure is a fixation method 
which retains the antigenicity and oestrogen binding capacity, as 
opposed to the other commonly used fixation methods or to the use of 
unfixed tissues. Rehydration, when used, is generally carried out by 
brief immersion in PBS containing bovine serum albumin. Other 
authors do not mention the used of rehydration.
Care in the preparation of tissue has been found to be 
essential. This procedure depends very much on the antigen to be 
tested and also on the choice of the method of detection of the 
steroid receptor. Walker (1981) found that detecting oestrogen 
receptor using peroxidase labelled ligand (peroxidase-oestradiol- 
BSA), using formalin-fixed or paraffin-embedded tissue were 
unsuitable. Rapid freezing of fresh tissue, with only brief air drying
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or acetone fixation of tissue sections and a short term storage were 
important. They found that tissue which had been formalin fixed and 
paraffin-embedded consistently gave negative results. According to 
Walker (1981), exposure to paraffin would explain the loss of 
activity because of the lability of the oestrogen receptor protein. 
Loss of activity of receptor binding to Eg takes places rapidly at 
high temperature. This resulted in loss of staining in the paraffin 
embedded tissues.
Treatment of frozen sections with acetone for 3 or 5 min 
resulted in clearly defined staining within cells but acetone 
treatment for any longer resulted in loss of staining. Walker also 
found that fixation at 4°C or at room temperature gave similar
results. The use of ethanol at any time resulted in granular 
cytoplasmic staining in the stroma rather than in the epithelial
cells. Using 4% glutaraldehyde even for 10 min caused a negative 
staining. Air drying for 5-10 min gives similar result to acetone 
fixation.
1.5.6.6.3 Incubation
This is the most constant step of all the procedures involved in 
the histochemical/cytochemical methods. The incubation time is
usually 1 or 2h and temperature is between 20-25*C. In the present 
section only the cytochemical studies using BSA as the protein
carrier and FITC as the fluorochrome dye for antibody to oestrogen
are considered.
According to Chamness et al. (1980) the lowest concentration of 
E2 conjugate which gives sufficienct fluorescence is 10“% .  They 
suggested that at this concentration Type I binding alone is 
observed. At the higher concentration of 10“®-10“% ,  Type II
binding is said to occur. Accordingly, it appears that the
concentration of E-BSA-FITC plays a major role in the extent of
binding capacity and in the possible interpretation of the
labelling. Many of the studies discussed here used E2
concentrations of about 10 ^M and their findings are therefore open
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to question.
Danguy et al. (1981), Hanna et al. (1982) and Panko et al.
(1982) used the method described by Lee (1978, 1979), hence they
used the E-BSA-FITC concentration of 5x10 % .  McCarty et al. (1979)
-9used a lower concentration: 1-3x10 M, as did Pertschuk et al. 
(1979). Tominaga et al. (1981) and Walker et al. (1980) did not 
specify the concentration of the ligand in the incubation solution.
1.5.6.6.4 Processing After Incubation.
Basically most authors recommended gentle rinsing in PBS 
followed by immersion in PBS, the latter varying from 3x5 min to 
2x30 min or even 2h. Tominaga et al. (1981) used subsequent air 
drying of the sections, while postfixation in acetone-ethanol (for 
10 min) was carried out by Pertschuk et al. (1979) and Curtin et al. 
(1982).
Processed slides were mounted in buffered glycerol, pH=7.0
(Curtin et al., 1982), glycerin/water, (1:1) at pH=7.4 and 80%
glycerin, pH=9.0 (Tominaga et al., 1981).
1.5.6.7 A Morphological Study of Oestrogen Receptor Using Cytoche­
mical and Immunochemical Techniques
Cytochemical and immunochemical techniques offer an alternative 
to biochemical techniques as a means of localizing cellular 
oestrogen receptor. Fluorescence may be evidenced either in the 
nuclei or in the cytoplasm, or in both cell compartments. The 
localization depends on the chilling method and the concentration of 
the ligand-conjugate. Some authors do not stress the location of
the staining (Tominaga et al., 1981 and Panko et al., 1982). Hanna
et al. (1982) observed only cytoplasmic fluorescence in their 
preparation. Danguy et al. (1981) reported staining in both the 
cytoplasm and the nuclei.
Walker et al. (1980) observed a mixture of positive and
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negative cells in the same piece of tumour. The number of positive 
cells ranged between 25% to 85%. The staining was predominantly
intracytoplasmic, with an occasional concentration at the cell 
periphery or the perinuclear region. They also observed granular
staining in the nucleus and sometimes the nucleolus was the main 
site of reaction.
Pertschuk et al. (1980) found that both tissue sections and
aspirates of breast cancer displayed similar patterns of
fluorescence. In fact individual cell morphology was clearer, and 
nucleolar and cytoplasmic binding were more vivid in the needle
aspirates.
Mori et al. (1984), using the indirect immunofluorescence
technique with an antibody to E^, also observed cytoplasmic staining 
in the epithelial cells, stromal cells and muscle cells of the 
vagina of the neonatal mouse.
Heterogeneity of tumour cells has been observed by many
investigators. Even though Walker (1981) did not find a high 
variation of the number of positive and negative cells between
different sections from the same tumour (only about 10%), she 
demonstrated the presence of oestrogen receptor positive cells lying 
adjacent to oestrogen receptor negative cells which she said, could 
be due to the clonal origin of the breast carcinomas.
The use of peroxidase labelled antibody to Eg was also 
reported to have direct correlation of oestrogen receptor 
localization with morphology (Taylor et al., 1981). They reported 
that when routinely fixed embedded tissue was used, they could 
differentiate between types of tumours that contained a large amount 
of fibrous stroma from those neoplasms composed of densely packed 
tumour cells. Another advantage which could be observed with this 
method is that it permits an assessment of not only overall tumour 
positivity, but also of the proportion of receptor positive and 
negative cells within an individual tumour (Taylor et al., 1980). 
In addition, because most biochemical, cytosol-based methods rely on
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the specific binding of to empty receptor, the large amounts
of endogenous ££ in premenopausal women, produce blocking of binding 
of labelled hormone and thereby lower the apparent oestrogen 
receptor level.
Alonso and Brownlee (1981) found that the staining intensity of 
the cells was independent of topographic location, and they also 
discovered that tumour cell populations were heterogenous for 
oestrogen receptor as had been seen by others (Lee, 1978; Mercer et 
al., 1978; Pertschuk et al., 1977, 1978, 1979). The location of
oestrogen receptor within malignant cells could be determined but 
with some difficulty. Cytoplasmic staining predominated.
Apart from the distribution of oestrogen receptor within one 
cell type, Mori et al. (1984) concluded that, at the age of 1-15 
days postnatal life, staining occurred exclusively in the stroma of the 
vagina of normal mouse. They thus suggested that epithelial cells 
are not the actual target of oestrogen during normal development. 
However, they observed labelling in the mullerian vagina and 
cuboidal cells of the sinus vagina in neonatally oestrogenised mice. 
This suggests the possible existence of a difference in the nature 
of the vaginal epithelium between the neonatally oestrogenised mice 
and normal mice.
Most of the experiments done were followed by a specificity 
test. To make sure that the binding reflects oestrogen receptor 
only, the tissue sections were subjected to preincubation in an 
excess of unlabelled oestrogen with or without antioestrogen. Other 
methods include incubating the sample with bovine serum albumin 
without FITC or in fluorochrome dye without conjugation to 
oestrogen.
Nenci et al. (1976) also reported the absence of staining in 
human spleen, mouse liver and non-target tumour cells. Cell 
suspensions from breast tissue of a pregnant woman and from other 
premenopausal breast cancer patients displayed a moderate 
cytoplasmic and faint nuclear fluoresence, without exposure to £%.
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Nenci et al. (1980) tested the receptor specificity of the E2 
binding by blocking experiments. They compared the hormone uptake in 
the presence and also absence of blocking compounds (Nafoxidine, 
N-ethylmaleimide). They found the E2 bound specificically to the 
receptor.
1.5.6.8 In Vitro Translocation of Oestrogen
There was a shift from predominantly cytoplasmic to nuclear 
binding after treatment with coumestrol (Pertschuk et al., 1980). 
They observed in their experiments that there exists two groups of 
patients: a larger group that exhibits nuclear translocation and a
smaller group that does not. The phenomenon could be related to the 
success of breast cancer hormone therapy since a significant 
proportion of women with ER+ breast cancer fail to respond to 
endocrine therapies. These could, at least in part, reflect patients 
whose tumours contain an abnormal oestrogen binding protein which is 
unable to undergo activation and so cannot induce genetically 
mediated responses.
Nenci et al. (1976) used the immuno cyt ochemic a1 indirect 
technique with FITC labelled antibody to E2 in E2 target cells. They 
used an £2 concentration of 2x10“% .  The first experiment on in 
vitro translocation used temperatures of 4*C, 20-22°C and 37*C. 
They observed three general patterns depending on the treatment. The 
cells incubated in the cold showed a homogeneously diffuse 
fluorescence in the cytoplasm. The nuclei were unstained. In many 
breast tumour samples negative cells were also observed.
The second pattern of fluorescence was shown by cells incubated 
at room temperature. They observed nuclear staining together with 
cytoplasmic staining.
The third staining pattern was seen after the slow 
post-incubation warming up to 37®C. In addition to cytoplasmic 
fluorescence, increasing nuclear staining occurred which, later, 
filled the whole nuclear area. In some breast tumours they did not
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observe any nuclear labelling after warming, despite the clear 
cytoplasmic fluorescence. They referred to this as a double cell 
population.
The translocated staining was concentrated in nuclear chromatin 
in small fluorescent dots after 5-6h. These dots disappeared after 
12-15h, leaving only one or rarely two roughly spherical, bright 
nuclear bodies still stained. Phase contrast microscopy and 
cytological staining showed that these bodies are the nucleoli. It 
is interesting to note that Raam et al. (1982) reported the same 
observation but using an antibody to oestrogen receptor protein.
Mori et al. (1984) also investigated the in vitro temperature- 
dependent nuclear translocation. Vaginal sections were incubated in 
10r& M E2 for Ih at 4*C. Other sections were incubated with 
oestrogen for Ih at 4°C and then postincubated in medium without 
oestrogen for Ih at 37“C. For competitive binding, the vaginal 
tissue was incubated with 10“^M diethylstilboestrol (DES), followed 
by exposure to 10"% E2 for Ih at 4°C. After incubation, vagina 
sections were placed on brass tissue holder and frozen by liquid 
nitrogen. Sections were cut at 6um by a cryostat and were kept in 
a desiccated slide box at 20°C. In tissue exposed to oestrogen at 
4"C and postincubated without oestrogen at 37°C, fluorescence was 
diffusely distributed over the cytoplasmic and nuclear area. This 
may indicate the occurance of temperature dependent nuclear 
translocation of oestrogen. They also found that the staining was 
effectively blocked by prior incubation with excess DES. However, 
the levels of steroid used cast doubt on the nature of the binding 
proteins studied.
1.5.6.9 Interpretation of the Results
The interpretation of the results had not been standardised and 
therefore reported according to different authors' chosen 
criteria. Pertschuk et al. (1980) classified a tumour as negative 
when the tumour specimen showed only 10% positive cells. Hanna et 
al. (1982) too used the same criteria. Tominaga et al. (1981)
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recommended a threshold value of less than 20% positive tumour cells 
before the tumour be considered negative. Walker et al. (1980) 
apparently did not find positive tumours exhibiting staining less 
than 30% (in other words all positive tumours yielded at least 30% 
of positively stained cells).
Some investigators related the findings with hormone therapy. 
Mercer et al. (1980) stated that hormone therapy of breast cancer 
was found to be active only when 90% or more of the cells exhibit 
positive staining.
The percentage of labelled cells is not the sole parameter to 
investigate. Hanna et al. (1982) emphasized that the intensity of 
fluorescence is as important as the percentage of stained cells. 
Many tumours contain a certain number of cells that fail to 
translocate the hormone into the nucleus despite normal cytoplasmic 
uptake (Nenci et al., 1980). Since nuclear translocation is a 
prerequisite for the functionality of oestrogen receptor, nuclear 
staining after 37°C incubation would appear to be the important 
finding.
1.5.6.10 Comparison with the Biochemical Assay
Pertschuk et al. (1979), detected oestrogen receptor through 
the use of a fluoresceinated bovine serum albumin-oestradiol 
conjugate linked to E2 at position 17 and containing 5 mol 
fluorescein and 4 mol E2 per mol albumin. From 120 specimens of 
breast cancer, they compared their results with the biochemical 
dextran coated charcoal method and found a 92% correlation, compared 
to their earlier work (Pertschuk et al., 1978) which showed 89.4% 
correlation. They reported that divergent results most often 
occurred in specimens sparsely populated with malignant cells.
Walker (1981) compared the cytochemical results with those of 
biochemical results done on parallel tissue sections. She found a 
good qualitative correlation between the two sets of results.
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Taylor et al. (1980) found a 60% correlation between the 
histochemical method and the biochemical technique. They reported 
that in most cases which were negative by the biochemical method, 
they found the tumours consisted of cords and nests of tumour cells 
interspersed with predominantly stroma or adipose tissue, the 
carcinoma cells constituting only a minor proportion of the tumour 
tissue. They found that the peroxidase technique could identify 
those small numbers of positive tumour cells, surrounded by large 
amounts of fibroadipose tissue.
Alonso and Brownlee (1981) reported that the use of 
immunofluorescent steroid antibody techniques showed a 67% 
correlation with the DCC method in the detection of oestrogen 
receptor levels on 21 cases of breast cancer. Both direct and 
indirect fluorescent antibody assays were used.
1.5.6.11 Validity of Histochemical Method in the Detection of 
Oestrogen Receptor
Almost all immunocytochemical studies reported have used rabbit 
anti-oestradiol antiserum which has been absorbed with bovine serum 
albumin (BSA); The purpose of the adsorption step is to prevent the 
'unadsorbed' antiserum cross-reacting with the cellular antigen and 
albumin from the culture medium or prepared specimen thus giving a 
false positive staining. The elimination of Eg binding with 
anti-oestradiol is to prove its immunocytochemical specificity for 
oestrogen. Usually a marked reduction or total elimination of 
fluorescence staining is observed. This indicates specificity for 
Eg (Mercer et al., 1981).
In order to prove that the antibodies are able to recognize 
receptor associated E2, one must be able to show the presence of the 
immune complexes of antibody-oestradiol-receptor. Mercer et al.
(1981) failed to detect the existence of this complex, as did 
Castaneda and Liao (1975). Both groups used sucrose density 
gradient analysis (SDGA). Using radioimmunoassay (RIA) to detect
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competition between cytosol oestrogen receptor and antibody for E2 , 
they could not show that a complex of antibody to oestrogen receptor 
existed (Fishman and Fishman, 1974; Castaneda and Liao, 1975; 
Fishman et al., 1975). These experiments involved the use of 
insolubilized antibodies to Eg which were incubated with [ H]E2 and 
cytosol from breast tumour preparations. It was observed that the 
antibody would bind to free [%]Eg and [%]E2 bound to nonspecific 
sites but not to the oestrogen receptor complex.
Mercer et al. (1981) found that at least 3 types of
oestrogen-binding components in breast cancer cells can be detected
i.e. Type I binding (the oestrogen receptor itself). Type II and 
Type III.
Type I has the highest affinity for E2. The dissociation 
constant (Kj) is in the order of InM.
Type II has a lower affinity for E2 but it has a higher 
capacity for the hormone. Clark et al. (1978) and Eriksson et al. 
(1978) refer to this receptor as Type II oestrogen binding sites in 
the rat uterine cells. Below lOnM few of these sites are occupied 
but as the Eg increase to IpM most of the binding sites are 
occupied.
Type III sites are the other oestrogen-binding molecules within 
the cells, albumin and other membrane associated molecules which 
have low affinity for the hormone, but have a high total binding 
capacity. These sites will be occupied at a very high E 2 
concentration. They are also called nonspecific oestrogen binding 
sites.
Therefore during the immunocytochemical assays which use very 
high levels of steroid (>10nM) detection of oestrogen binding 
protein (EBP) other than Type I must occur. Mercer et al. (1981) 
discovered that, using lOnM E 2» there was no detection of Eg specific 
immunofluorescence in the cells. Mercer and co-workers also mention 
that in the rat uterus the sites detectable in the cell nuclei
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increase greatly after oestrogen treatment. However the cytosol 
sites are not depleted by this oestrogen treatment. Since Type II 
nuclear sites are independent of Type II cytosol sites, they 
conclude that this technique measured the Type II sites in the MCF-7 
cell lines. They even calculated the binding sites of Type II by
subtracting the total binding (incubated with lOxlOnM Eg) from
oestrogen receptor (Type I) binding (incubated with lOOnM Eg). It 
was estimated that nearly half of the total Eg binding was due to 
lower-affinity but compatible E2 binding sites.
The use of antioestrogens or DES in excess in the 
immunofluorescent detection should have eliminated only the specific 
staining since it would fill the high affinity receptor sites. 
However the DES concentration that was commonly used (IpM to IraM) 
was far too high to saturate only the specific binding sites. 
Besides, Eg solubility decreases in the presence of high 
concentrations of DES. These observations weaken the value of 
immunofluorescence techniques in routine assays.
Nenci (1981) disputed the idea of Type II sites as contributing 
to the positivity of oestrogen receptor in the intact cells. He 
showed that no residual cytoplasmic staining was observed in these 
systems after nuclear translocation has taken place and noted that 
cytosol Type II binding sites do not translocate (Clark et al., 
1978; Eriksson et al., 1978). However, even if it is Type II binding 
sites that are measured, this does not form a limitation in the use 
of the technique if the growth response of target tissues elicited
by oestrogen requires both nuclear receptors and cytosol Type II
sites (Nenci, 1981).
Pertschuk et al. (1978) reported that no immunohistochemical 
staining of oestrogen receptor was observed after the specimen was 
treated with the anti-oestrogen (Cl-628). Dandliker et al. (1978) 
observed that there was no effect of excess competitor, DES or 
excess Eg, on the staining by fluorescent oestrogen in the incubated 
sections. This makes it impossible to differentiate definite 
binding from nonspecific binding.
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Histochemical methods of oestrogen receptor detection also face 
several minor weaknesses which need to be overcome before they can 
be of potential clinical value. Firstly, the fact that oestrogen 
receptor is a component of the soluble part of the cell may cause it 
to 'leach out' into aqueous processing media if the cells are not 
fixed. Secondly, when the cells are fixed, this might adversely 
affect the ability of the receptor to bind to E 2. Thirdly, the 
modifications of the Eg molecule, such as conjugating it to tracers 
(peroxidase or fluorescence substances) might disturb the quanti­
fication of results as, at present, there is no standardardization 
of the data collected (Alonso and Brownlee, 1981).
1.6 TECHNIQUES
1.6.1 Purification of Oestrogen Receptor
1.6.1.1 DNA-Cellulose Chromatography
Many proteins that function in association with intracellular 
DNA recognise purified DNA as a substrate and bind tightly to it at 
physiological ionic strengths in vitro. When DNA-free crude 
extracts are passed through a column consisting of DNA adsorbed onto 
an inert cellulose matrix ("DNA-cellulose"), these proteins are 
specifically retained. After an extensive wash to remove unbound 
proteins, the DNA-binding proteins are recovered in active form by
elution with buffers containing either an elevated salt
concentration, competing nucleic acids, or specific biological 
inducers. With a proper choice of conditions, the binding of 
non-DNA-related proteins to DNA can be avoided. This type of proce­
dure, discovered by Litman (1968), has been successfully used in the 
purification of glucocorticoid receptor by Westphal (1982).
1.6.1.2 Ion-exchange Chromatography
Ion-exchange chromatography is a type of adsorption chroma­
tography in which the interactions between the chromatographic
medium and the solute are based primarily on ionic charge.
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The development of ion exchangers based on cellulose 
(Peterson and Sober, 1956) or other polysaccharides were found to 
be suitable for protein separation. The most common types available 
are:
(a) DEAE (diethylaminoethyl)-cellulose, Sephadex or Sepharose; an 
anion exchange resin used primarily for neutral and acidic 
proteins.
(b) CM (carboxylmethyl)-cellulose, Sephadex or Sepharose; a cation 
exchanger used primarily for the separation of neutral and 
basic proteins.
In general, however, the major attractive force between 
proteins and these adsorbents is believed to be electrostatic (Wofsy 
and Burr, 1969). The adsorbed protein could be eluted by altering 
the pH such that either the protein or the adsorbent loses its net 
charge.
1.6.1.3 Affinity Chromatography
Affinity chromatography represents the ultimate extension of 
adsorption chromatography since it has the complete set of forces: 
Van der Waal's, hydrophobic, steric and electrostatic. These forces 
are involved in the specific binding of substrates and other ligands 
to proteins.
In affinity chromatography the ligand is attached to an 
insoluble support which is packed into a chromatographic bed. 
In principle, if a mixture comprising several proteins is applied to 
the column, only that protein which possesses appreciable affinity 
for the ligand will be retained or retarded; others which show no 
recognition of the insolubilized ligand will pass through the bed. 
The specifically adsorbed protein can subsequently be eluted by 
altering the composition of the solvent to permit dissociation from 
the insoluble ligand.
Generally speaking, the volume of the sample applied to an 
affinity adsorbent is not critical if the substance of interest has
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a high affinity for the immobilised ligand. On the other hand, 
weakly-bound proteins should be applied in a relatively small 
volume, to circumvent co-elution with the inert proteins in the void 
volume. The adsorption equilibrium between the immobilized ligand
and the macromolecule to be purified is often reached at a very slow
rate.
1.6.1.3.1 The Effect of Temperature
In general, the strength of adsorption to an affinity gel 
decreases with increasing temperature. Furthermore, the use of 
different temperatures for adsorption and elution can have very 
beneficial effects on the subsequent purification. Tight binding 
may be effected at 4°C and subsequent elution achieved under mild
conditions by raising the temperature to 25®C or above (Harvey et 
al., 1974).
After inert proteins have been washed off the column the
composition, pH, ionic strength or temperature of the buffer is 
changed and elution effected by passing the new buffer through the 
column.
1.6.1.3.2 Non-specific Adsorption
More often than not, despite the careful design of the affinity 
adsorbent, the adsorption and elution of the desired macromolecule 
does not achieve the expected specific activity. It is now widely 
recognised that this is due to non-specific adsorption of inert 
proteins to the affinity adsorbent (O'Carra et al., 1974). The 
presence of ionic groups on any chromatographic adsorbent will 
affect the elution behaviour of polyelectrolytes such as proteins. 
These interactions may generate problems of non-specific binding in 
affinity chromatography. Incomplete attachment of ligands to 
preformed matrix-spacer arm assemblies can introduce extraneous 
ionic groups into the adsorbent.
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1.6.1.3.3 The Solid Matrix Support
The solid matrix support must be given careful consideration. 
The matrix should form a loose porous network which allows the 
uniform and unimpaired entry and exit of large macromolecules 
throughout the matrix. It must possess chemical groups which can be 
activated, under conditions which do not modify its structure, to 
allow the covalent linkage of a variety of ligands. Also the solid 
support must be physically and chemically stable in the conditions 
selected for sampling, adsorption and elution.
The water-insoluble beaded derivatives of agarose have many of 
the properties of an ideal solid support matrix. They have now 
been used successfully in numerous purification procedures. They 
have a very loose structure which allows ready penetration by 
substances of molecular weight up to the order of several million. 
The uniform spherical shape of the gel particles is of particular 
significance. Also these polysaccharides can undergo substitution 
reactions by activation with cyanogen halides e.g. cyanogen bromide 
readily. They are also very stable and have a moderately high 
capacity for the substitution.
Agarose is a linear polysaccharide consisting of alternating 
residues of D-galactose and 3,6-anhydro-L-galactose (Lowe and Dean, 
1974). The agarose gels are stabilized by hydrogen bonding. Thus 
there is very little dénaturation or adsorption of sensitive 
biochemical substances because of their hydrophilic nature and 
nearly complete absence of charged groups.
1.6.1.3.4 Spacer Molecules and Steric Considerations
For a successful purification by affinity chromatography, there 
must exist a sufficient distance between the chemical group (ligand) 
and the matrix backbone to avoid the effect of steric hindrance. 
This exists if the ligand is attached directly to the matrix 
backbone. The problem can be solved by placing the ligand at the 
end of a long chain or "arm", so that it extends into the solvent.
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Cuatrecasas (1970) suggested that the effect of extension arm 
length is due to the relief of steric restrictions imposed by the 
matrix and in part by the increased flexibility and mobility of the 
ligand as it protrudes further into the solvent. The flexibility 
and folding of the extension arm could be the reason for the clear 
decrease in binding observed with longer extension arms.
However, the use of an extension arm may not be the only 
consideration involved in their use (O'Carra et al., 1973). Spacer 
units may interfere with the affinity of a ligand for a 
macromolecule, i.e. by generating a local steric interference.
1.6.1.3.5 Batchwise Adsorption
This is applicable when a small amount of protein is to be 
extracted from a large amount of inert protein with an adsorbent of 
high affinity. The purification is made possible by adding a slurry 
of the specific adsorbent to the crude mixture. It may be preferable 
to apply the sample to a product column, thoroughly wash it, then 
proceed with the elution by dismantling the column and incubating 
the matrix in an appropriate buffer.
1.6.1.3.6 Elution of Specifically Adsorbed Macromolecules
The principal of elution is to drive the adsorption equilibrium 
of the adsorbed solute from the stationary to the mobile phase. 
This can be done using either of the following methods:
(1) Displacement analysis, whereby a buffer containing a displacing
agent is applied to the column and is so strongly adsorbed 
that it expels the already adsorbed macromolecules;
(2) Extremes of pH or protein dénaturants such as guanidine-HCl or
urea can be used. Restoration of the native protein may be 
affected by neutralization or dialysis. An alternative 
approach to eluting the specifically bound protein is to 
cleave the the matrix-ligand bond selectively. This method
68
means the removal of the intact ligand-protein complex. This 
is applicable in cases where the ligands are attached to 
Sepharose by susceptible bonds such as those involved in azo,
thiol or alcohol ester linkage. Where the ligand itself is
charged, reduction of the ligand affinity for the 
complementary macromolecule can be achieved with increasing 
ionic strength. In many cases, the elution of a specifically 
adsorbed protein with a buffer containing a high concentration 
of competing ligand results in a greater elution of the 
protein (Lowe and Dean 1974). If this is done together with 
an increase in temperature, a decrease in affinity adsorption 
takes place improving the final percentage recovery still 
further (Harvey et al., 1974)
Sica et al. (1973) have shown that effective adsorbents for 
oestrogen receptors could be obtained by coupling oestradiol-1^- 
hemisuccinate to agarose derivatives containing diaminodipropyl- 
amine, serum albumin, poly - L-lysine or poly-L-lysine-L-alanine 
copolymer. Between 60 and 80% of the ££ binding protein from a calf 
uterine supernatant was adsorbed by these columns. Also, the 
adsorbents could be washed with large volumes of buffer and with IM 
KCl without release of receptor. Elution was effective during
incubation with 0.2 to 2pg per ml E2 for 15 min at 30°C. With the
best adsorbents the E^ binding protein was purified from 10,000 to 
100,000 fold with a recovery of about 50%.
1.6.1.4 Gel Filtration
Gel filtration (Porath and Flodin, 1959) is a technique of 
partition chromatography in which the partitioning is based on the 
molecular size of the substances to be separated.
The chromatographic gels used in gel filtration comprise 
macromolecules with a high affinity for the solvent. The gels are 
allowed to swell in the solvent and, in so doing, imbibe large 
amounts of the liquid. Gel filtration separates substances according 
to their molecular size; large molecules emerge from the bed first
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followed by the smaller molecules. Large molecules cannot penetrate 
into regions close to the cross-links in the gel lattice because of 
steric obstruction. In contrast, small molecules can approach these 
regions more closely and thus have access to most of the space 
between the chains of the gel matrix. As a result small molecules 
are distributed fairly evenly between the free solvent and the 
solvent present within the gel matrix, whilst large molecules are 
more restricted within the gel. The partition coefficient of large 
molecules is thus shifted in favour of the liquid outside the gel 
particles with the consequence that large molecules emerge from the 
gel bed earlier than small ones.
The solvent in a chromatographic column packed with swollen gel 
beads may be regarded as being in two phases (Flodin, 1961); in the 
spaces between the gel beads is the void volume, Vo, and entrapped 
within the gel matrix the internal volume, Vi. The Vo, may be 
determined by chromatography of a substance that is completely 
excluded from the gel beads and so is its elution volume. In 
practice, a polysaccharide with an average molecular weight of 
2x10^, Blue Dextran 2000 is commonly employed.
1.6.2 Antigens and Antibodies
Antibodies are characterised by certain physicochemical and 
biological properties. Salting-out procedures combined with column 
chromatography or Sephadex filtration have made it possible to 
isolate five main classes of antibodies usually called IgA, IgG, 
IgM, IgD and IgE depending on their antigenic properties. The IgG 
immunoglobulins have a molecular weight of 150,000-160,000 and are 
composed of two identical halves each of which contain two 
polypeptide chains: a heavy chain of molecular weight 55,000-60,000 
and a light chain of molecular weight 20,000-24,000 which are held 
together by disulphide bridges and non-covalent interactions. 
When an antibody combines with its complementary antigen, the 
binding energy is derived from the relatively weak non-specific 
attractive forces which exist between atoms, ions and molecules. 
This energy is strengthened by the effect due to the interaction
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between solvent molecules which push the antibody and antigen 
together. However, these attractive forces are effective over short 
distances only and require that the combining region of the antibody 
fit closely over the antigen to produce sufficient binding forces to 
hold the molecule together. Therefore, the specificity of the 
antigen-antibody interaction is very important for a strong 
interaction. In addition, the distribution of groups on the antigen 
must be matched by complementary groups on the antibody.
It is essential in understanding immunological reactions to 
grasp the fact that a particular preparation of antibody globulin, 
even that from a single animal immunised with 'a single antigen’ is 
a mixture of closely similar molecules and not a preparation of 
identical molecules. This is explained by the fact that most 'pure' 
antigens contain multiple sites (or chemical groups) every one of 
which gives rise to specific antibody formation.
1.6.2.1 Antigen-antibody Reaction
The quantitive nature of antigen-antibody reaction was first 
exploited by Heidelberger and Kendel (1929, 1935) who found that it 
is possible to isolate and estimate the immunoprecipitate formed by 
adding increasing amounts of an antigen to a fixed amount of 
antibody. The amount of the precipitated complex increases with 
rising quantities of antigen up to a certain point. This region of 
increasing precipitation in referred to as the interval or zone, of 
antibody excess. Above this point there is no further increase in 
precipitated complex as long as some degree of equivalence exists 
between the two reactants (zone of equivalence). With increasing 
quantities of added antigen, a so-called zone of inhibition of 
complex formation is reached (antigen excess). Here, there is a 
progressive decrease in the amount of antigen-antibody complex 
precipitated.
The antigen-antibody reaction shows temperature dependence of 
the rate of association of the two reactants between about 0-40®C. 
The reaction was maximal at a low salt concentration (Clausen,
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1970). Finally, the antigen-antibody reaction is dependent on pH, 
showing an optimum at 7.0 (Kleinschmidt and Boyer, 1952). The
immunoprecipitate is soluble below pH 4.5 and above pH 10.0.
Small changes in the thermodynamic constants and a positive 
entropy change, which may be partly related to displacement of water 
from the antibody site and partly to conformational changes in the 
reactants, occurs after establishment of the antigen-antibody
complex. These changes may be related to formation of hydrophobic 
bonds (Clausen, 1970).
The physicochemical event during the antigen-antibody reaction 
depends on the type (horse and rabbit) of antibody used. The
antigen-antibody complex formed is usually characterised by being 
soluble in excess of antigen and also, in the case of horse type 
antibody only, in excess of antibody.
1.6.2.2 Immunoblotting
Several method have been applied to determine the 
immunological reactivity of proteins after being separated by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Burridge, 1976; Renart et al, 1979; Towbin et al., 1979). Proteins 
of interest can be transferred to a nitrocellulose membrane (NCM) from 
polyacrylamide gels (Towbin et al., 1979). The polypeptides that are 
bound to the NCM can be incubated with antisera and can be localised 
by antibody labelled with a staphylococcal protein A followed by 
autoradiography of the NCM (Batteiger et al., 1982). These authors 
also report on the use of nonionic detergent Tween 20 to block the 
unoccupied protein binding sites on NCM. Other proteins such as
bovine serum albumin (BSA) or gelatin are generally used for this 
purpose (Towbin et al., 1979; Burnette, 1981; Cohen and Falkow, 
1981; Vaessen et al., 1981).
1.6.3 Biopsy Techniques.
The aim of any biopsy is to make a definitive histological
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diagnosis for treatment. It would be advantageous to both the 
patient and the surgeon if a diagnosis could be made preoperatively 
by either needle biopsy or aspiration cytology.
1.6.3.1 Frozen Sections
It has been widely accepted that frozen section histology is an 
accurate diagnostic method. In a review by Lessells and Simpson 
(see Crawford and George, 1984), they reported an accuracy of 99.4%
in 2,197 frozen section biopsies. There were 13 false negative
diagnosis, 7 due to sampling errors, and 6 due to errors of 
interpretation. One false positive diagnosis was subjected to 
an unnecessary radical mastectomy.
1.6.3.2 Fine-needle Aspiration (FNA)
The technique of FNA is simple and requires no special 
equipment. An ordinary 10ml syringe and needle are used. Constant 
suction is applied as the needle is passed through the lesion
several times in several directions to allow for tumour 
heterogeneity. The suction is then released before the needle is 
withdrawn and the contents of the needle are expelled on to glass 
slides for cytological examination. Despite its simplicity the
technique requires considerable practice before good quality samples 
can be produced consistently (Crawford and George, 1984).
The ability to interpret smears accurately required a 
considerable period of learning. The accuracy rate in the diagnosis 
of both malignant and benign lesions has been reported to be in 
excess of 95%. Like frozen sections, FNA false-positive diagnoses 
are also reported. For this reason some surgeons would not be 
prepared to consider mastectomy on a cytological diagnosis alone.
However, some reports of FNA cytology must be interpreted with 
caution. Disadvantages include unsatisfactory smears which 
lead to false positives. Also the need for an experienced cytologist 
might be the reasons why the technique is not in more widespread use
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in this country.
1.6.3.3 Tru-cut Needle Biopsy
This is a biopsy of discrete breast lesions with a large-bore 
needle. Atru-cut needle biopsy is a simple, safe procedure and it has 
the advantage of high diagnostic accuracy with no false 
positive results. Its disadvantage is false negative results often 
reported which could be due to sampling errors but this can be 
reduced with experience. It also requires a local anaesthetic and 
can leave significant bruising.
1.6.4 Modes of Application
Iramunohistochemistry can be carried out on cytological smears, 
frozen and paraffin sections, cell and tissue cultures. Frozen 
sections are used mainly for fluorescent labelled antisera, but the 
results are not permanent and peroxidase techniques on frozen 
sections or imprints often give a heavy background stain. This is 
reported to be reduced by treating the slides with 20% acetic acid 
solution prior to incubation in the primary antiserum (Colman et 
al., 1976). In smears and frozen sections both cytoplasmic and 
surface immunoglobulins are demonstrated.
In tissue sections, cytoplasmic, nuclear and interstitial 
antigens can be demonstrated. The morphological detail seen in 
paraffin sections is one of the advantages of the method.
1.6.5 Technical Aspects
1.6.5.1 Fixation
It is thought that fixation and processing may denature or 
alter the antigenicity of the tissue components, so that specificity 
and sensitivity are impaired. Prompt fixation is essential for 
consistent results, since poor fixation causes loss of antigenicity 
or diffusion of the antigens into the surrounding tissue. A wide
Ik
range of fixative may be used to demonstrate various antigens. Many 
of the antigenic determinants may be lost during fixation, but 
enough may remain to enable them to be visualised using the PAP 
technique. There is not one fixative that can be said to be ideal 
for the demonstration of all antigens. Some may still require fresh 
frozen sections. However, in general, many antigens can be 
demonstrated after fixation in formal saline, formal mercury, 
Zenker's or Bouins'. (Some antigens can be localised after osmium 
fixation. Periodate-lysineparaformaldehyde fixative gives good 
preservation of antigens and can be used for both light and electron 
microscopy).
Certain fixatives can be used only if enzyme digestion is 
carried out on the section prior to immunostaining, e.g. isotonic 
formaldehyde solutions. Other fixatives gives good results without 
the use of enzymes, e.g. formal mercury, Bouins' and Carnoy's. Very 
good results are obtained if 2 - 10% acetic acid is added to formal 
saline.
1.6.5.2 Processing
In some cases the tissues may be washed in buffer to reduced 
background staining.
Cutting
The thickness and quality of the sections is important, the 
average thickness for immunohistochemistry being 4pm Adhesives are 
not always necessary, but slides coated with chrome-gelatine or egg 
albumin solutions may be used.
Endogenous Peroxidase Blocks
Peroxidase is found under normal conditions in red blood cells 
and granulocytes. At first this endogenous peroxidase was stained 
red using alpha-napthyl pyronin, distinguishing it from the brown 
antigen/antibody complex. It is now usually inhibited before
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staining. There are a number of methods available: 0.5% H2O2 in 
methanol 30 min, 3% in water, 3-10 min periodic acid, followed
by sodium borohydride, 1% acid alcohol and methanol/picric acid. 
Probably the most commonly used blocking method is hydrogen 
peroxide/methanol. Some tissue antigens may be sensitive to 
blocking agents in which case it is best to leave the sections 
blocked.
Antisera and Dilution
To obtain the best possible results the antisera must be used 
at the correct dilution. This is found by carrying out a range of 
dilutions on the same tissue, with all other steps being constant. 
A compromise is made between the staining of the positive cells and 
background, to get a clear picture. Each time a new batch of 
antisera must be titrated to find its optimum dilution. Too strong 
a solution will result in a false negative - a prozone effect. Most 
antisera are incubated on the sections for 30 min at room 
temperature. However, some antisera may require longer periods of 
incubation, in which case they are left at 4®C for anything up to 
24h. It is possible that incubating the sections at 37*C will 
shorten the incubation time.
Controls
Any immunological staining will be only as good as the 
antibodies used. Many antisera contain impurities causing 
cross-reactions. However, with most other antisera controls must be 
carried out as follows, to obtain a meaningful result:
1. Replacement of the primary antiserum with a normal serum of the 
same species.
2. Replacement of the primary antiserum with another primary 
antiserum directed against a different antigen.
3. Absorption of the primary antiserum with purified antigen.
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The last is the most useful specificity control if the purified 
antigen is available. The antigen must be pure enough to prevent it 
absorbing out both wanted and unwanted binding; giving a false 
impression of monospecificity.
1.7 OBJECTIVES
Studies utilizing radiolabelled E^ had demonstrated that the 
soluble oestrogen receptor found in oestrogen responsive tissue 
bound the hormone with high affinity and transported it to the 
nucleus (Muldoon, 1980). Steroid conjugated to fluorescent compounds 
or anti-oestradiol antibody are all tools that have been applied for 
studying the intracellular distribution and translocation of the 
oestrogen binding proteins (Nenci et al., 1976, 1981; Pertchuk et
al., 1978, 1979, 1980; Lee 1978, 1979, 1981). However these tools are 
still in the investigational stage and their relation to 
physiological receptor is unclear (Morrow et al, 1980; Mercer et 
al., 1981). Antibodies that are specific to the oestrogen receptor 
are the most suitable means of determining the distribution and 
concentration of the receptor in the cells.
The main objective of this study was to obtain anti-oestrogen 
receptor antibodies and use these antibodies as a tool in 
investigating the receptor distribution, quantification and 
translocation at cellular level. The antibodies are produced from a 
rabbit immunized with affinity purified oestrogen receptor of human 
origin. The next step in the study was to find out the specificity 
of the antibodies towards oestrogen receptor. The aims of the study 
were:
1) to investigate how far the antibody could provide infor­
mation on the oestrogen receptor distribution, quantifi­
cation and translocation,
2) to investigate the correlation of the antibody technique
with the standard biochemical method (DCC),
3) to investigate the heterogeneity of the oestrogen receptor
in the tumour specimen,
4) to assess the clinical value of the antibody in studying
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breast tumour fine needle aspirates (FNAs) taken from breast 
cancer patients at out-patient clinic.
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MATERIALS AND METHODS
2.1 REAGENTS
2.1.1 Fine Chemicals
Acrylamide and Bis-acrylamide
Ammonium persulphate
Ammonium sulphate
Bovine Serum Albumin (fraction V)
DEAE-Cellulose
DEAE-Sepharose
Deoxyribonucleic acid (DNA)-Cellulose 
(calf thymus type V sodium salt, 
highly polymerized)
Dextran blue 
Dextran T70
Dimethyl Formamide (DMF)
Dithiothreitol (DTT)
Ethanolamine
Freund complete and incomplete adjuvant 
Human-J-Globulins (fraction II) 
Methanol, ethanol, ethylene glycol, 
acetone, isopropanol, isopentane 
Norit A activated charcoal (untreated) 
Oestradiol-1^ 17-Hemisucciny 1-Albumin 
Sephadex G25 
Sepharose-4B
Sodium molybdate (AnalaR)
Sodium thiocyanate 
Sucrose (AnalaR)
TEMED
Trichloroacetic acid (TCA)
Sigma, London 
Sigma, London 
Sigma, London 
Sigma, London 
Pharmacia, Sweden 
Pharmacia, Sweden
Sigma, London 
Sigma, London 
Pharmacia, Sweden 
Sigma, London 
The Boehringer Corpora­
tion (London) Ltd.
Sigma, London
Difco Laboratories, Detroit 
Sigma, London
Fisons, England 
Sigma, London 
Sigma, London 
Pharmacia, Sweden 
Sigma, London 
BDH chemicals Ltd.,
England 
Sigma, London 
Sigma, London 
Sigma, London 
Koch-Light Laboratories
Unless otherwise stated, all other chemicals used were of AnalaR 
grade, supplied by BDH chemicals Ltd., England.
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2.1.2. Buffer reagents
Hydroxypiperazine-N'-2-ethane Sulphonic acid (HEPES) was obtained
from The Boehringer Corporation (London) Ltd.
Tris (hydroxymethyl) aminothane was obtained from Sigma, London.
2.1.3 Steroids
Steroids prepared in 95% alcohol were stored at -20°C for up to 6 
months.
Oestradiol 17p, progesterone, and cortisol were obtained from 
Sigma, London.
2.1.3.1 Radioactive Ligands
[2,4,6,7-3h ] Oestradiol-17 , specific activity 101 Ci/mmol
[3H]-dehydrotestosterone, specific activity 105 Ci/mmol
[^Hj-ORG 2058, specific activity 45 Ci/mmol
All these radioactive ligands were obtained from the Radioche­
mical Centre, Amersham, now Amersham International.
2.1.3.2 Competitor for Receptor Analysis
Diethylstilboestrol (DES) was obtained from Sigma, London.
2.1.4 Radioactive Sedimentation Markers
[14c]-iabelled BSA (4.6S), molecular weight 69,000 and speci­
fic activity 58-60 pCi/mg was obtained from the Radiochemical 
Centre, Amersham.
[^^C]-labelled human-^-globulin (7.IS), molecular weight 150,000 
and specific activity 11.5-26.9 pCi/mg was obtained from New 
England Nuclear, Southampton, U.K.
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The sedimentation constants were taken from Fazekas and MacFarlane 
(1980) and S represents Svedberg Units (IS = 10 *^sec).
2.1.5 Scintillation Materials
The following materials were obtained from Koch-Light Laboratories, 
Colnbrook, England.
Toluene (AnalaR grade)
2,5-diphenyloxazole (PPG)
1,4-di-[2-(5-phenyloxazolyl]-benzene (POPOP)
Triton X-100 was obtained from Rohm and Haas, Croydon, England.
2.1.6 Livestock
Livestock used were mature (250-280g) and immature (16-21 days old) 
female Albino Wistar rats (Glasgow University Colony), and mature 
( 3 - 6  months old) New Zealand white rabbits.
2.1.7 Human Tissue
2.1.7.1 Normal Uterine Tissue
Normal human uterine tissue was kindly supplied by the following 
hospitals:
Victoria Infirmary, Glasgow 
Western Infirmary, Glasgow 
Royal Infirmary, Glasgow 
Stobhill General Hospital, Glasgow 
Southern General Hospital, Glasgow
2.1.7.2 Human Breast Tumour Tissue and Fine Needle Aspirates (FNA)
Human breast biopsies and FNAs were obtained from the Western 
Infirmary and the Royal Alexandria Infirmary, Paisley.
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2.1.8 Immunochemicals
Normal goat serum was obtained from the Scottish Antibody 
Production Unit (SAPU).
Goat anti-rabbit IgG was obtained from Miles.
Fluorescein conjugated Goat anti-rabbit IgG was obtained from 
Miles.
2.1.9 Buffers
2.1.9.1 Phosphate Buffered Saline (PBS-A) (without Calcium and Magne­
sium) , Tris-EDTA-DTT (TED) and Hepes-EDTA-DTT (HED)
For PBS, these salts were dissolved (w/v) in distilled water:
NaCl 0.8%, KCl 0.02%, NSgHPO^ 0.115%, KH^PO^ 0.02% , pH=7.2.
For TED, these chemicals were dissolved in distilled water:
Tris-HCl lOmM, EDTA ImM and dithiothreitol (DTT) ImM, pH*7.5.
For HED, thé following chemicals were dissolved in distilled water;.
HEPES lOmM, EDTA 1.5mM and DTT 0.5nM, pH=7.4.
2.1.10 Supplements
2.1.10.1 Bovine Serum Albumin (BSA)
A stock solution of BSA 10 % (w/v) in PBS-A was prepared. The pH 
was readjusted to 7.2 and stored at -20°C, in 1ml aliquots.
2.1.11 Serum
Foetal calf serum (PCS) was purchased from either GIBCO or Flow. 
This was either used as supplied, or was treated with dextran 
coated charcoal (DCC) (see below)
2.1.11.1 Heat Inactivated Charcoal Stripped Foetal Calf Serum 
(HIDCCFCS)
FCS was heat inactivated at 56°C for 30min, during which the 
temperature was monitored continuously. This heat inactivated
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serum was then cooled to 4°C.
Norit-A charcoal 2.5% (w/v) and dextran T-70 0.025% (w/v) were
added to PBS-A and stirred gently at 4"C for about 16h. The 
DCC was pelleted by centrifugation (lOOOxg, lOmin, 4®C) and the 
supernatant discarded. The pellet was resuspended in 10 times its 
original volume of precooled heat inactivated FCS, then stirred 
continuously for >16h at 4°C. Most of the DCC was removed by 
centrifugation. The remainder was removed by millipore 
filtration: 0.8, 0.45 then 0.2pm filters, filter sterilised and
stored at -20*C.
2.1.12 Fixatives and Staining
2.1.12.1 Trichloroacetic Acid (TCA) for PAGE
A solution of TCA 50% (w/v) was prepared in distilled water.
2.1.12.2 Staining Solution
Coomassie brilliant blue solution (0.1%) was made up fresh in 50%
TCA. The destaining solution contained 7.5% acetic acid and 5% methanol
2.1.12.3 Fixatives for Cytological Specimens
Acetone (100%) was kept at -20*C.
MethanollAcetone (1:1) made before use and kept in ice.
Ethanol 100% was kept at 4°C
2.1.12.4 Hoechst 33258
Hoechst 33258 was obtained from Sigma, London. A stock solution of
Img/ml was made in PBS and kept at -20®C. A working solution of
Ipg/ml was made just before use.
2.1.13 Miscellaneous
Photographic film 'Ectachrome' daylight was obtained from Kodak.
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Polystyrene tubes used in the receptor assay, and specimen jars 
used for human tissue collection were obtained from Sterilin Ltd., 
Teddington, England.
Cellulose nitrate tubes for sucrose density gradient analysis were 
supplied by Beckman, RIIC Ltd., High Wycombe.
Glass microfibre filter discs (GF/C 2.5cm diameter) were obtained 
from Whatman Ltd., England.
Glassware was washed and rinsed in glass distilled water, as the 
presence of divalent metal ions have been reported to affect the 
receptor measurements (Laing, 1980). All glassware which came 
into contact with human tissue was treated overnight with 
Kirbychlor, obtained from Kirby Pharmaceuticals, Suffolk, England.
All solutions were made in glass distilled water.
2.2 DEVELOPMENT LEADING TO THE FINAL PROCEDURE OF OESTROGEN RECEPTOR 
PURIFICATION
2.2.1 Tissue Handling
2.2.1.1 Collection
Tissue was collected fresh from the operating theatre and
transported on ice in a sterile container.
2.2.1.2 Storage
The fresh uterine and breast cancer tissues, if not used straight 
away were either stored in sucrose/glycerol at -20°C (Crawford at al.,
1984) or chopped up into fine pieces, frozen in liquid nitrogen and
stored in -70®C until used.
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2.2.2 Assay of Oestrogen Receptor in Uterine Tissue
2.2.2.1 Cytosol Preparation
The tissue stored in sucrose/glycerol at -20® was rehydrated in 
TED for 15min at 4®C and then dissected free of mucus and mesentry. 
Frozen tissue was thawed prior to use. Five gm of tissues was then 
homogenized in 5 volume TED (section 2.1.9), 2xl5sec burst with Ultra-' 
Turrax at a setting of 150, with Imin cooling periods. This rough 
homogenate was then further refined using a glass/glass homogenizer 
(Leake et al.,1981a). The temperature of the homogenate was maintained 
below 8°C at all times, as warming the homogenate results in receptor 
loss (King, 1979). The homogenate was then centrifuged at 105,000xg 
in a Beckman 60 Ti rotor for 30min at 4°C. The clear supernatant was 
carefully decanted, avoiding the thin layer of fat. The protein 
content of the cytosol was measured according to the method in section
2.2.2.7 and the final protein concentration was usually in the range 
of 3-8mg/ml.
2.2.2.2 Preparation of [3H]-0estradiol-1^9 Solutions ([^H]E2)
Stock [^H]E2 was prepared to a concentration of 10“^M in 
absolute alcohol and stored at -20*C. Appropriate amounts of the 
stock solution were aliquoted into small bottles in two batches to 
give the range of 4 - 40 x 10”^® M. Into the second batch 
of aliquots were added an equal volume of DES (10 stock solution) 
in absolute alcohol. The alcohol was evaporated in a stream of 
compressed air or nitrogen and the [^lEg and [^HjEg+DES redissolved 
in the TED buffer. The batch containing the 100-fold excess DES, is 
for determining the non-specific binding.
2.2.2.3 Incubation of Soluble Fraction (Cytosol) with Steroid
Fifty pi of each of the E2 solutions prepared as above were mixed 
with 150pl aliquots of cytosol. This gave a final range of 
concentrations of steroid in the tubes of Ix, 1.5x, 2x, 4x, 6x,
8xlO” *^^ M and 10"^ M [3h ]Eo±DES. A set of control tubes to give total
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values was also set up for the cytoplasmic assay which were identical 
to those above except that TED buffer was substituted for cytosol. The
mixtures were incubated at 4®C for 16-18h.
2.2.2.4 Dextran Coated Charcoal Solution (DCC)
DCC solution was prepared by resuspending Norit A charcoal and 
dextran T-70 in TE containing 0.25M sucrose to final concentrations 
of 0.15% (w/v) Norit A charcoal and 0.0015% dextran T-70. A DCC solution 
containing 0.5% (w/v) Norit A charcoal and 0.005% dextran T-70 was
also made.
2.2.2.5 Separation of Unbound from Bound Steroid by DCC Adsorption
At the end of the incubation 900pl of buffer was added, 200 pi 
from the ’totals' tubes were counted for total activity and 500 pi DCC 
solution, as prepared in section 2.3.2.4, was added to each of the 
other tubes. After leaving at 0®C for 15min with periodic mixing, the 
charcoal was pelleted at 2xl000g for 5min at 4®C. One ml of the
supernatant counted was in 10ml Triton toluene scintillant.
2.2.2.6 Radioactivity Counting
Radioactivity was measured in a Searle Mk III liquid scintil­
lation spectrometer. Scintillant contained 1400ml toluene/PPO 
(5g/l)/P0P0P (0.24g/l):600ml Triton-XlOO:200ml absolute alcohol. The 
counting efficiency of a 1ml aliquot mixed with 10ml of scintillation 
cocktail was 30%.
2.2.2.7 Protein Determination
Protein concentrations were estimated with bovine serum albumin 
as the standard using the BIORAD assay based on the method of 
Bradford (1976). The standard curve was set up using duplicate 
standards of 0, 10, 20, 40, 60 and 80 pg/ml.
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2.2.2.8 Expression of Results
The receptor level and the dissociation constant were calculated 
using Scatchard plot analysis (Scatchard, 1949) and the final receptor 
concentration was expressed as fmol/mg cytosol protein.
2.2.3 Polyacrylamide Gel Electrophoresis
The first attempts in the purification of the oestrogen receptor 
used polyacrylamide gels. Protein separation were done on 4 % 
polyacrylamide tube gels using the continuous Tris-borate-EDTA 
buffer system (Raam et al., 1981).
2.2.3.1 Preparation of the Gels and Buffers
The gel/electrode buffer was the Tris-borate EDTA buffer (0.09M 
Tris, 0.09M Boric acid, 0.0025M EDTA pH=8.9). A 4% gel was prepared 
from a stock solution of 16% by weight of acrylamide and 0.8% of 
N,N'-bis-methylene acrylamide prepared in borate buffer. Insoluble 
material was removed by filtration through Whatman No.l filter paper. 
The stock solution was kept in the dark at 4*C.
To polymerise the gel, TEMED and ammonium persulphate were added. 
Two hundred pi TEMED and 140mg ammonium persulphate were dissolved in 
100ml buffer. From the above solution 4% gels were made in the 
following proportions, gel stock solution :TEMED:ammonium persulphate 
(1:1:2).
2.2.3.2 Preparation of Samples
Oestrogen receptor positive cytosol, from breast cancer biopsies, 
as determined in the laboratory by routine DCC analysis, were used. 
The cytosols were either labelled with E2 or at a concentration
of lOnM. Before the sample was loaded onto the gel, 3 parts of cytosol 
was mixed with 1 part of sample buffer (50% sucrose in HED buffer 
pH=7.4 and 0.1% bromophenol blue). A lOOpl aliquot was layered onto the 
surface of each gel and electrophoresis was run at 2mA/gel* Human 
uterine cytosol and known molecular weight markers , (240K, 68K, 45K)
were also run.
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2.2.3.3 Preparation of Immunogen
One gel was sliced horizontally into 2mm discs. These were 
counted to locate the labelled protein (oestrogen receptor). The 
corresponding position from the other eleven gels was then removed. 
These portions were pooled, frozen in liquid nitrogen and ground to 
a fine powder which was mixed with complete Fruend's adjuvant for 
primary injection and incomplete adjuvant for booster injections. In 
this experiment Balb c mice were used. Due to the small amount of 
antigen, the experiment was not successful.
2.2.4. Procedure for DNA- Cellulose Chromatography
Chromatography was then used in the next attempt at 
purification. Five gm of DNA cellulose (4.1mg DNA/gm DNA cellulose) 
was equilibrated in TED buffer overnight. It was packed into a 
column (IxlOcm)and the column was washed with 2x50ml TED. Samples 
(100ml cytosol) prepared in this buffer (as described in section 
2.2.2.1) were labelled by incubating with lOnM E2 overnight and the 
unbound steroid was removed by DCC (section 2.2.2.4) pelleted from 
0.15% DCC solution. The sample was heated to 30®C for 30min and 
applied to the packed columns using a peristaltic pump, followed by 
a 200ml wash with TED buffer. Buffer containing 0.2M KCl (50ml) was 
passed through to salt extract the DNA bound receptor. Fractions 
(2ml) were collected at lOml/h, and 0.1ml of each fraction was used 
for radioactivity measurement and a graph of cpm versus fraction 
number was constructed. Protein concentration was measured using 
absorbance at 280nm and protein under the radioactive peak was 
measured using the dye method (section 2.2.2.7). The fractions under 
the peak (20ml) were pooled, dialysed overnight in O.OIM phosphate 
buffer pH=7.4 at 4®C and applied to the ion-exchange column, as 
prepared in the next section (2.2.5).
2.2.5 DEAE Sepharose Ion Exchange Chromatography
Microgranular DEAE sepharose was equilibrated in TED buffer 
overnight and packed into a column (lx4cm). Pooled, dialysed sample
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(from section 2.3.4) was applied to the packed column followed by a 
150ml wash with the TED buffer. Buffer containing 0.13M KCl was 
then introduced to extract the receptor. Fractions (2ml) were 
collected at 20ml/h, and 0.1ml of each fraction was used for 
radioactivity measurement. Protein concentrations were measured at 
280nm absrobance and proteins under the radioactive peak were 
measured using the dye method (2.2.2.7). A graph of cpm versus 
fraction number was constructed and the fractions under the peak 
(20ml) were pooled and subjected to phenyl sepharose hydrophobic 
chromatography.
2.2.6 Hydrophobic Chromatography
The phenyl sepharose was equilibrated in TED overnight and 
transfered to a column (1x5cm). The fractions containing the
oestrogen receptor from the DEAE sepharose column was passed
through the phenyl sepharose column at the rate of lOml/h with the 
help of a peristaltic pump. This was followed by a 500ml wash with 
TED. The receptor was eluted in 2ml fractions using ethylene
glycol:TED;glycerol (40:30:30) at the rate of lOml/h. A 0.1ml
fraction was counted in triton-toluene scintillant for radioactivity 
to calculate the degree of purification of the receptor as well as 
to determine the position of the peak. Protein concentrations were 
measured at 280nm absorbance and the proteins under the peak were 
measured using the microassay of the dye method (section 2.2.2.7). 
The overall purification procedure is shown in Figure 6.
2.2.7 Affinity Chromatography
2.2.7.1 Preparation and Washing of Oestradiol—1^8 17-hemisuccinyl- 
albumin-Sepharose 4B
Oestradiol-1^ 17-hemisuccinnyl-albumin-sepharose 4B (Eg-Succ- 
Alb-Sepharose) the structure as shown in Figure 7, was prepared 
according to the method described below (Figure 8). All the 
procedures were carried out at room temperature unless otherwise 
stated. Cyanogen bromide-activated Sepharose-4B (1.5gm) was swollen
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Figure 6: Flowsheet for the Overall Purification Procedure
of Oestrogen Receptor Involving DNA Cellulose, 
DEAE Sepharose and Phenyl Sepharose
Activated [^HjEg-receptor from human uterine cytosol 
was applied to DNA-cellulose column. The column was 
washed with 2x50ml TED. Bound receptor was eluted with 
0.2M KCl and subjected to the next purification step
\ /
The receptor
containing fractions 
from DNA-cellulose 
were loaded onto 
a DEAE Sepharose 
column. Bound
receptor was eluted 
with 0.13M KCl
Protein concentration 
and radioactivity de­
termined
Fractions eluted 
from the DEAE 
sepharose were
transferred onto 
a phenyl Sepharose 
column. Bound
receptor was eluted 
with ethylene
glycol:TED:glycerol 
(40:30:30)
Protein concentration 
and radioactivity de­
termined
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Figure 8: Flowsheet for the Preparation of the Affinity
Resin.
1.5g CNBr-Sepharose 4B + 2mg E 2'Succ-Alb in 
10ml 0.2m NaHCOj and 8M urea at pH=9
V
Mixture rotated end-over—end overnight at 4®C
V
Filter gel and filterate assayed 
spectrophotometrically at 280nm. Protein 
bound vas measured as the difference of input 
and filtrate
Wash gel with 200ml 1 M NaCl and 200ml H2O
V
Inactivate the remaining active sites by 
washing in 50ml of IM ethanolamine in 0.2M 
NaHCOg buffer overnight at 4°C
\/
Wash gel with 300ml IM NaCl and 200ml HgO
V
Resulting affinity gel was washed thoroughly 
with 2.5L of 80% methanol
V
Prior to use the affinity gel was washed with 
TED (lOOml/ml gel)
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in 500ml of ItnM HCl (to preserve the reactive groups) for 30min. 
Using a scintered glass filter, the resin was washed with the acid 
solution and once with coupling buffer [(0.2M NaRCOg and 8M urea 
pH=9.0) (5ml/gm gel)]. The washed gel was immediately transferred to 
the solution containing 2mg of oestradiol-hemisucciny1-albumin 
(E^-Succ-Alb) dissolved in 20ml of coupling buffer. The higher pH is 
chosen as the coupling reaction proceeds most efficiently in the pH 
range 8-10 where the amino groups on the ligand are predominantly in 
the unprotonated form. Coupling at low pH is less efficient. The 
mixture containing ligand and the swollen gel was rotated 
end-over-end overnight at 4°C. The complex was filtered through the 
scintered glass and the protein reading of the eluate was taken to 
ensure more than 90% binding. The resulting gel (4ml) was washed 
with IN NaCl (100ml). The remaining active groups were blocked by 
incubating the gel with (50ml) IN ethanolamine overnight at 4°C.
The excess adsorbed protein and the blocking agent were washed 
off with coupling buffer followed by 300ml of IN NaCl. The resulting 
gel was washed thoroughly with methanol (2.5-31) to remove the 
loosely bound steroid and kept in methanol (80%) until use. The 
concentration of Eg-Succ-Alb is 0.3-0.5 pmol/ml of gel. Prior to use 
the affinity resin was washed with TED (lOOml/ml gel).
2.2.7.2.Stability Testing of Affinity Adsorbent
Breakdown of the E2~Succ-Alb-Sepharose used during chromato­
graphy could lead to leakage of Eg-Succ-Alb or Eg into the incuba­
tion medium. Checks on hormone leakage after incubation with 
cytosol were carried out as follows:
Twenty five ml human uterine cytosol, as prepared in section
2,2.2.1, was incubated with the gel (1.5ml gel). The gel was 
separated from the cytosol by centrifugation at lOOOg for lOmin. An 
aliquot (5ml) of the supernatant was extracted with ether (2xl0ml). 
Evaporation of the ethereal extract resulted in a residue which was 
soluble in 0.2ml of dimethylformamide:water (1:1, v/v). Aliquots 
(20pl) of this solution were added to 0.5 ml of fresh rat uterine
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cytosol prepared in the same way as the human cytosol but incubated 
with [^HjEg (InM) prior to use. Control incubation consists of rat 
cytosol only incubated with the same concentration of [^HjEg. Binding 
inhibition was measured by comparison of the binding in both cases. 
If a significant quantity (more than 10% inhibition) of free hormone 
was detected, the affinity resin was washed again with large volumes 
of methanol.
2.2.7.3 Affinity Chromatographic Procedure
2.2.7.3.1 Preparation of Human Uterine Cytosol and Ammonium Sul­
phate Precipitation
Homogenates from lOOg of human uterus were prepared (as described 
in section 2.2.2.1). To the high speed supernatant, potassium chloride 
was added to a final concentration of 0.4M, followed two hours later 
by calcium chloride to a final concentration of 4mM. The solution was 
incubated for 45 min at 4*C to convert the oestrogen receptor to the 
4.5S form (Sica et al., 1973). An aliquot of the supernatant was
assayed for oestrogen receptor while treating the rest with ammonium 
sulphate.
Ammonium sulphate precipitation was carried out by slowly adding 
0.144 g of finely powdered salt per ml (25% saturation) with 
continuous magnetic stirring. The suspension was centrifuged (4*C) for 
20min at 18,000xg. The precipitate was dissolved in a volume of 
TEDKg 2' Undissolved material was removed by centrifugation for 3Qmin 
at 105,000 xg in 60 Ti rotor in Beckman L2-65B ultracentrifuge.
The clear supernatant (100ml) was mixed with the affinity resin 
and the suspension was either rotated end-over-end at the speed of 
Irpm or applied into a column and recirculated overnight at 4®C using 
a peristaltic pump. The column was then washed with 0.5L of TED con­
taining O.OIM KCl (TEDKq .o i )» with 0.5L of TED with 0.4M KCl (TEDKg^) 
and 0.5L of TED containing l.OM KCl (TEDK^ g) the order as shown in 
Figure 16 (section.3.2.2). The bound receptor was eluted from the
column with lOpM DES in 8ml (2xvolume of affinity resin) TED buffer 
containing in O.AM KC1,0.5M NaSCN and 10% dimethylformamide. The 
elution was carried out either at 4"C overnight or 30°C for 15min. 
In three experiments the receptor was eluted from the column by 
using IpM [^HjEg (Figure 16). Aliquots were pooled and desalted 
through Sephadex G-25 (fine), lyophilized and analysed by SDS-PAGE, 
heat exchange assay (section 2.2.8) and for protein concentration.
2.2.8 Heat Exchange Assay (Assay of Oestradiol Receptor Binding 
Activity)
The purpose of this assay was to check the binding activity of 
the above eluted proteins by exchange assay i.e. by incubating with 
[3h]E2. This assay was based on the separation of oestradiol- 
receptor complexes from free £2 by gel filtration on Sephadex G-25 
(Puca et al., 1971). The sample to be tested (0.1 to 0.3ml) 
was adjusted to a volume of 1ml by the addition of 10 mM Tris-HCl, 
pH 7.5, containing lOmM KCl, ImM EDTA, lOnM of [%]E2, and a trace 
of blue dextran (as a marker). The mixture was incubated at 4®C for 
6h, and the free and the macromolecular bound E2 components were 
separated by passing the mixture over a Sephadex G-25 column (diameter 
1.0cm; total volume, 10ml and flow rate, 0.5ml/min). The 
protein-bound hormone appeared in the first macromolecular peak 
together with the excluded dextran blue Vo, while the free hormone 
appeared very late as a peak which emerged after the included volume 
of the column. The excluded peak was collected, pooled, and 
examined for oestrogen receptor content. Under these conditions of 
gel filtration,nonspecific binding of E2 was negligible (Puca et 
al., 1971). Nonspecific binding of E2 was the relatively low 
affinity E2 binding by macromolecules other than receptors. The 
binding of E2 to such molecules was directly proportional to the 
concentration of E2 and was not experimentally saturable with 
respect to the steroid.
The specific binding of E2 to receptor proteins is destroyed 
by exposure to a temperature of 65°C, whereas nonspecific binding is 
actually enhanced by this treatment (Puca et al., 1973). All
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oestrogen-binding proteins eluted from affinity columns were 
therefore examined for thermolability properties. The sample, in 
0.1 to 0.3ml of water, was heated at 65°C. The sample was quickly 
cooled to 4*C, and the oesradiol-binding activity was determined by 
gel filtration.
2.2.9 Checking the Purity of the Affinity Eluate on Acrylamide Disc 
Gel Electrophoresis
2.2.9.1 Preparation of Gels
The method as described by Laemmelli (1970) was followed with 
some modifications. The stacking gel (3% acrylamide) and the 
separating gel (5% acrylamide) were prepared from a stock solution 
of 30% by weight of acrylamide and 0.8% by weight of 
N,N'-bis-methylene acrylamide. Insoluble material was removed by 
filtration through Whatman No. 1 filter paper. The solution was kept 
at 4*’C in a dark bottle. The gels were polymerized chemically by the 
addition of tetramethylethylenediamine (TEMED) and ammonium persul­
phate.
In the separation gel the final concentration of Tris was 
0.375M Tris-HCl (pH 8.8) and 0.1% SDS (w/v). The 3% stacking gel of 
1cm, contained 0.125M Tris-HCl (pH 6.8) and 0.1% SDS and was 
polymerized chemically in the same way as for the separating gel. 
The electrode buffer (pH 8.3) contained 0.025M Tris, 0.192M glycine 
and 0.1% SDS,
The samples (0.2-0.3ml) contained a final concentration ("final 
sample buffer") of 0.Û625M Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 
5% 2-mercaptoethanol, 0.001% bromophenol blue as marker dye and
O.Olmg of loaded protein per gel. The proteins were completely 
dissociated by immersing the samples for 1.5min in boiling water.
The glass gel tubes were 15cm long with an inner diameter of 
6mm. Before use they were soaked in cleaning solution, rinsed, and
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oven-dried. For a typical run of 12 gels, 15ml of gel buffer was 
deaerated and mixed with 13.5ml of acrylamide solution. After further 
dearation, 1.5ml freshly made ammonium persulphate solution 
(15mg/ml) and 0.045ml of TEMED were added. After mixing, each gel 
tube was filled with 2ml of the solution. Before the gel polymerised 
a few drops of water were layered onto the top of the gel solution. 
After 20 to 30min an Interface could be seen indicationg that the 
gel had polymerised. Gels with a normal amount of cross-linkage 
remained clear, those with double cross-linkage turned opaque. Just 
before use the water layer was sucked off, and replace by gel 
buffer. The tubes were placed in the electrophoresis apparatus. The 
two compartments of the electrophoresis tanks (made by Mr. Harvey, 
Glasgow University) were filled with electrode buffer.
2.2.9.2 Running the Gel Electrophoresis
Usually O.Olmg protein was applied per gel. The amount could be 
lowered if the gel was stained for a longer period. If O.lmg was 
applied, although the trailing edge of the band was diffuse, the 
leading edge was still very sharp and the molecular weight could 
still be found very accurately. For each standard solution/purified 
receptor, 3pl of tracking dye (0.05% Bromophenol blue in water), and 
50pl of sample buffer was mixed in a small test tube or eppendorf 
tube. Then 10-50pl of the protein solution were added (final 
concentration of protein of O.Olmg/SOpl). After mixing, the tubes 
were immersed in boiling water for 1.5min. Fifty pi of the sample 
solution was carefully applied on the gel.
Electrophoresis was carried out at a constant current of 4mA 
per gel with the positive electrode in the lower chamber. Under 
these conditions the marker dye moved three-quarters of the way 
through the gel in approximately 4h.
After electrophoresis, the gels were removed from the tubes by 
squirting water from a syringe between the gel and the glass wall 
and using a pipette bulb to exert pressure. The length of the gel 
and the distance moved by the dye were measured. The proteins were
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fixed in the gel with 50% trichloroacetic acid (TCA) for Ih before 
staining for Ih at 37°C.
2.2.9.3 Staining and Destaining
The staining solution was prepared by dissolving 1.25 g of 
CooTOassie brilliant blue in a mixture of 454ml of 50% methanol and 
46ml of glacial acetic acid and removing the insouble material by 
filtration through Whatman No. 1 filter paper. The gels were put 
into test tubes filled with staining solution and stained for 2h at 
room temperature. The gel were removed from the staining solution, 
rinsed with distilled water, and placed in destaining solution (75ml 
of acetic acid, 50ml of methanol, and 875ml of water) for 2h. The 
length of the gels after destaining and the positions of the blue 
protein zones were recorded. The gels were stored in 7.5% acetic 
acid solution.
2.2.9.4 Calculation of Molecular Weight
The gels swell some 5% in the acid solution used for staining 
and destaining (Weber and Osborn, 1975). Gels with a lower amount 
of cross-linkage showed more swelling (low % gel). Therefore the 
calculation of the mobility has to include the length of the gel 
before and after staining as well as the mobility of the protein and 
of the marker dye. Assuming even swelling of the gels, the mobility 
was calculated as.
Mobility =
Distance of protein migration 
Length after destaining
Length after staining
X
Distance of dye migration 
For slab gel» the same procedure as disc gel was carried out 
except that the amount of solutions used were adjusted according 
to the size of the glass plate.
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The mobilities were plotted against the known molecular weight 
markers expressed on a semi-logarithmic scale. The standard proteins 
of known molecular weight used were: 90,000, 68,000, 45,000, 30,000, 
20,000 obtained from Boehringer Mannheim.
m
2.3 IMMUNIZATION
The purified oestrogen receptor was then ready to be used as an 
antigen in New Zealand white rabbits. Rabbits were chosen because 
they are relatively inexpensive, are easy to handle, and more than 
adequate volumes of serum may be bled from them on a weekly basis.
The principle of immunization is the administration of a 
water-in-oil emulsion containing the immunogen intradermally over a 
wide area on a particular part of the experimental animal. The 
purpose is to stimulate as many lymph nodes as possible in the 
stimulation of antibody production (Vaitukaitis, 1981).
The water-in-oil emulsion to be injected is prepared as 
follows. The purified oestrogen receptor complex (20-30pg) was 
first dissolved in PBS at pH=7.2. An equal volume of that solution 
is combined with Freund's complete adjuvant for primary
immunization. Freund's complete adjuvant contains 2mg/ml of 
heat-killed tubercle bacillus with Mycobacterium. The Mycobacterium 
is usually present as a precipitate in a small spot on the side or 
bottom of the vial. It may be suspended with gentle tapping. For 
subsequent booster injection, the immunogen was injected in the same 
volume of Freund's incomplete adjuvant. This does not contain
Mycobacterium but 5mg of heat-killed tubercle bacillus per 2ml of 
the emulsion. To form a good emulsion, an Ultra-Turrax was used at 
its maximum setting for 5xl5sec with intermittent cooling (Imin) 
until the reaction mixture thickens and forms peaks when stroked 
with a glass rod or spatula. The aqueous and oil phases of the 
preparation should not separate on standing. Usually the
syringe-transfer technique does not result in good émulsification 
of the reagents.
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The plunger of a syringe was removed and the barrel filled with 
the emulsion. The plunger was then re-inserted. The calibrated 
syringe facilitates the injection of 0.1-0.2ml administration per 
site. A total of 2ml of the emulsion was prepared to be injected at 
multiple sites (12-17 sites), subcutaneously usually with a 21-gauge 
needle.
The primary injection was followed by six subsequent booster 
injections over a period of 8 months (October 1983 - May 1984).
Three animals were injected. The sera were screened at 6-8 weeks 
after the primary immunization. When the antibody was detectable, 
the animal was bled forthnightly and the antisera assessed for 
titre (antibody concentration) and sensitivity (affinity). Two 
rabbits gave high reactivity with cell components (reacted with both 
positive and negative oestrogen responsive tissue) but very low 
specificity towards the oestrogen receptor (determined by the 
immunoprécipitation method). Only one animal (rabbit number 13) had 
a significant antibody titre and specificity towards the oestrogen 
receptor. This was first evident 3 months (January 1984) after 
the initial immunization. Blood was collected at 14 day intervals 
from the marginal ear vein.
2.3.1 Screening of Antisera
Screening the antisera can be done using ELISA solid-phase 
assays(Enzyme Linked Immuno Sorbent Assay). The chequerboard ELISA 
is a useful initial test of the sera against the antigen which has 
been used for immunisation. The ELISA method for soluble antigen has 
been applied for oestrogen receptor antibody screening.
Antigen (2.4ml) was prepared in PBS at a concentration of 
Ipg/ml. A series of 6 doubling dilutions in small tubes was made by 
adding 1.2ml of antigen solution to 1.2ml PBS. The final dilution 
was 1/64. A 96-well microtitre plate (Dynatech) was prepared as 
follows: lOOpl of the most concentrated antigen solution was put 
into all 12 wells of row A (Figure 9), lOOpl of the first dilution 
into all 12 wells of row B and so on to row G. PBS (lOOp.1) was
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put into all 12 wells of row H. The plate was incubated overnight 
at 4°C. The next day, the contents of the plate were discarded by 
shaking off the antigen solution with a sharp wrist movement and 
washing 4x with PBS plus 0.5% Tween 20. The plates were knocked dry 
by hammering them face down on paper towels. Aliquots, 150pl BSA (50 
mg/ml in PBS) were added to every well and the plate incubated for 
30 min at room temperature. The plate was washed 3x with PBS 
containing 0.05% Tween 20 and knock dried. Antisera was diluted 1 in 
25 in PBS containing 0.5mg/ml BSA and doubling dilutions (0.4ml 
antiserum into 0.4ml buffer) again made such that the last tube has 
a 1 in 64,000 dilution of the antibody. Control serum (1.2ml) was 
also made to a 1 in 25 dilution. To each well in column 1, lOOpl of 
the 1/25 dilution of control antiserum was added. To each well in 
column 2, lOOp.1 of the 1/50 and so on until in column 12 
a 1/100 dilution of the negative control was added. The plate was 
incubated at room temperature for l-2h. At the end of the 
incubation the plate was washed 3x in PBS containing 0.05% Tween 20 
and knocked dry. Aliquots (lOOpl) of goat anti-rabbit conjugated to 
horseradish peroxidase were added to every well at a dilution of 
1/500 (in 0.5mg/ml BSA and 0.05% Tween 20) and incubated for 2h at 
room temperature. After washing the plate 3x in PBS, 100 pi of sub­
strate in a solution of 0.4mg/ml of freshly prepared Orthophenylene dia- 
amin (OPD) dissolved In 0. IM sodium citrate, 0. 2M sodium phosphate pH=6 
containing 0.32 pl/ml H2O2 (0.01%) was added. The plate was covered 
with foil and incubated at room temperature for 30min. To stop the 
reaction, 50pl of 4N sulphuric acid was added. The plate was 
inspected by eye. The titre of the antisera was estimated by finding 
the highest dilution at which the antiserum gives more colour than 
the negative serum and the wells without antigen.
2.3.2 Isolation of Serum from Blood
Antibodies (IgG) are present only in the serum component of the 
blood. Therefore, serum should be separated from the blood cells as 
soon as possible after the collection. If this is not done, the 
cells lyse and release contaminating proteins including proteolytic 
enzymes which will degrade the antibodies. Blood was first allowed
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to clot at room temperature for about Ih. The clot was allowed to 
contract at 4^ 'C overnight. Glass containers were used as blood clots 
more quickly in glass than in plastic containers. The clot was 
detached off the wall of the container and the clot-free liquid was 
centrifuged at 1500xg at A®C for 20min.
2.3.3 Storage of Antibody
Polyclonal antisera are usually stable (Campbell, 1984). This 
could be due to a large number of disulphide bonds which are present 
on immunoglobulins. Bacterial inhibitor, sodium azide 0.1%,was added 
and the serum stored at 4®C or straight away aliquoted and kept at 
-20°C or -70*C.
2.3.4 Purification of Antibody to Oestrogen Receptor (IgG-ER) from 
the Immune Serum
In many cases purification of an antibody is not done since all 
that is required is specificity and each batch of antibody can be 
tested for titre and used directly. However, in SDG experiments 
partially purified immunoglobulin gave better results.
Ammonium sulphate (12g) was added to 50ml of rabbit serum to 
give a desired 40% saturated salt solution which was stirred at 4®C 
in the cold room until all the salt dissolved and then incubated for 
30min at 4®C. The mixture was then centrifuged at 3000xg for 30min 
at 4°C. The precipitated protein was resuspended in 15ml water and 
dialysed against IL of lOmM phosphate buffer (pH=7.2) overnight. An 
8ml column of DEAE Sephacel in the barrel of a 10ml pippete was 
prepared by first plugging the barrel with glass wool and then 
adding the resin which was equilibrated in 50ml lOmM phosphate 
buffer. The 8ml column was supposed to have the capacity to bind Ig 
albumin. The column should not be overloaded with more than Ig 
protein. The dialysed sample was then run through the column and 
washed with 10ml of the equilibrating buffer and 1ml fractions were 
collected at the rate of 30ml/h. Once the sample had fully entered 
the column, the IgG was then eluted with 100ml of lOmM phosphate
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buffer containing 40mM NaCl. The absorbance at 280 nm was read. The 
early fractions under the peak are the purest and the fraction in the 
tail region was discarded.
2.4 THE SPECIFICITY OF THE ANTISERUM
2.4.1 Preparation of Human, Rat and Rabbit Uterine Cytosol
Uterine soluble (cytosolic) oestrogen receptor was prepared 
according to the methods described in section 2.3.1.1. Five gm of 
the tissue (uterus of human, rat or rabbit) were homogenised at 4®C 
in five volumes of TED buffer, using an Ultra-Turrax 181W 
homogenizer with 5xl5sec burst, with Imin interval cooling periods. 
The homogenate was centrifuged at 600xg for lOmin. Cytosols were 
obtained as the supernatant fraction after further centrifugation at 
105,000xg for 60min in a L2-65B Beckman ultracentrifuge using SW50.1 
rotor. The high-speed supernatant fraction was incubated with 5nM 
E2 for 60 min at 4°C. The excess E2 was removed by incubating the 
cytosol (4°C, 15min) with a pellet of DCC (final concentration 0.25% 
DCC)
2.4.2 Antibody-receptor Interaction
2.4.2.1 Immunoprécipitation Assays
The principle of immunoprécipitation is the use of a second 
antibody directed against the first (primary antiserum). The 
original method required the addition of an exact amount of second 
antibody to cross-link and form a lattice with the first to induce 
precipitation. Since an imnunoprecipitate will not always form when 
an antibody encounters an antigen, the relative concentrations of 
antibody and antigen should be adjusted. The limited range of their 
relative concentration over which immunoprécipitation will occur is 
normally referred to as 'equivalence'. Outside of this range 
conditions of either antibody or antigen excess exist and complexes 
of antigen-antibody are small and soluble (Roitt, 1980). A maximum 
of 50-60% of the antigen-antibody complex at low dilution can be
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precipitated out. For the titre, either the antisera or semipurified 
IgG-ER [prepared as ammonium sulphate precipitate (as in section 
2.3.4) and dialysed against PBS) was used. The amount of IgG 
required to give half the maximal precipitation indicates the titre 
of the antibody.
Antibody specificity for rabbit IgG to oestrogen receptor 
(IgG-ER) was determined by a double antibody precipitation 
technique, using crude cytosol (350fmol/ml), semipurified 
(25pmol/ml) or purified receptor (lOpg) labelled with 5nM [%]E2. 
For rabbit IgG-ER specificity determinations, solutions containing 
labelled receptor from the above preparations were adjusted to 
contain 0.4pmol/ml PBS. Serial dilutions of rabbit IgG-ER (250, 50, 
5, 0.5, 0.05pg) from a stock solution of 5mg/ml was made in a volume 
of 250pl in PBS containing lOmM EDTA. Each incubation mixture 
contains O.lpmol oestrogen receptor, (0.25ml), O.lmg (0.1ml) of 
normal rabbit IgG-N and each of the concentrations of the IgG-ER 
(0.25ml). The final volume was 1 ml and the mixtures incubated 
overnight (14-20h) at 4°C in an eppendorf tube. Controls for 
determining nonspecific binding, contained only O.lpmol receptor, 
O.lmg normal rabbit IgG-N to replace the IgG-ER and PBS. At the end 
of the incubation 25pl goat antiserum to rabbit (as partially 
purified IgG) was added to precipitate all the rabbit IgG.
After an additional 4-5h at 4*C, the tubes were centrifuged at 
2000xg for 20min and the pellets were washed twice with PBS 
containing Img/ml BSA. The pellets were then dissolved in lOOpl of 
0.2M NaOH and neutralized with IM HCl. Radioactivity was measured 
in 4ml of scintillation mixture containing Triton X-100, as in 
section 2.2.2.6. (efficiency for [^H] was 30%).
2.4.3 Detection of IgG-ER Complexes by Sucrose Gradient Ultracen­
trifugation
To detect the anti-oestradiol receptor antibodies, the 
migration of this protein bound to [^HjFg receptor complex was 
studied using density gradient ultracentrifugation. For these 
studies, oestrogen receptor complexes were prepared from cytosols as
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in section 2.4.1. The cytosol was incubated for 2h at 4“C with 
[^H]E2 (final concentration 5nM). Nonspecific binding was deter­
mined by including, in parallel, incubations containing 100-fold 
excess of DES in TED buffer. The incubation mixture was transfered 
to pre-formed DCC pellets (from 0.5 % DCC suspension), and the tubes 
were shaken intermittently by hand for 15min at 4®C and spun at 
2300xg for lOmin. About 0.2-0.5pmol of oestrogen receptor in 
100-200jil cytosol was incubated with IgG-ER or IgG-N (50pg) at 4°C 
for 5h in a final volume of 220 pi in TEKq ^^(low salt) or TEK^  ^
(high salt) depending on the gradient to be used.
The gradient was layered by hand. Five, 10, 15 and 20% sucrose 
solutions were prepared in the appropriate buffer. Into 5ml SW50.1 
centrifuge tube 1.15ml of 20% sucrose solution was first layered.
The tube was kept in the -70°C freezer for I5min, sufficient to
freeze the sucrose solution. The next layer will be the 15% sucrose, 
followed by 10% and finally 5% each time followed by freezing at 
-70®C. Before use, the gradient was left to equilibrate overnight 
at 4“C.
A 200pl aliquot of the cytosol was layered onto 4.6 ml of 5-20% 
hand layered sucrose gradients in TEK i.e. either TEKq or TEKg 
The gradients were centrifuged for 16h at 4“C at 230,000xg in a 
L2-65B Beckman ultracentrifuge using a SW50.1 rotor. Two drop 
fractions were collected from the bottom of tube and the
radioactivity determined in 4ml of aqueous counting scintillant in 
Triton X-100. In separate experiments [14c] bovine plasma albumin 
(4.6S) and human globulin (7.IS), were sedimented in parallel 
gradients to serve as external markers.
2.4.4 Effect of IgG-ER on the Progesterone and Androgen Receptors
Progesterone receptor from rat uterine cytosol was labelled 
with [^H]ORG 2058 and androgen receptor from rat prostate was
labelled with [3h ]DHT. Both were incubated with IgG-ER (section 
2.4.3) and sedimented through a sucrose gradient.
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2.4.5 Specificity of IgG-ER-Complex Interaction Using Immuno- 
adsorbents
2.4.5.1 Preparation of Sepharose Bound IgG-ER for Immunoadsorption 
Chromatography
Cyanogen Bromide activated Sepharose (1.5g) was activated with 
400ml of IraM HCl. The use of HCl preserves the activity of the 
reactive groups which hydrolyse at high pH. The gel was left to 
swell for 30min, the ligand 15mg IgG-ER or IgG-N diluted in coupling 
buffer. The activated resin was washed once in 8ml of coupling 
buffer (0.2M, pH 9.0) containing NaCl (0.5M) and immediately 
transferred to the solution containing the IgG-ER. The coupling buffer 
solution should have a high salt content to minimise protein-protein 
adsorption caused by the polyelectrolyte nature of proteins.
The mixture containing IgG-ER and swollen gel is rotated
end-over-end overnight at 4®C. At the end of the incubation the
remaining active sites were blocked in 8ml 0.2M glycine overnight at 
4®C. To remove the excess uncoupled ligand that remained after
coupling, the adsorbent was washed four times in alternately high 
and low pH buffer solutions. Acetate buffer (O.IM, pH 4) and 
coupling buffer (pH 8.3) each containing 0.5M NaCl are suitable. 
This is important as protein adsorption occurs only when the pH is 
changed. The protein content of each solution was determined before 
and after the first step in the coupling procedure in order to 
ensure that more than 90% of the proteins were coupled to Sepharose. 
The immunoadsorbent was then incubated with cytosol containing 
25pmol receptor and the mixture was incubated end-over-end 
overnight. The immunoadsorbent with the bound receptor was 
transferred to a column and was washed with 200ml of TEDKq q j , 200ml 
of TEDKq ^ and 300ml of TEDKq to remove nonspecific binding. The 
bound receptor was eluted using TEDKq ^ containing 0.5M NaSCN, 10% 
dimethylformamide and lOpM DES and the eluate was desalted on 
Sephadex G-25 (10ml). The Vo was lyophilized and run on native PAGE 
as described in section 2.2.2.
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2.4.5.2 Time Course Study: Interaction of Immobilized Antibody with 
Oestrogen Receptor
The immunoadsorbent loaded with ligand-free oestrogen 
receptor, (section 2.4.5.1) was re-suspended in 6ml TED. Two batches 
of six portions (50pl) of the receptor-loaded immunoadsorbent were 
placed in polypropylene test tubes. They were incubated for 1.5h at 
4®C with 500 pi aliquots of buffer containing labelled ligand (5nM) 
with or without a 100-fold excess of unlabelled E 2 and aliquots 
taken at 0, 30, 60, 90, 120, 150min. Untreated Sepharose-IgG was
used as a control. At the end of the indicated time period the 
resin was washed three times with buffer (3x2ml), radioactivity 
bound to the adsorbent was measured in Triton-X-100 scintillation 
mixture with a counting efficiency of 30%.
2.4.5.3 Western Blot: Protein Transfer and Antibody Overlay
A Western blot is the electrophoresis of the antigen followed by 
its subsequent transfer to nitrocellulose paper and then incubation 
with a specific antibody which is recognised by a labelled second 
antibody. Western blotting was originally developed by Towbin et al. 
(1979) with polyclonal antiserum.
Incubation/Washing buffer was prepared as follows: 20ihM
Tris-HCl (pH 7.2), 0.15M NaCl, 0.5mg/ml NaNg, 0.5% Tween 20 (w/v).
This solution may be used as blocking buffer with 30mg/ml BSA.
The transfer buffer or tank buffer was prepared as follows: 
25mM Tris, 192mM Glycine, 20% w/v Methyl Alcohol (Analar), 0.02% SDS 
and the pH was adjusted to 8.3 with concentrated HCl. The antibody 
solution (1:100) plus carrier protein (normal horse serum) and 
^2^I-Protein-A solution (3xl06cpm) were prepared in incubation 
buffer.
Nitrocellulose paper of 0.4pm diameter and 0.1% Amido Black 
(Naphthalene Black) in 45% MeOH (v/v) and 10% Acetic acid (v/v) were 
also prepared. Using a shallow tray and gels with protein already 
separated as in the method described in section 2.2.7 but using a
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slab gel in place of disc gel, a sandwich of gel/nitrocellulose was made 
as follows:
Scotch Brite pad 
Filter paper 
polyacrylamide gel 
Nitrocellulose paper 
Filter paper 
Scotch Brite pad
Two.sandwiches were prepared from two gels. The sandwich should 
be totally submersed in tank buffer, all air bubbles eliminated and 
the sandwich carefully positioned into the transfer tank such that 
the nitrocellulose paper was nearest the anode. The transfer was 
carried out at 40mA overnight (o/n) in LKB Transfer apparatus with 
the cooling system on.
At the end of the transfer, the nitrocellulose papers were 
removed and to check the efficiency of the transfer, one was stained 
in 0.2% Amido black solution for 1-2 min, then destained with a 
solution of 45% MeOH, 10% Acetic acid. The remainder of the 
nitrocellulose blot was placed in blocking buffer o/n at 4®C with 
shaking.
The next day the blocking buffer was removed and the blot 
washed with several changes of incubation buffer with shaking over a 
period of 10-15min at room temperature. The blot was then incubated 
for 90min at 37®C with the antibody in incubation buffer containing 
5% inactivated carrier serum. The blot was further washed with 5 
changes of incubation buffer, with shaking, over a period of 30min.
Finally the blotwas incubated for Ih at 37*C in ^25j_pjQ^g£n-A 
solution with shaking (lOOpl IZ^I-Protein-A, 3xl0^cpm in 20ml 
incubation buffer) and washed with 5 changes of incubation buffer at 
37*C with shaking within 30min and then dried between two filter 
papers. Autoradiography of the blot was then obtained after 6 days 
exposure at -20*C.
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2.5 THE ANTI-ER ANTIBODY AS PROBES FOR OESTROGEN RECEPTOR DETECTION
AND DISTRIBUTION
2.5.1 The ZR-75-1 Cell Line
Two cell lines: ZR-75-1 and MCF-7 resemble those human breast 
tumours in vivo which are ER+ and regress following ovariectomy or 
oestrogen therapy.
Both cell lines possess specific, high affinity, low capacity 
receptors for E2 demonstrable by Scatchard analyses of competitive 
binding assays performed by the dextran-coated charcoal or protamine 
sulphate method, and in sucrose density gradients (Brooks et al., 
1984; McGuire and De La Garza, 1973; Chamness et al., 1974; Horwitz 
et al., 1978; Lippman et al., 1976; Lippman et al., 1977).
The MCF—7 cells contain 60-100fmol of cytosol oestrogen 
receptor per mg cytosol protein with a Kd for E2 which has been 
reported by different investigators to range from 0.06-2.5nM (Brooks 
et al., 1984; Lippman et al., 1976). The ZR-75-1 cells possess 
approximately 30fmol/mg cytosol protein with a Kj=0.06-2.5nM, same 
range as MFC-7 cells (Engel et al., 1978).
The ZR-75-1 and MCF-7 cells survive and grow slowly for 
approximately 5 days under completely serum-free conditions in 
Eagle's minimal essential medium (MEM). Hence some serum-derived 
factors are essential to long-term cell survival. Strobl and 
Lippman, (1978) found that ZR-75-1 and MCF-7 cells can be grown 
indefinitely in Eagle's minimal essential medium supplemented with 
10~7m  porcine insulin and 5% calf serum stripped of most endogenous 
steroid by treatment with DCC. Growth under these conditions is 
considerably faster than that observed under completely serum-free 
conditions, yet much slower than that occurring in MEM plus 10% foetal 
calf serum which is enriched in many growth promoting substances 
including steroid hormones.
The proliferative effect of oestrogen on the ZR-75-1 cells is
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demonstrated upon the addition of as little as 10~ H m  Eg to cells in 
serum-free media, and maximal at 10"^M to 10~®M Eg (Lippman et al., 
1976; Lippman et al., 197 7). The ZR-75-1 cells do not grow when Eg 
is omitted from the defined medium. Exponential growth is elicited 
by the addition of Eg to the medium.
2.5.1.1 Medium and Hormones
The ZR-75-1 cells were grown in Ham's FlO/Dulbecco's 
modification of Eagles medium, 1:1 (v/v) buffered with 20mM HEPES 
(pH 7.4). The medium was supplemented with L-glutamine 2mM, 
0.375g/dm^ sodium bicarbonate, 10% (v/v) FCS to which insulin
(5pg/ml) was added. All medium which was oestrogen free was
prepared in the Preparation Unit at the Department of Oncology, 
Glasgow University.
Progesterone and E^ stock solutions in ethanol were stored at 
-20*C until use. Final concentrations in the medium were 10~^M 
progesterone and 10“^M Eg. The final concentration of ethanol was
0.1% and this concentration had no effect on the growth of the cells 
(Lippman et al., 1976).
Cultures with or without steroid were seeded at 2x10^ 
cells/16mm well or 4x10® cells/Winchester and maintained at 37°C in 
a humidified incubator in an atmosphere of 2% COg (v/v) in air.
2.5.1.2 Oestrogen Receptor Measurement
Cytosol was prepared as described below. About 10 million cells 
were harvested from 2 Winchesters and scraped off the wall with a 
rubber policeman into TED buffer at 4®C. The cells were washed twice 
in buffer to remove all the medium present. Four ml of TED was added 
and the cells homogenised in a glass-glass homogeniser at 0-4“C with 
Imin interval cooling period. The tube was rotated on ice in order 
maintain uniform cooling. To make sure that the cells (about 75%) 
had been fully disrupted, a drop of the homogenate was placed onto a 
slide and examined under a phase contrast microscope. The high
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speed supernatant was obtained by spinning the cell homogenate in a 
SW50.1 rotor using a L2-65B Beckman ultracentrifuge at the speed of 
105,000xg for 60min. Scatchard plot analysis was carried out to 
check the level of receptor available (section 2.2.1).
2.5.1.3 Oestrogen Receptor Detection by the Immunofluorescence (IF)
Technique and In Vitro Translocation Studies
The ZR-75-1 cells were grown on coverslips in 4 x 6  wells 
multi-well plates in an oestrogen-free medium as prepared in section
2.5.1.1. and maintained for 6 days prior to growth in:
1. E2 for 1, 24 or 48h.
2. Progesterone for 1,24 or 48h.
3. Charcoal treated, heat inactivated serum (56°C) (section 
2.2) for 24 or 48h.
At the end of each growth period, each group of cells was 
transferred into fresh medium containing InM Eg or lOnM DES and 
maintained at different temperatures (4, 22, 37°C) for 45-60min as 
shown in Table 1.
At the end of the incubation period, the medium was discarded, 
the coverslips washed and fixed in acetone (-20*C) for 30sec and 
were processed for detection of oestrogen receptor. The receptor is 
detected using an IF technique which used an antibody to oestrogen 
receptor and a second antibody conjugated to fluorescein. The 
technique is described in the section 2.5.1.4.
For the in vitro translocation studies, quantification of 
extranuclear and nuclear oestrogen receptor in ZR-75-1 was carried 
out using MPV compact linked to a fluorescence microscope. It could 
measure the intensity of staining in the extranuclear (E) space and 
in the nucleus (N). The ratio of nuclear to extranuclear staining 
(N/E) was taken as a translocation index of the oestrogen receptor 
in the ZR-75-1 cells.
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2.5.1.4 IF Technique Using an Anti-Receptor Antiserum.
After the cells are fixed (Section 2.5.2.2) the coverslips are 
allowed to dry for lOmin at room temperature. The cells are then 
immersed in PBS, pH=7.2. . The cells should not be allowed to dry 
out. Sufficient normal goat serum (i.e. diluted 1:30 in PBS) to 
cover the cells is applied to the coverslip. Normal serum from the 
species supplying the second antibody is always used. This is 
essential to block non-specific binding.
Prior to application, the primary antibody, the antiserum, was 
diluted 1:100 in 0.1% BSA in PBS. This pre-absorption with albumin 
prevents non-specific attachment of immunoglobulins to tissue 
components. The cells were incubated with the diluted antiserum 
(lOOpl)at room temperature for Ih, after which they were rinsed 5x in 
PBS (3min each rinse) before the second antibody was applied. 
FITC-conjugated anti-rabbit IgG made in goat was the second 
antibody. It was diluted 1:50 in PBS. Fifty pi was added onto the 
slide and incubated for a further Ih at room temperature. The 
coverslip was rinsed 5 times in PBS and then counterstained with 
Hoechst 33258 and mounted in Citi-Fluor to prevent fading. The 
edges of the coverslips were sealed with PBX to prevent drying of 
the cells and the fluorescence was examined under the U.V. 
microscope linked to the MPV photometry. The intensity of specific 
staining for individual cells was characterized qualitatively as not 
present (-), weak but definitely detectable (+1), strong (+2), and 
very intense (+3). Quantitatively the intensity of the fluorescence 
was measured using a suitable window. More than 200 cells were 
measured. For translocation studies the window was adjusted to fit 
the size of the nucleus and any area of the extranuclear space. The 
ratio of the fluorescence intensity of the nuclear (N) to 
extranuclear (E) area was taken as an index of translocation of oes­
trogen receptor.
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2.5.2 Tissue Preparation for IF Techniques
2.5.2.1 Frozen Sections
Tissues (breast tumour biopsies, human uteri, rat uteri, rat 
liver, rat spleen) were cut into 0.5cm cubes. The cut tissues were 
then transfered onto a 1cm square board containing a drop of OCT and 
the tissue was quickly plunged into a beaker of isopentane 
surrounded by liquid nitrogen. Frozen sections, 6 pm
thick, were kindly prepared by Mr Hector Cairns, Microbiology 
Department, Western Infirmary, Glasgow and Mrs Sheila Byres, 
Physiology Department, Glasgow University. The prepared sections 
were then stored at -20°C for short term use (2-4 days) or at -70*C 
for a long term use (5-10 days).
2.5.2.2 Fixative for the Frozen Sections
Pilot experiments were conducted to choose a suitable fixative.
They showed that the most commonly used fixatives such as acetone 
(100%) for 30sec at -20®C, acetonetmethanol (1:1) for lOmin at 4®C, 
and ethanol (100%) for lOrain at 4°C did not destroy the antigenicity 
to any appreciable degree and were found to give a satisfactory 
clear staining. Of the three fixation method, the one with acetone 
gave slightly the better results. Use of unfixed tissues was found 
to be inadequate as the tissues appeared to become detached from the 
slides rather easily. Also access of antibody to intra-cellular 
antigens was impossible due to absence of perforation usually made 
by the fixatives.
The sections were then assessed by the IF technique (section
2.5.1.1). A few of the slides were processed for haematoxylin/eosin 
staining.
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2.5.2.3 An In Vitro Oestrogen Receptor Translocation study in
Human Uterine Frozen Sections
Method 1
A portion of the uterus was frozen in dry ice for biochemical 
estimation of oestrogen receptors. The rest of the tissue was cut 
into pieces of approximately equal size (0.3cm cube) and each piece 
was put in a vial containing 1ml of either plain PBS or PBS 
containing l.OnM of E2 , DES, or progesterone. The incubation lasted 
for Ih. At the end of the incubation period the liquid was drained 
from the vial, and the tissues were frozen in liquid nitrogen and 
treated the same way as in section 2.5.2.1 and stored at -70®C until 
use.
Method 2
Frozen sections which had been air-dried for 10 min were used. 
Two slides, each with two sections, were processed without exposure 
to steroid to determine the native distribution and intensity of IF 
in the tissue (unincubated control). Four sections were treated 
with plain PBS or PBS containing one of the following ligands: E 2»
DES, or progesterone at l.OnM concentration. To expose the cells in 
the unfixed frozen sections to steroid solutions without any 
appreciable loss of cytoplasmic proteins, the following steps were 
carefully performed. To the air-dried section, 20pl of the ligand 
solution or plain PBS were added to cover the sections. All the 
liquid was immediately aspirated back into the pipette tip leaving 
only a thin layer of the ligand solution on top of the frozen 
section. The immediate draining of the excess liquid from the 
air-dried section was important to prevent the loss of cells which 
may become detached from the glass if too much liquid was left. The 
slides were transferred to a moist chamber kept at 37®C, and 
incubated for Ih. The sections were then fixed in methanol:acetone 
and processed as usual for IF studies. The sections were examined 
for the intensity and intracellular distributions of IF in cells.
115
2.5.3 Fine-needle Aspirates
Cell smears from needle aspirates or body fluids were performed 
by Mr. Derek Crawford, Department of Surgery, Western Infirmary, 
Glasgow. They were transported to the laboratory. The smears were 
air-dried for lOmin and then fixed with methanol/acetone (1:1) at 
4®C for another lOmln. The fixed slides were either kept at -70“C 
or immediately processed. For all patients from whom FNA were 
obtained, biopsy material was taken from the tumour during surgery 
and used for the standard laboratory assay (DCC method) of oestrogen 
receptor.
2.5.4 Experimental Controls
Specific staining is defined as staining that was present in 
oestrogen positive tissues when the antibody to oestrogen receptor 
was used alone but the staining was absent when the antibody was 
replaced with normal rabbit IgG or pre-adsorbed with oestrogen 
receptor-containing cytosol.
To check the specificity of the staining, various controls were 
set up. The cells on coverslips as prepared earlier (section
2.5.1.1) were treated as follows.
(A) Reagent Controls
The acetone fixed ZR-75-1 cells were:
(1) Treated with the serum obtained from the rabbit prior to
immunization (pre-immune serum) and diluted 100-fold in PBS and 
used in place of the anti-receptor anti-serum.
(2) Treated with FITC-conjugated goat anti-rabbit IgG, omitting
the primary antiserum ih order to assess the non-specific 
adherence of this reagent.
(3) Treated with antiserum preadsorbed for 16h at 4®C with
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cytosol containing oestrogen receptor (>500fmol/mg protein) and used 
in place of antiserum.
(4) Treated with antiserum preadsorbed for 16h at 4®C with negative 
cytosol pooled from oestrogen receptor negative breast cancer 
biopsies and
(5) Treated with antiserum preadsorbed for 16h at 4®C with normal 
rabbit serum diluted 100-fold and used in place of antiserum.
(B) Tissue Control
(1) Oestrogen Receptor-Negative Tissue
Tissues, known to lack oestrogen receptors were pre-checked 
by the DCC assay to confirm the lack of oestrogen receptors and 
used as negative controls. Frozen sections of rat spleen and 
human mammary fibroadenoma (biochemically oestrogen receptor 
negative) were used.
(2) Oestrogen Receptor-Positive Tissue
In addition to human uterus, rat uterus and human breast 
tumour tissues rich in oestrogen receptors were also tested.
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RESULTS
3.1 PURIFICATION OF OESTROGEN RECEPTOR
A variety of methods to purify oestrogen receptors were tried. 
This includes disc PAGE, DNA cellulose, DEAE sepharose and phenyl 
sepharose chromatography.
3.1.1 Purification of Oestrogen Receptor by Disc-PAGE
Using disc-PAGE continuous Tris-borate-EDTA buffer system on 
human uterine cytosol two peaks A and B were observed (Figure 10). 
Peak A appeared at 240,000 molecular weight while peak B 65,000. 
Cytosol prepared from ER+ human breast tumours yields a single peak 
which had a migration equivalent to peak A (Figures 11a and b). The 
sections under the peak were taken, ground to a fine powder and used 
as an antigen. However, antibody raising using this technique of 
purification was not successful.
3.1.2 Purification of Oestrogen Receptor by Chromatography Technique
A single, sharp peak of specific binding to Eg was obtained by 
using the DNA cellulose column, eluted with 0.2M KCl (Figure 12). 
The binding activity of the pool fractions under the peak was 6-9 
times greater than that of the starting material. However, a peak of 
specific binding to Eg was also obtained by using a DEAE sepharose 
column, eluted with 0.13M KCl (Figure l3). One peak of specific 
binding to £3 was.obtained by using phenyl sepharose columns eluted 
with TED:ethylene glycol:glycerol (30:40:30) (Figure 14).
A summary of the extent of purification after each step is 
shown in Table 1. The procedures involved in the purification were 
rather complicated and the yield was very low. The purification fold 
was only 258 times therefore a better technique of purification was 
sought.
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Figure 10: PAGE analysis of oestrogen receptor from human
uterine cytosol using Tris-borate-EDTA
continuous buffer system. • Cytosol was
prepared from human uterine tissue (section
2.2,2.1) and then incubated with lOnM [^ HjEg 
alone (o) or in the presence of a 100-fold 
excess DES (•). After removal of unbound 
steroid (section 2.2.2.5), 150pg of cytosol 
protein was analysed by the PAGE. Known
molecular weight proteins were run in
separate gel. Electrophoresis was carried out 
at 2mA/gel (4 C). At the end of the
electrophoresis, the gels were cut into 2.5mm 
thick slice and radioactivity in each slice
was counted. Gel with protein markers was
stained and destained as described in section 
(2.2.9.3) The arrows indicate the position 
of molecular weight proteins. Two peaks were 
observed and designated as peak A and peak B. 
Peak A appeared in the region of 240,000 
molecular weight protein while peak B in the 
65,000, just slightly below 68,000 molecular 
weight protein. This experiment revealed the 
presence of two typ es of oestrogen receptor 
in this particular sample, a higher molecu­
lar weight and a lower molecular weight 
species.
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Figure 11; PAGE of oestrogen receptor from the cytosol 
of ER+ breast cancer biopsy. The receptors 
were either labelled with [^H]E2 (o) or [%]E2 
+ DES a 100 fold excess (•). Electrophoresis 
was carried out at 2mA/gel. At the end of the 
electrophoresis, the gels were cut into 2.5mm 
thick slices and radioactivity in each slice 
was counted. The portion of each gel 
corresponding to the radioactive peak was cut 
out, pooled, frozen, ground to a fine powder 
and injected into an experimental animal for 
antibody production.
(a) female patient with breast cancer
(b) male patient with breast cancer.
Only one peak was observed from this sample 
of ER+ breast cancer biopsy. The peak cor­
responds to peak A of Figure 10 thus with 
a molecular weight of 240,000. It was the 
protein that was used as an antigen . Cal­
culation based on this molecular weight 
from lOOfmol receptor .gave only 24ng pro­
tein.
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Figure 12: DNA cellulose elution profile of human
myométrial cytosol. Aliquots of cytosol 
labelled at 4"C with lOnM [%]E2 in the 
absence (o) and presence (•) of DES a 100 
fold, were heated to 30°C for 30 min and 
applied to DNA cellulose column. Two ml 
fractions were collected and lOOpl from 
each fraction was counted for 
radioactivity. The peak of specific binding 
to E^ was obtained by 0.2M KCl elution. The 
fractions under the peak were pooled, 
protein concentration was determined 
(Bradford, 1976) and applied onto DEAE 
sepharose column. The purification using 
DNA cellulose gave only 80 purification fold 
and resulted in significant loss of receptor 
protein.
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3.2 AFFINITY CHROMATOGRAPHY
3.2.1 Selectivity of the Oestradiol-hemisuccinate-Albuinin-Sepharose 
4B Column
As shown in Table 2, an average of 81.2% of the receptor in the 
initial fractions was adsorbed by the column. The affinity column 
was clearly very selective since the protein concentration of the 
flow-through remained essentially unchanged.
Since the affinity resin material used here was known to bind 
oestrogen receptor non-specifically, this possibility was eliminated 
in this study by including lOpM E2 or DES in the tissue cytosol. 
Progesterone at lOpM had no effect on the binding of oestrogen 
receptor to this affinity column (Table 2 and Figure 18)
3.2.2 Elution of Receptor
The washing procedure used to remove the noncovalently bound Eg 
from the affinity column include the use of organic solvent. The 
column was washed with 2000 to 3000ml of 80% methanol over a period 
of 12 to 15h at 24*C. After this washing procedure, a sample (1ml of 
gel) of the affinity column was removed to determine whether any 
free or loosely bound E2 remained. This sample was incubated with 
mature rat uterine cytosol. This incubated cytosol was then 
extracted with ether. This extract was assayed for free Eg (Figure 
15).
Next the conditions for the elution of receptor from the 
affinity resin were defined. Weakly adsorbed protein was removed 
most effectively by washing with 0.4M KCl. Several combinations of 
washing buffer were attempted in trying to obtain the best recovery 
and purification. The following washing steps were performed for the 
best results: TEDKg TEDKg^, TEDK^ g, TEDKg^^ and TEDKg g^
(Figure 16). Washing with TEDK^ g helped to reduce washing volume 
and time. Increasing the final yield of receptor by adding 0.5M 
sodium thiocyanate into the lOpM DES elution buffer was not very 
effective but 0.5M sodium thiocyanate and 10% dimethylformamide
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Table 2: Selectivity of the Oestradiol-1^ 17-Hemisuccinyl-
Albumin-Sepharose 4B Affinity Resin
Preparations
Column efficiency
(%)
Cytosol of human uterus 81.2 ± 3.3(10)
Cytosol + diethylstilboestrol (10*'®M) 11.2 ± 1.1(5)
Cytosol + oestradiol-1^ (10~^M) 10.5 ± 1.3(5)
Cytosol + progesterone (10”^M) 85.0 ± 4.0(3)
Cytosol + Sepharose 4B 9.5 ± 1.0(3)
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Figure 15: Detection of free Eg in the eluate from the Eg
—Succ-Alb-Sepharose column. Detection of free 
E ^  from the affinity resin was carried out 
as described in section 2.2.7.2. The etherial 
extract of cytosol not incubated with 
affinity resin was incubated with fresh rat 
uterine cytosol. The Eg binding capacity was 
measured. This is considered as 100% (I) The 
Eg binding capacities were measured in 
various etherial extracts:
(II) affinity column flow-through was 
incubated with fresh rat uterine cytosol and 
the E^ binding capacity was measured.
(III) affinity column eluate, after passing 
through a Sephadex G-25 column was incubated 
with fresh rat uterine cytosol and the Eg 
binding capacity was measured.
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(DMF) seemed to be effective (Greene et al., 1980). Eluting at 30°C 
for 20min or 4°C for 16h was found to have no significant difference 
in the yield (Table 3). Only 6--8% of the activity initially added 
to the column can be recovered by the DES elution procedure, but the 
application of 10% DMF increased the yield (Table 3).
3.2.3 Purification
Purification was performed with a column containing 3ml of the 
resin. About 80% of the oestradiol-binding activity of a supernatant 
was adsorbed onto the column. Elution was carried out by using the 
basic procedure as described in section 3.2.2. The purification 
achieved in one experiment was about 46,000-fold (Table 4).
3.2.4 Characterization of Receptor Protein Eluted from Affinity 
Column
Typical electrophoresis patterns of oestrogen receptor and of 
reference proteins run in parallel are shown in Figures 17 and 18. A 
single band of receptor protein was observed, which was positioned 
slightly below the BSA. By interpolation in the semilogrithmic plot 
of molecular weights of reference proteins against their R^ values, 
an apparent molecular weight of 64,4001600 (S.D) is found for the 
denatured oestrogen receptor.
When the purified receptor was analysed by SDG it was found to 
have a sedimentation coefficient of about 4S, essentially the same 
as that of the native receptor in crude preparation (Figure 19). 
The oestrogen receptor purified by the affinity chromatography 
procedures described here thus appears to be the same macromolecular 
species as in the crude homogenate.
Experiments were performed to estimate the binding activity of 
the purified oestrogen receptor for E2 (Figure 20). The free and 
the macromolecular bound E2 components are separated by filtration 
on Sephadex G-25 at 4°C. The protein-bound hormone emerged in the 
first macromolecular peak in coincidence with Vo.
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Figure 17: SDS-PAGE of purified oestrogen receptor. The
single protein band on this electrophoresis 
is evidence that oestrogen receptor has been 
purified to at least 60% homogeneity.
Lane 1: A protein standard, BSA molecular
weight 68,000
Lane 2: A semipurified receptor preparation. 
Treatment with 25% ammonium sulphate
precipitation as in section 2.2.7.3.1.
Lane 3: Oestrogen receptor purified by
affinity chromatography.
6 8 ,0 0 0  —
2 3
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Figure 18: Determination of the capacity and selectivity
of E^-Succ-Alb-Sepharose for oestrogen 
receptor. Fifty ml of semipurified human 
myométrial oestrogen receptor was incubated 
with lOpM E 2 overnight at 4*C. It was then 
applied to a 2 ml affinity column. One 50ml 
fraction of ammonium sulphate treated cytosol 
was incubated overnight with lOpM 
progesterone and was passed through another 
column containing the same amount of affinity 
resin. After washing with 230ml TEDKq ^ the 
affinity column was eluted with lOpM DES in 
TEDKQ ^  0.5m NaSCN and 10%DMF. The eluate
was subjected to 5% SDS-PAGE. Only the column 
with progesterone treated cytosol shows the 
presence of 65,000 molecular weight protein.
Lane 1. Eg treated cytosol.
Lane 2. reference proteins, 94,000, 67,000,
43,000, 30,000 and 20,000 molecular weight. 
Lane 3. progesterone treated cytosol.
The effect of washing is also evident in 
this experiment. Lane 3 shows protein eluted 
from a column which was washed with only 
TEDKq ^ The presence of higher molecular 
weight proteins was clearly observed. But 
when a complete washing sequence (as in 
Figure 16) was carried out, no other protein 
(Figure 17) was found. This indicates that 
these proteins have no affinity towards Eg
43,000.
30,000.
94.000
67.000
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Figure 19: Sucrose density gradient profile of the
affinity gel eluate. Gradients of 5-20%
sucrose were made in TEDK. , Purified
0.4
receptor (200fil) was layered on a 5-20% 
sucrose gradient and centrifuged at 230,000xg 
for 16h at 4"C in a SW50.1 rotor using an 
L2-65B Beckman ultracentrifuge. The gradient 
were fractionated at 4®C and each fraction 
was assayed for radioactivity. The arrow 
indicates the sedimentation of [ C] BSA 
(4.6S).
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The oestradiol-binding proteins eluted from the affinity column 
lose their oestradiol-binding activity if they are heated for 5min 
at 65®C. The affinity binding activity characteristic of oestrogen 
receptors is known to be destroyed by such treatment, whereas 
nonspecific Eg binding is actually increased by such heating (Figure 
20).
3.3 ANTISERA
3.3.1 Titre
Of three rabbits receiving a primary immunization of 20-30pg of 
purified oestrogen receptor and 6 consecutive booster injections 
each about lOpg per animal, only 1 animal showed a reasonable level 
of response to the antigen. Figure 21 shows that the antibody titre 
of rabbit number 13 reached a plateau between 4 to 8 months after 
the primary immunization. The first significant titre was observed 
3 months after the primary immunization. The titres fluctuated with 
time and were quite low, which could be due to the small amount of 
antigen injected during each booster.
3.3.2 Crossreactivity of Antisera
The antisera obtained from the early bleeds were screened using 
ELIZA where a rough guide to the titre was obtained. The antigen 
used were crude cytosol, semipurified ammonium sulphate 
precipitation and purified oestrogen receptor from human myometrium.
Several cytosolic preparations known to contain oestrogen receptor 
have been checked for crossreactivity with the antiserum (Table 5 ). 
The antisera showed crossreactivity with several preparations from 
different species including rat and mouse uterine cytosols, ZR-75-1 
and ER+ human breast cancer cytosols. Tissues known to lack 
oestrogen receptor were used as control. These included cytosol of 
skeletal muscle (4fmol/mg protein) and cytosol from ER- breast 
cancer biopsies.
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3.3.3 Purification of Antisera
The purification of the serum used an ion-exchanger from which 
the IgG was eluted by 40mM NaCl in phosphate buffer in a single 
asymmetric peak (Figure 22) and impurities are bound and retarded by 
the exchanger. The early fractions were the purest and so pool I 
was aliquoted into small tubes and stored at —20°C. Pool II was 
discarded. The protein obtained was calculated using absorbance at 
280nm and was found to be 5mg/ml serum.
3.4 SPECIFICITY OF ANTISERUM
3.4.1 Double Immunoprécipitation Assay
The antisera were screened by an ELISA solid phase assay for a rough 
guide to the titre. However a more specific titre was determined 
using the double immunoprécipitation assay (Figure 23). The 
precipitation of the immuno-oestrogen receptor comolex could 
indicate the specificity of the antisera toward oestrogen receptor. 
The specificity of the antisera was further analysed using SDG and 
Western blotting techniques.
3.4.2 Sucrose Density Gradients
Sedimentation analysis of the oestrogen binding protein showed 
a single radioactive peak sedimenting at about 4S (mean valueiSE 
(n=4) = 4.25±0.5] for high salt and at about 8S [7.9±0.4S] for low
salt. The radioactivity was completely displaced by a 100-fold 
excess of unlabelled DES.
The antigen-antibody reaction was seen through the shift of 
sedimentation peak which was measured according to the internal 
markers [^^C] human- ^-globulin (7.IS) and [^^C] BSA. Figure 24 
shows the clear separation of 4.6S and 7.IS markers which sediment 
in approximately a linear fashion. The sedimentation value of 
oestrogen receptor in low salt was affected by the antibody. In the 
presence of antibody the sedimentation value shifted from 8S to 
about lOS (Figure 25). In high salt the oestrogen receptor
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Figure 23: The titre of March antiserum from rabbit number 
13 using an immunoprécipitation method. The 
procedure was carried out as described in 
section 2.4.2.1. Specific binding was plotted 
on the y-axis using the following 
calculation
<B - N)
100
(T - N)
where :
3
N = non-specifically bound [ H]ER in the 
normal rabbit IgG-N.
B = bound [^H]ER and
I = Total count without IgG-N and IgG-ER. 
1/dilution = dilution of IgG-ER.
100
80
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o
40
20
2 3 4
dilution
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Figure 24: Separation of C-labelled marker
proteins on sucrose density gradient
[ C]-BSA (4.6) and human- ^-globulin 
(7.IS) were mixed with 200pl aliquot of 
cytosol prepared from rat uterus (protein 
concentration 4mg/ml). Cytosol was then 
layered on the top of a 5-20% (w/w) 
sucrose density gradient prepared in TED 
and centrifuged at 230,000xg for 16h at 
4®C. The rest of the procedure is
described in section 2.4.3.
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Figure 25: Effect of IgG-ER on the Sedimentation
Values of Oestrogen Receptor (low salt).
Aliquots of I 3 HjEji-receptor complex were 
incubated with normal rabbit serum (o) or 
with antiserum (•) in a final volume of 
250pl. After 4h at 0°C, 200pl of the samples 
were centrifuged for 16h at 230,000xg on a 
sucrose gradient in TEDK lOmM buffer. Arrows 
indicate the migration of standards (1) 4.6S
BSA (2) 7.IS human-Y -globulin. Similar
preparation in the presence antibody cause 
the sedimentation value to shift from 8S to 
about lOS.
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sedimentation value was shifted from 4S to about 8S in the presence 
of antibody (Figure 26), Rat ventral prostate cytosol labelled with 
[^H] dihydrotestosterone and [^HjORG 2058 labelled rat uterine cytosol 
also were also run on SDG but there was no change in the peak of sedimenta­
tion value observed (Figure 27) in the presence of the antiserum.
3.4.3 Immunoadsorption Chromatography
Specificity was also checked using immunoadsorption 
chromatography. IgG-ER was immobilized onto sepharose-4B resin and 
incubated with cytosol from various preparations. The resin was 
washed to remove non-specifically bound protein. The retained 
proteins were then eluted with DES containing 0.5M sodium 
thiocyanate and 10% DMF. The eluate was analysed on native gels 
(Figure 28). A single band on the gel of each uterine sample 
(human, rat and rabbit) had a molecular weight in the region of
240,000. The dark region on the surface of the origin was due to 
oestrogen receptor aggregation which had failed to gain entry into 
the 4% gel in the continuous Tris-borate-EDTA buffer system. Sica 
and Bresciani (1979) added heparin in their buffer system to 
facilitate entry of protein into the gel while Skipper et al. (1985) 
used agar in place of PAGE for the stacking gel to allow entry of 
aggregating oestrogen receptor. The appearance of a single band 
indicated that the antiserum immobilized on the resin was retaining 
protein in a highly selective manner.
3.4.4 Time Course Study of IgG-ER Interaction with Oestrogen 
Receptor
O
The time course of the preincubation of the [ H]E2 cytosol with 
antibody is shown in Figure 29. As expected for specific protein- 
protein interaction, with the antibody present in limiting amounts, 
the time course indicates a single saturation curve.
3.4.5 Blotting
Transferring the electrophorised protein from the 5% SDS-PAGE 
onto the nitrocellulose paper overnight seems to be successful in
1A5
Figure 26; Effect of IgG-ER on the Sedimentation 
Values of Oestrogen Receptor (high salt).
Aliquots of [ ^HjE^-receptor complex were 
incubated with normal rabbit serum (o) or 
with antiserum (•) in a final volume of 
250pl. After 4h at 0®C, the samples (200|il) 
were centrifuged for 16h at 230,000xg on a 
sucrose gradient in TEDKq Arrows indicate 
migration of standards (1) 4.6S BSA, (2) 7.IS 
human-^-globulin. In the absence of antibody, 
the major radioactive component (receptor) 
sedimented in the region of 4S. Incubation of 
labelled cytosol with antibody resulted in a 
shift from 4S to about 8S.
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Figure 27 Sedimentation pattern of progesterone and 
DHT : receptors in the presence of antibody to 
oestrogen receptor.
Progesterone-receptor complex was prepared 
according to (Logeât et al., 1981) by 
incubating InM ( H]ORG 2058 with rat uterine 
cytosol for Ah at 4*C. [^H]DHT-receptor complex 
was prepared by incubating 2nM with rat
prostatic cytosol (Greene et al.,1977) for 4h at 
0°C. Aliquot from each receptor complex 
preparation was incubated with antiserum (50pg) 
in a final volume of 250pl. After 4h at 0°C, 
200pl of the samples were centrifuged for 16h at 
230,000g on a sucrose gradient in TEDKq ^ . No 
difference in the sedimentation value was 
observed in the absence and the presence of 
antibody. The radioactive receptors were found
in the 4S region.
(•) t^H]DHT receptor 
(o) progesterone receptor
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Figure 28: Characterization of Protein Eluted from
Immobilized IgG (Immunoadsorbent).
Cytosols containing oestrogen receptor from 
uterine tissues of different species (human, rat 
and rabbit) were prepared as in section 2.2.2.1. 
The cytosols were then incubated with antibody 
immobilized onto Sepharose 4B and the rest of 
the procedure was described in section 2.4.5.1. 
The eluates from the immunoadsorbent were run on 
PAGE in Iris-borate-EDTA continuous system.
lane 1. Standard molecular weight markers 
lane 2. human myometrium 
lane 3. rat uterus 
lane 4. rabbit uterus
240,000-
170,000.
97,000
55,400.
36,000-
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demonstrating the presence of antibody specific to the oestrogen 
receptor. Three preparations: crude cytosol, ammonium sulphate 
precipitate-treated oestrogen receptor and purified oestrogen 
receptor were run on the gel for 2h before transfer to the 
nitrocellulose paper. In each of the three samples, a band in the 
region of molecular weight 65,000 was evident (Figure 30). The 
appearance of these bands demonstrated that oestrogen receptor 
immobilized on nitrocellulose paper can be used to detect its 
antibody and secondly the specificity of the antisera can be 
deduced.
3.5 OESTROGEN RECEPTOR DISTRIBUTION AND TRANSLOCATION
3.5.1 Oestrogen Receptor Distribution in Oestrogen Responsive 
Tissues
The antiserum was produced against oestrogen receptor from 
human myometrium; therefore, it was tested for its capacity to react 
with the receptor from human myometrium and endometrium. Frozen 
sections of human uterus obtained from a patient of perimenopausal 
age were utilized for this purpose. Reactivity studies of the 
anti-receptor (anti-ER) antiserum with the human myometrium and 
endometrium revealed two types of staining. In the frozen sections 
of the endometrium processed for immunohistochemical demonstration 
of oestrogen receptor, cytoplasmic as well as nuclear fluorescence 
of the glandular cells lining the ducts were seen. The stromal 
cells also exhibited a weaker fluorescence. The nuclei were free of 
fluorescence in these cells (Figure 31a). This uneven distribution 
of oestrogen receptor in human endometrium had been reported by 
Tsibris et al. (1981). In the frozen sections of the myometrium, 
most of the cells (about 90%) exhibited cytoplasmic staining, with a 
few cells (about 10%) showing nuclear staining (Figure 31b). A 
section of the human myometrium was stained using haematoxylin/eosin 
(H&E) (Figure 31d).
In the immature rat endometrium, immunochemical staining was 
observed in both the cytoplasm and the nucleus of the epithelial 
cells of the endometrial glands. However, the staining of the
150
Figure 30; Electrophoretic blotting of oestrogen receptor 
from 5% SDS-PAGE.
Three preparations containing oestrogen receptor 
were run on 5% SDS-PAGE, transferred to 
nitrocellulose paper overnight and incubated 
with antibody to oestrogen receptor. Iodine 
labelled protein-A was used to detect the 
antigen-antibody reactivity. The nitrocellulose 
paper was then subjected to autoradiography.
lane 1. Crude cytosol from human myometrium 
lane 2. Ammonium sulphate treated cytosol 
lane 3. Affinity chromatography eluate
94.000-
67.000-
43.000-
1 2 3
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Figure 31(a-d): Oestrogen responsive tissues displayed 
the presence of oestrogen receptor by the 
IF technique.
(a) Frozen section of human endometrium 
was incubated with anti-ER antiserum 
followed by FITC goat anti-rabbit IgG. The 
tissue was observed using an oil immersion 
lens. Bright positive staining in the 
cytoplasm and nucleus of the cells lining 
the duct was observed. Stromal cells are 
weakly stained, mostly in the cytoplasm 
(xlOOO),
(b) Frozen section of human myometrium. IF 
was localized in the cytoplasm of most 
cells. Only a few cells showed nuclear 
staining (xAOO).
m m
(b)
152
Figure 31(c): Demonstration of oestrogen receptor
translocation in human myometrium. 
Adjacent sections from the same uterus 
were taken and incubated with InM E2 at 
37®C for Ih. A different staining pattern 
from the above (b) was observed. Most of 
the staining was seen in the nuclei with 
few cells having cytoplasmic staining. 
The increase in the number of nuclei 
stained showed that translocation had 
taken place (x400).
(d) Haematoxylin/eosin-stained frozen 
section of human myometrium showed the 
distribution of cells.
(c)
;
(d)
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Figure 31(e): Frozen section of rat uterus. The tissue
displayed a marked degree of IF staining. 
The fluorescence was seen localized in the 
cytoplasmic as well as nuclear compart­
ments of the glandular cells, a similar 
pattern of staining to that seen in the 
human uterus. The stroma exhibited weaker 
staining, mostly cytoplasmic (x400).
(f) A breast carcinoma which was ER+ by 
biochemical assay (112fmol/mg cytosol). 
There was strong cytoplasmic fluorescence 
in some of the tumour cells. Faint IF+ was 
also observed in some cells (x400).
(f)
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stroma cells was exclusively cytoplasmic (Figure 31e).
Frozen sections of ER+ breast carcinoma (112fmol/mg cytosol 
protein) showed positive cytoplasmic staining. The intensity of 
cytoplasmic staining varied in some areas (Figure 31f). The nuclear 
staining was not observed. The staining intensity varied from one 
cell subpopulation to another and some cells were negative. Similar 
results were obtained by Garancis et al. (1983) using monoclonal 
antibodies to oestrogen receptor. However this group used paraffin 
embedded tissues and the PAP technique as the method of receptor 
detection. Their results, using frozen instead of paraffin embedded 
sections were disappointing. Greene and Jensen (1982) who reported 
cytoplasmic staining using monoclonal antibodies on frozen sections 
of the breast, later reported nuclear localization of oestrogen 
receptor.
3.5.2 Oestrogen Receptor Distribution in ZR-75-1 Cells
The experiments described were carried out on the ZR-75-1 cell 
line. Being derived from the metastatic pleural effusion of a 
patient with breast cancer, these cells are generally accepted as an 
appropriate model for hormone-dependent breast tumours. Biochemical 
assays showed that the cell line contains 30-50fmol/mg protein. In 
the cytoplasm of ZR-75-1 cells, the immunochemical staining was seen 
localized in granules. The staining was diffused, and it appeared as 
a fine granular precipitate. The cytoplasmic staining was present 
in the form of fine, yellowish-green intracellular particles which 
varied from a few to many (Figure 32a). The nuclear staining 
appeared in the form of fine, green (yellowish green) intranuclear 
particles which were often so numerous that the nuclei appeared to 
be almost entirely filled with the stain (Figure 32b). The same 
observation was reported in the pituitary cells by Morel et al. 
(1981) using goat antibody to oestrogen receptor. In the nucleus, 
they were distributed all over the chromatin. Detailed observations 
by Morel et al. (1981), using electron microscopy, revealed the 
distribution of the oestrogen receptor in the euchromatin and the 
neighbouring dense heterochromatin of the nucleus.
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Figure 32 (a-g): In Vitro Translocation Experiments on 
ZR-75-1 cells.
The ZR-75-1 cells were transferred to 
fresh medium containing InM E2 or DES
incubated for Ih at;
(a) 4®C prior to localization of oestrogen
receptor using the IF technique. All the 
cells retained their IF in both nuclei and
cytoplasm in the form of localized
granules (x400).
(b & c) 22*C prior to localization of oestrogen
receptor. Besides the cytoplasmic 
staining, the cell also exhibited a dense, 
distinctive, nuclear staining which shvwud 
that translocation was beginning to occur 
(b) xlOOO, (c) x400.
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Figure 32(d & e): The ZR-75-1 cells were transferred
to fresh medium containing InM E2 or DES 
incubated for Ih at 37°C prior to oestro­
gen receptor localization. Only nuclear 
staining was evident. Fluorescence was 
not seen in the cytoplasm of the cell, 
making it difficult to see the outline of 
the entire cell (d) xlOOO, (e) x250.
» (d)
a
(e)
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Figure 32(f & g ): The cells were incubated with E2 for 
2h. Nucleolar fluorescent and a membrane 
fluorescence were demonstrated in this 
cell. The nucleolar staining appeared in 
spot like fluorescent in this highly mag­
nified cell (xlOOO).
( g) The phase contrast photograph of (f) sho­
wing the detail structure of the cell 
(xlOOO).
% (£)
(g)
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Figure 32 (h); Rat endometrial cells in culture. The 
cells were grown in the presence of E2 at 
37*C and fixed with methanol:acetone prior 
to oestrogen receptor localization. The 
IF was found to be distributed mostly in 
the nucleus of the cells.(xAOO)
(h)
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3.5.3 Control Experiments
3.5.3.1 Reagent Controls
When the antiserum was preincubated with a saturating 
concentration of oestrogen receptor cytosol from positive human 
breast carcinoma (>500 fmol/mg protein), no such staining was 
observed i.e. no granules indicating immunoreactivity were present 
(Figure 33a). Another set of experiments was carried out on 
translocated receptor in ZR-75-1 cells with antiserum preadsorbed 
with purified oestrogen receptor and similar results were seen 
to occur. Preabsorbing the anti-ER antiserum with ER- cytosol 
of breast tumour was ineffective in eliminating the antibody- 
specific immunofluorescence (Figure 33b). Also preabsorbing the 
antiserum with E2 (Figure 33.c) showed similar staining distribu­
tion.
3.5.3.2 Tissue Controls
Frozen sections of ER- breast tissue showed neither cytoplasmic 
nor nuclear staining (Figure 33d and 33e). A section of ER- breast 
tissue was stained with H&E as shown in Figure 33f. Another 
negative control was obtained with spleen (Figure 33g).
3.5.4 Translocation of Hormone-receptor Complexes
Additional confirmation for the specificity of the antiserum to 
oestrogen receptor could be derived from the in vitro experiments on 
translocation.
3.5.4.1 Oestrogen Receptor Localization in Cells Grown in the 
Absence of E2
In all the cells grown for Ih in the absence of cytoplasmic 
as well as nuclear immunofluorescence was evident. If the cells were 
maintained in an oestrogen-free medium for 24 or 48h and then each 
left at 4, 22 or 37*C for Ih, the fluorescence was distributed both 
within the nuclei and in the cytoplasm. Figure 34a and 34b show the
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Figure 33(a-h): The Specificity of the Antiserum by IF and 
Preabsorption Technique.
The specificity of the antiserum 
towards oestrogen receptor was checked by 
using preadsorbed antiserum in place of 
primary antiserum with ZR-75-1 cells. The 
anti-ER antiserum, was preadsorbed with 
various reagents:
(a) cytosol from ER+ breast cancer 
biopsies, >500fmol/mg protein (determined 
biochemically). The fluorescence in the 
ZR-75-1 cells was reduced from the normal 
level (x250).
(b) cytosol from ER- breast cancer. The 
intensity of the staining was the same as 
in cells incubated with unabsorbed anti-ER 
antiserum (x250). -
(a)
(b)
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Figure 33(c); The antiserum was preabsorbed with E2.
This absorption does not seem to affect the 
fluorescence level in the cells (x250).
%i
(c)
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Figure 33(d-h): Various tissue controls were used to
determine the specificity of the anti­
serum.
(d) A breast fibroadenoma which was ER- 
(biochemically determined) was taken as a 
negative control for human tissue. Nega­
tive cytoplasmic and nuclear staining 
indicated the absence of oestrogen recep­
tor in this tumour (xAOO).
(e) The presence of the epithelial cells 
was shown by the staining of the DNA with 
Hoechst 33258 (x400).
(f) A section of human breast stained with 
H & E (xlOO)
': -c, -'M
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Figure 33(g): Rat spleen was taken as negative control
for rat tissue. The frozen section was 
incubated with primary antiserum followed 
by IF localization ofthe oestrogen recep­
tor. Only very faint non-specific fluores­
cence is seen in this negative tissue 
(xlOOO).
(h) A frozen section of rat liver pro­
cessed for oestrogen receptor localiza­
tion by the IF technique. Staining was 
seen in the cytoplasm though the intensity 
was much less than the uterine tissue of 
the same species (xlOOO).
(g)
i t4L
(h)
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Figure 34: The ZR-75-1 cells were grown in the
absence oestrogen and processed for 
oestrogen receptor using IF technique.
(a) ZR-75-1 cells unexposed to ligands at 
4°C and processed for IF localization 
of oestrogen receptor. The IF 
localized in both cytoplasmic and 
nuclear compartment in all the cells.
(b) ZR-75-1 unexposed to ligand at 37*C 
and processed for IF localization. No 
change was seen in distribution 
pattern of the IF compared to (a).
(a) x400
(b) x400
(a)
(b)
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IF distribution in cells maintained at 4 and 37®C respectively. 
Exposure of these cells for >48h in the medium without ligands at 22 
and 37°C did not alter the cellular distribution of immuno­
fluorescence.
3.5.4.2 Effect of Exposure to ££ and DES
ZR-75-1 cells, grown in the continued presence of E2 (10“% )  
for 24 and 48h, were incubated with ligand for Ih at 4, 22 and 37®C. 
The fluorescence, seen in the cells exposed at 4"C to E2 or DES, 
appeared to be homogenously distributed over the cytoplasm as well 
as the nucleus, while those incubated with ligand at 22*C showed 
denser staining within the nuclear membranes (Figure 32b,c). 
Incubation at 37*C for Ih showed nuclear but no cytoplasmic 
staining (Figure 32d,e). When the incubation time was increased to 
2h nucleolar-like spots of fluorescent with no detectable 
fluorescence in the chromatin network or the nuclear matrix 
('nucleolar' fluorescence) (Figure 32f) were seen in cell. Raam et 
al. (1983), working on an endometrial cell culture and Tamura et al. 
(1984) on ER+ breast cancer frozen sections, incubated with 
different concentrations of Eg, DES, or monohydroxytamoxifen (2.5 to 
250nM) for 2h at 37*C found that immunofluorescence was localized 
only in the nuclei. However, Lope-Pihie et al. (1985) found that Ih 
incubation was sufficient for complete translocation to take place 
which was found insufficient by the above mentioned groups. They 
found that when the incubation time was reduced to one hour, 
although the fluorescence was localized predominantly in the nuclei, 
in all the cells the cytoplasm also retained fluorescence. This was 
weaker compared to the controls, but when reexamined the 
fluorescence had become intranuclear and the cytoplasm was free of 
fluorescence. In other studies in vivo translocation of oestrogen 
receptor and progesterone receptor (PgR) has been demonstrated by 
Morel et al. (1981, 1984) on pituitary cells using goat antibody to 
oestrogen receptor and the PAP technique. They observed a reduction 
in cytoplasmic staining and an increase in nuclear staining after an 
injection of Eg into an immature rat. In the present study, quanti­
tative measurement of the staining had been carried out. Figure 36a, 
b and c are histograms of the ratio of staining in the nucleus (N) 
to staining in the extranucleus (E). A value more than 1 denoted 
translocation had taken place.
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Figure 35(a-c): In vitro translocation study in
ZR-75-1 cells in the presence of proges­
terone.
(a) The cells were transferred to fresh medium 
containing InM progesterone and incubated 
for Ih at 4*C. The cells were processed 
for IF localization of oestrogen receptor. 
The cells retained the IF in the cytoplasm 
only. The cytoplasm is vacuolated in most 
of the cells shown in this area (x400).
(b) When the cells were exposed to proges­
terone longer (24 and 48h), the staining 
pattern remained in the cytoplasm but the 
IF intensity was much reduced compared to 
cells grown in medium without exogenous 
progesterone (x400).
(c) Cells were transferred into progesterone 
• containing medium and incubated for Ih at
37°C. They exhibited slightly stronger 
staining in the nucleus indicating that 
some translocation had taken place, though 
not completely as shown by the presence of 
cytoplasmic staining (xlOOO)
(a)
f
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»
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(b)
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3.5.4.3 Incubation with InM Progesterone Alone
The cells grown in the presence of progesterone alone in Eg 
free medium for 1, 24 and 48h showed a different pattern of staining 
from above. In the presence of progesterone (exposure for Ih at 4®C) 
the cells exhibited only cytoplasmic fluorescence (Figure 35a). The 
same was observed when the cells were grown for a longer period (24 
and 48h) in progesterone. However the quantity of staining was 
obviously reduced when compared to cells grown in Eg (Figure 35b) 
which is consistent with the finding that progesterone inhibits the 
synthesis of oestrogen receptor (Soutter et. al., 1979) in human 
endometrium (at late follicular phase). When cells were incubated 
at higher temperatures (22 or 37°C) for Ih, they exhibited nuclear 
fluorescence along with some cytoplasmic fluorescence (Figure 35c). 
Quantitatively, the extra-nuclear/nuclear ratio (E/N) of staining 
was <1 after incubating at 4®C in all the three cases but increased 
to >1 when incubated at higher temperatures (Figure 36c). In the 
presence of progesterone translocation seems to occur, even though 
quantitatively there was less than in the presence of Eg. Similar 
translocational behaviour was observed by Raam et al. (1983) and 
Tamura et al. (1984) on ER+ and PgR+ tumours. They found that 
translocation only occurred in ER+ tumours in the presence of 
progesterone. In ER+ PgR- tumours only cytoplasmic staining was
found. Using goat anti-ER and anti-PgR antibodies. Morel et al.
(1981, 1984) demonstrated the presence of both receptors in the 
cytoplasm of the same cells (gonadotropic, lactotropic and
somatotropic cells) of the pituitary.
Biochemically, it has been seen that cytosol oestrogen receptor 
can be translocated to the nucleus in vitro by a process which 
depends on temperature, time and dose of Eg (Sumida and Pasqualini, 
1979; Sumida et al., 1982; Holt et al., 1983; Giambiagi et al.,
1984).
3.5.4.4 Myométrial Frozen Section
Incubating with InM Eg for Ih at 37°C showed immunofluorescence
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localized in the nuclei of most cells and in the cytoplasm in some 
cells (Figure 31c).
3.5.5 Tissue Cultures of Immature Rat Endometrial Cells in Eg Con­
taining Medium
Endometrial cells, cultured for this experiment by Dr. R. 
Field (Glasgow University), contained a population of glandular 
epithelial cells (Figure 32h). Some of the cells demonstrated 
cytoplasmic as well as nuclear immunofluorescence while others 
showed denser nuclear staining. The cells were grown in Eg and 
immediately fixed (acetone ; methanol) after removal from the growth 
medium.
3.5.6 Oestrogen Receptor in the Liver
Additional experiments were performed on frozen sections of 
immature rat liver. Immunoreactivity of oestrogen receptor was 
detected in the cytoplasm though the staining was less intense after 
incubation of the ultra-thin slices with the antibody diluted to 
50-fold (Figure 33k). However, contrary to the result obtained in 
the human and rat uteri, there was very little immunoreactivity 
observed with more diluted antiserum (100-fold). This immunohis- 
tological observation was of interest, since the report of the 
presence of oestrogen receptor (Hester and Baulieu, 1972) and E2 
action (Greengard et al., 1965) in the liver.
3.6 QUANTITATIVE APPLICATION OF IMMUNOCYTOCHEMISTRY
3.6.1 Immunofluorescent Studies on FNAs of Breast Cancer
In 50 breast cancer cases, FNA samples were collected at the 
out patient breast clinic at the Western Infirmary and R.A.I., 
Paisley. Whenever possible a parallel experiment was conducted 
using the biochemical assay on the biopsy sample obtained at surgery 
and the results compared with those of the anti-ER antibody assay.
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Immunofluorescence (IF) technique for detection of oestrogen
receptor in FNA is very similar to that for frozen tissue and
ZR-75-1 cells. Immediately after acetonetmethanol or acetone
fixation, the cells were incubated with anti-ER antiserum at 
100-fold dilution for 45-60min, rinsed, then incubated with 
secondary antibody (which is goat anti-rabbit conjugated with FITC) 
and the receptor quantified using a MPV compact linked to a 
fluorescence microscope. For quantitation, the IF in the area 
occupied by the cell was measured. Some samples exhibited 
heterogeneity in the IF. The intensity values of the IF were divided 
into three categories viz. A = <30, B = between 30-60 and C = >60 
(Figure 37). Each value was corrected by subtracting the IF from 
sample treated with normal rabbit serum in place of primary serum. 
If more than 90% cells fell into category A, the sample was
considered negative. The number of cells counted was 100 to 150 
cells. If the cell numbers in the FNA was less than this then the 
sample was reported as having insufficient cells.
Figures 38a,b and c show samples, positive by both anti-ER 
antibody and biochemical assays. The staining was clearly 
demonstrated in both the nucleus and the cytoplasm. Heterogeneity of 
the staining was observed and found to vary according to the 
oestrogen receptor status (Figure 39a,b,c). The antibody was 
selective, as indicated by the lack of any specific staining in 
cells taken from a tumour that was biochemically ER- (Figure 41a,b).
3.6.2 A Study of Heterogeneity of Tumour Cell Population in Relation 
to Oestrogen Receptor Distribution
3.6.2.I ER+ Tumours.
The results of 21 ER+ tumours, by biochemical assay, are given 
in Table 6. Tumours which had an oestrogen receptor content of >400 
fmol/mg cytosol protein were characterized by a high proportion of 
tumour cells and clearly a high degree of homogeneity with 5/21 
cases composed exclusively of IF( + ) cells (Figure 38a,c). Tumours 
with an oestrogen receptor content between 150 to 399 fmol differed
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Figure 37: Quantitative values of intensity of IF
staining
(a) Comparison of the intensity of staining 
with the oestrogen receptor concentration 
(cytosol and nucleus) obtained from the 
biochemical assay. Corrected intensity values 
were obtained by subtracting the staining 
with the normal rabbit serum from the 
staining of the cells with antiserum.
(b) Distribution of IF staining in the cell 
smears showing heterogeneity in cell 
population.
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Table 6: Comparision of oestrogen receptor results by the
biochemical method and anti-ER antibody assays.
Oestrogen Receptor Status 
by Standard Biochemical 
Assay
Pre-operative
Antibody
+
FNA Anti-ER 
Assay
ERc+/ERn+ 21 20 1
ERc-/ERn- 26 2 24
ERc+/ERn- 3 0 3
ERc-/ERn+ 0 0 0
Total 50 22 28
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Figure 38(a-c): The FNA samples were analysed using the 
anti-ER antibody assay.
(a) Intense cytoplasmic as well as nuclear 
staining indicated that the anti-ER 
antibody reacted with most cells in this 
sample which fell into the group with 
>400fmol/mg protein (Patient C.B., Figure 
37) (x250).
(b) The phase contrast showed the tumour cells 
among the red blood cells (x250).
(c) FNA sample from another patient in the 
same group. Similar pattern of staining 
were seen (x250).
(a)
(b)
& (c)
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from the first category of tumours in exhibiting a degree of 
heterogeneity containing a mixed population of IF(+) and IF(-) cells 
(Figure 39a,b). The next category of ER+ tumours (20-149 fmol/mg) 
showed extensive tumour heterogeneity (Figure 39c). Tumour with no 
ERri (ERc+/ERn-) had >95% IF(-) cells (40a,b).
3.6.2.2 ER- Tumours
Of 26 biochemically ER- tumours, 24 were exclusively IF(-) and 
the remaining 2 contained a mixture of IF(+) and IF(-) cells of 
which the latter was in the majority. One sample showed a group of 
tumour cells which had nuclear staining (Figure 41c).
3.6.3 Anti-ER antibody assay Versus Standard Biochemical Assay
A good correlation of results was obtained with the oestrogen 
receptor status of the tumours for 47 out of 50 cases of FNA samples 
in which the biochemical data on oestrogen receptor values were 
available (Table 6). Twenty out of 21 cases were ER+ by both 
antibody and biochemical assays. In the one exception, it was not 
possible to estimate the proportion of tumour: mesenchyme cells in 
the biopsy, but in the FNA sample the number of IF(-) cells 
outnumbered the IF(+) cells.
Since the smears of cells were spread over a wide area, it was 
impossible to count all the cells. Therefore 100 to 150 cells picked 
at random were quantitated and the number of IF(+) and IF(-) cells 
were tabulated based on the intensity values (Figure 37). No direct 
correlation was found between the intensity of IF and quantity of 
oestrogen receptor (Figure 37). However the cell morphology was 
very well preserved. Therefore, for cases in which the tissue 
material was limited, a study of cytological smears by anti-ER 
antibody procedure may prove to be the best alternative for 
determining the oestrogen receptor status of the tumour.
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Figure 39(a-c): Photographs (a) and (b) were from FNA
samples from tumours with 150-399fmol/ag 
protein (biochemically determined).
(a) Patient S.C., Figure 37. (x250)
(b) Patient C.H., Figure 37.
Heterogeneity existed among the IF+ tumour 
cells from these patients. The IF- cells 
appeared to be dispersed and small in 
number (x400).
(c) This sample was from a group of tumours 
with 20-149fmol/mg protein (Patient U.G., 
Figure 37). Heterogeneity of IF+ and IF- 
cells are shown in this photograph (x40C).
' ‘ v V
(a)
(b)
(c)
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Figure 40(a): This sample (Patient J.M., Figure 37),
which contained cytoplasmic but no nuclear 
receptor (clinically receptor negative) 
displayed cells which were IF(-).
(b) A phase contrast photograph of (a) (x400).
(a)
m
ë
(b)
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Figure 41(a): Antibody assay on ER- breast cancer. No 
cytoplasmic as well as nuclear 
fluorescence indicated the absence of any 
anti-ER antibody reactive cells in this 
tumour which is ER- by the biochemical 
assay (x400).
(b) The same sample counterstained with 
Hoechst. The presence of the DNA staining 
showed that tumour cells were present in 
this sample (x400).
(c) Nuclear staining observed in a group of 
cells from one of the ER- breast cancer 
biopsies (determined biochemically) 
(xlOOO).
(a)
(b)
(c)
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DISCUSSION
4.1 EARLY ATTEMPTS ON OESTROGEN RECEPTOR PURIFICATION
The initial efforts to purify the oestrogen receptor from human 
breast cancer tissue involved the use of protein separation by 
disc-PAGE, DNA-cellulose chromatography, DEAE Sepharose and 
Phenyl-Sepharose. Using these techniques the degree of purification 
obtained was less than 260-fold, primarily due to the loss of 
substantial amounts of binding activity.
Two peaks (peaks A and B) of protein binding were detected when 
the cytosol prepared from human uterus were run on SDS-PAGE. Peak A 
appeared at 240,000 molecular weight while peak B was about 65,000 
molecular weight. The comparatively high levels of E2 binding sites 
in the tracking dye peak of the uterine cytosol was probably due to 
vascularity of this tissue and hence high levels of [3h]E2 
dissociating from the serum albumin. Skipper et al. (1985) reported 
the appearance of two peaks from rat uterine cytosol designated as 
F-fast peak and S-slow peak. The F peak had been calculated as 
65,000 molecular weight. To account for the effect of stacking on 
the oestrogen receptor, a hypothesis was postulated by Skipper et 
al. (1985) based on the events occurred during the stacking process 
and on the three assumptions concerning the structure and 
transformation of the native receptor. These assumptions are as 
follows: (a) the peak of 65,000 molecular weight is the native 
receptor; (b) looking at the number of peaks, at least some of its 
subunits are different proteins which are bound together by 
noncovalent forces; and (c) dissociation of these subunits causes 
transformation. During the stacking process, each protein in the 
sample is concentrated into individual ultrathin zones which are 
arranged in an order according to their individual surface charge 
(Ornstein, 1964).
The hypothesis is stated as follows: (a) the oligomeric
subunits of the receptor are dissociated by the stacking forces of
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disc-PAGE; (b) the subunits do not reassociate because they are 
different proteins which are separated into individual zones of the 
"stack"; (c) from the third assumption (dissociation = transforma­
tion), the preceding steps result in transformation of the 
oestrogen-binding subunits to a DNA-binding state which then binds 
tightly to some extraneous component (perhaps RNA) in the crude 
cytosol, thus forming aggregates which are too large to move into 
the polyacrylamide-separating gels. Ben-Or and Chrambach (1981) 
also concluded that the glucocorticoid receptor is converted to 
similar aggregates in disc-PAGE analysis. Applying this hyphothesis 
to the observations seen in this study, peak A is the peak that is 
equivalent to the aggregated form of oestrogen receptor that is too 
big to pass through a great distance in the disc-PAGE. It was this 
peak that was being cut, pooled and injected to the experimental 
animal. This peak of 240,000 molecular weight, a species which 
according to others (Puca et al., 1973; Sica et al., 1976; Bresciani 
et al., 1978; Sica and Bresciani, 1979) is the large molecular 
weight oestrogen receptor.
According to the calculation, the amount of oestrogen receptor 
complexes used for immunizing the experimental animals for antibody 
production was equivalent to lOOfmol, and assuming a molecular 
weight of 240,000 and a stoichometric ratio of four E2 per molecule 
of receptor, 24ng was injected. However no antibody was detected 
even though Raam et al. (1973; 1981) reported that polyacrylamide 
had an adjuvant effect. Overestimation of the total protein injected 
was a possibility that cannot be excluded. The presence of 
non-functional receptors incapable of binding £2» was also another 
possible factor. If the non-functional phenotypes had an 
electrophoretic mobility identical to that of the [^H]E2 -receptor 
complexes, they will be included to the protein bulk.
Using chromatography techniques, the purification procedure 
described in this study was based on the ability of the 
steroid-receptor complex to interact with DNA following an 
activation step. The differential affinity of the nonactivated and 
activated forms of the steroid-receptor complexes for DNA-cellulose
1.83
had proved a useful tool in the characterization or the partial 
purification (or both) of the androgen receptor in rat prostate 
(Mainwaring and Irving, 1973), the subunit of the progestin receptor 
in chick oviduct (Kuhn et al., 1977), the glucocorticoid receptor in 
rat liver (Kalimi et al., 1975; Wrange and Gustafsson, 1978) and the 
oestrogen receptor in rat uterus (Yamamoto and Alberts, 1972;
Yamamoto, 1974).
Several groups had reported the partial purification of steroid 
receptor by chromatography procedures on DNA cellulose and/or DEAE 
Sepharose (Soloff and Szego, 1969; Puca et al., 1973; Wrange et al.,
1979). However, these previous studies, as well as this work, did 
not result in either a sufficiently pure receptor preparation or in 
sufficient amounts of the purified receptor to allow further
characterization of the protein by, for example, SDS-gel electropho­
resis. Available evidence suggested that variable degrees of 
dénaturation of the receptor molecule were responsible for the wide 
distribution of binding activity in eluates from DEAE Sephadex. 
Dénaturation was likewise believed to be the cause of loss in the 
receptor activity occurring during the purification (Soloff and 
Szego, 1969).
The use of phenyl-Sepharose had some advantages. Phenyl 
Sepharose had a capability of binding non-activated receptor. The 
use of this matrix as the last chromatographic step was to recover 
as much oestrogen receptor as possible from the previous
preparation. In addition, the eluted steroid receptor complex seems 
to be more stable in TED:ethylene glycolrglycerol solution than in 
buffer containing high concentrations of salt that were required to 
elute the complex from DNA cellulose and DEAE sepharose.
Furthermore, when eluted with TED:ethylene glycolrglycerol, the 
resulting receptor preparation can be further characterized on 
SDS-PAGE without undergoing dialysis as the ionic ètrength was low. 
However, disc-electrophoresis showed that this final purification 
step resulted in a relatively heterogeneous protein content. Due to 
this reason a better and more efficient method of purification was 
sought.
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4.2 AFFINITY CHROMATOGRAPHY
Because of the minute amounts of oestrogen receptor in target 
tissue extracts (less than 5mg of oestrogen receptor is recovered per 
kg uterine tissue processed) it was convenient to employ a concentration 
step using ammonium sulphate precipitation prior to the subsequent 
purification procedure. Purification of soluble oestrogen receptor 
of uterus was also facilitated by the treatment of the uterine 
cytosol with calcium ions in the presence of salt to yield a 
'stabilised' 4S binding unit which did not aggregate or revert to 
the native low-salt form (8S) when the salt was removed (Sica et 
al., 1973).
The purification of oestrogen receptor had been hindered by 
various factors such as endogenous proteases, heat liability, and 
the low levels of receptor in available tissues. These problems 
could be overcome by the use of affinity chromatography, by the 
addition of the appropriate protease inhibitors, and by working at 
lower temperatures (Puca et al., 1977; Sherman et al., 1983). The 
problem of stabilization of the binding activity of the oestrogen 
receptor long enough to load it on an affinity column has been 
solved primarily by: (1) working at 5°C; and (2) using compounds 
which can act as protease inhibitors, in particular, EDTA. EDTA is 
presumed to inhibit a Ca^^-activated protease present in uterus 
(Puca et al., 1972; Sica et al., 1976; Puca et al., 1977). All these 
compounds have been found to stabilize the E2 binding activity of 
crude cytosol for at least 2 days at 4®C in TRIS buffer. Although E 2 
affinity columns had been available for the last 10 years, they had 
been of limited use because of stability and elution problems due to 
certain physical properties of both E2 and the receptor. The 
receptor has a Kj of 10~^®-10“^^M with a dissociation rate half-life 
of over a day at 4®C (Clark and Peck, 1979). The limited solubility 
of E2 (micromolar range) in aqueous buffers and the fact that the 
unbound receptor itself is unstable required special attention. 
Overall, rapid processing of large volumes of material with low 
levels of unstable receptor, elution in a nondenaturing solvent, and 
storage under stable conditions were essential in the purification 
of the receptor protein.
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The stability of the affinity column is essential and they 
should also have the proper selective binding affinity. Two 
procedures of synthesis of affinity resin have been published. One 
involved E2 linked to agarose through the \1^ position via an ester 
bond (Sica et al., 1973; Sica and Bresciani, 1979; Puca et al.,
1980) and the other involved E2 linked to agarose via a 
\lj£ -thioester bond (Greene et al., 1980).
Affinity chromatography with adsorbents containing steroid 
molecules linked to agarose through the \ip> position via an ester 
bond had been employed in this study of oestrogen receptor 
purification. This method of purification has also been applied to 
oestrogen receptor purification by Luden et al. (1972) and specific 
serum binding proteins for testosterone by Burstein (1969) but they 
were not successful in the elution procedure. Luden et al. (1972) 
had described in detail the general problem also reported by others 
(Cuatrecasas and Anfinsen, 1971; Cuatracasas, 1972). Rosner and 
Bradlow (1971) had described the purification of corticosteroid- 
binding proteins from human plasma by using agarose columns 
containing cortisol hemisuccinate and Sica et al. (1973), on 
oestrogen receptor purification, using agarose columns containing 
E^-hemisuccinate.
Some problems that had been commonly met were; (1) the removal 
of the noncovalently adsorbed hormone in the preparation of E2 
affinity chromatography. This is important before the columns could 
be used (2) The tenacious nature of the oestradiol-gel interaction 
requires the gels to be extensively washed over prolonged periods of 
time with very large volumes of organic solvents or with protein 
solutions such as albumin or crude uterine supernatant. This is 
important as it could alter the partitioning properties of E2 
between the gel and the aqueous medium and thus markedly enhance the 
release of adsorbed hormone from adsorbents, (Cuatrecasas, 1972; 
Luden et al., 1972). Failure to wash the gel adequately can result 
in the release of large quantities of E2 into the sample containing 
oestrogen receptor. Release of adsorbed E2 during chromatography of 
the sample may lead to the erroneous conclusion that the column is 
effectively removing the receptor from the sample. Of course, the
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subsequent recovery of oestrogen receptor by specific elution was 
conclusive proof that the affinity column had extracted the 
macromolecule.
The amount of E2 release was found to be negligible in this 
study. Puca et al. (1973) also reported the same observation, but 
others (Atrache et al., 1985; Binder, 1985; Lubahn et al., 1985) had 
reported a significant release of the free hormone especially when 
kept at room temperature. Even if there is a release of some free E2 
from the gel this does not necessarily mean that the adsorbent will 
be ineffective in selectively extracting the receptor from the 
sample. If the affinity of the free hormone released from the gel is 
not very different from that of the gel-bound hormone, the small 
amount of free hormone will not compete effectively with the much 
greater amount of immobilized hormone and the receptor will thus 
preferentially bind to the solid support. If, however the free 
hormone had a much greater (e.g. 10  ^ times) affinity, a very small 
free fraction (0 .1% of the total) would interfere with selective 
adsorption.
The application of tissue extracts to affinity columns with • an 
E2 derivative in which the hormone was attached to agarose through 
position 3-0-ester bond was reported to result in the catalytic 
cleavage of matrix-bound hormone molecules as well as resulting in 
the facilitated release of hormone which is adsorbed to the gel by 
noncovalent forces (Sica et al., 1973). The E2 derivative in which 
the hormone was attached to agarose through position 11^  of the E2 
molecule (Figure 7) proved to be more stable from attack of 
esterase, even though Lubahn et al., (1985) reported its lack of 
stability compared to the attachment of the E2 derivative to agarose 
via the thioester bond. These E2 derivatives retain substantial 
affinity for the receptor and immobilization of these derivatives 
on the agarose gels does not cause a further serious decrease in the 
affinity for the receptor. The presence of macromolecular polymers 
attached to the agarose backbone at several points could greatly 
increase the stability of the subsequently attached ligands. This 
phenomenon could reduce the loss of E2 into the solution. The other
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factor that should be considered is the basic cyanogen bromide 
linkage in the agarose gel. Sica et al. (1973) found a certain 
instability, which must be taken into consideration in experiments 
of receptor purification. However the presence of multipoint 
attachment of a branch protein copolymer should drastically reduce 
the potential problems which could result from spontaneous cleavage 
of the basic cyanogen bromide linkage groups. For this reason a 
branched copolymer of albumin or denatured albumin is used. Such a 
derivative also possesses numerous functional groups (acid-amino 
groups) which would serve as focal points for further substitution 
reactions. The present studies show that, at 4*C, these bonds are 
sufficiently stable to permit experiments under conditions where the 
release of free hormone is negligible and does not interfere with 
effective adsorption of the receptors to the gel.
Another factor which governed the release of free E2 was 
insufficient washing by organic solvent. The gel can be diluted with 
unsubstituted agarose and still effectively adsorb receptor. This is 
due to the presence of the macromolecular arms, as explained by 
Cuatrecasas (1972). This diluted gel can be washed relatively easily 
to remove noncovalently bound steroid, and it will give little 
nonspecific adsorption of non-receptor proteins during chromato­
graphy of the uterine extracts. The hormone molecules in these 
derivatives are separated from the backbone of the agarose by about 
150A and chemically neutral extensions, features which are known to 
be very favourable for selective interactions in affinity 
chromatography (Cuatrecasas and Anfinsen, 1971; Cuatrecasas, 1972).
4.2.1 The Use of Fresh Tissue in Antigen Preparation
In this experiment, the freezing of human uteri prior to 
oestrogen receptor isolation had no apparent influence on receptor 
molecular size. Atrache et al. (1985) reported a similar observation 
with calf uterine tissue. However, Sherman et al. (1983) had 
demonstrated a decrease in the size of glucocorticoid receptor 
complexes isolated from frozen rat liver as compared to fresh
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tissue. The results indicated that the activity of particular
enzymes responsible for receptor degradation may be lower in cytosol 
prepared from frozen uterus than in extracts derived from frozen 
liver. Other explanations for these observations include the
differences in the levels of endogenous inhibitors and/or activators 
of proteolysis in different tissue systems.
The experiment did not use molybdate treated cytosol, since it 
was found that it did not change the sedimentation coefficient or 
molecular weight of the affinity purified receptor. Atrache et al. 
(1985) reported the same observation. They found difficulty in the 
isolation of "molybdate-stabilized 9-lOS oestrogen receptor from 
human uterus. In contrast to the calf oestrogen receptor, they 
found that the receptor from human uterus was completely converted 
from the 9-IOS species present in crude cytosol to a AS receptor 
during their heparin-Sepharose chromatography. This might suggest 
the existance of a component, present in human uterine cytosol, 
which allows salt-induced dissociation of the 9S oestrogen receptor 
even in the presence of molybdate. Purification procedures using 
Ca^* ions and high ionic strength together inhibit aggregation and 
result in AS oestrogen receptor on a sucrose gradient (De Sombre et
al., 1969; Puca et al., 1970). Puca et al. (1971) showed that Ca^*
ions activate a macromolecular receptor transforming factor (RTF) 
which operated the transformation of 8S into stable AS oestrogen 
receptor.
A.2.2 Extraction of Receptor by Eg-Succ-Alb-Sepharose 4B
Despite many reports regarding the instability of the
adsorbent, it is of interest that the E^-Succ-Alb was effective in 
terms of its ability to extract receptor molecules from tissue 
extracts. Oestrogen receptors bind to oestradiol-hemisuccinate with 
an affinity of Kj|=l .OxlO“^M, a value which is lower than the
affinity of receptor for E2 but slightly higher than the affinity 
of receptor for oestrone carboxymethyloxime (K^=1.3xlO“®M) (Atrache 
et al., 1985). This is consistent with the report of Bresciani et
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al. (1970) who found that the oestrogen receptor has an affinity 
towards oestrone one order of magnitude less than E2. This 
oestrogen-hemisuccinate displayed sufficient selectivity to be a 
useful ligand in the preparation of an affinity resin. Sepharose 
4B, with spacer arm activation, gave a number of affinity gels 
ranging in steroid content from 0.3 to 0.5pmol/ml packed gel. The 
more dilute gels, in which nonspecific ion-exchange effects were 
eliminated by complete steroid coupling of the spacer chain gave 
consistently purer receptor preparations.
Purification of the receptor on the affinity column requires a 
ligand-free binding site. Incubation of human uterine cytosol with 
Sepharose-bound conjugates resulted in a significant decrease of 
cytosolic oestrogen receptor content. This decrease in oestrogen 
receptor content suggests an in vitro interaction of conjugate with 
cytosolic oetrogen receptor. As E2 release was sufficiently low, it 
had been possible to detect the non-specific binding proteins 
contaminating the preparation. These experiments required prebinding 
of the receptor with saturating levels of very low specific activity 
E2 and then loading, washing and eluting the affinity column in the 
regular manner. When the oestradiol-saturated crude extract was 
applied to the column and then subjected to affinity column 
chromatography under the same conditions as the crude extract, but 
without added Eg, the 65,000 molecular weight was singularly absent 
(Figure 18). Washing the column with insufficient amount of TEDKq  ^
showed the presence of all the other endogenous proteins (Figure 18) 
suggesting that they are not binding to the oestrogen receptor but 
rather directly to the affinity column by a nonspecific interaction 
which was oestrogen independent. Also after treatment of cytosol 
with control columns (resin without Eg-succ-Alb), very little 
oestrogen receptor was bound [not exceeding 10% according to this 
study, (Table 2)] which futher supports the low nonspecific binding 
of oestrogen receptor to the control materials. Thus this small 
percentage of binding was not due to conjugate-receptor interaction. 
This derivative, however, had been found difficult to handle in the 
elution steps thus making the yield very small but nevertheless very 
pure (Table 5).
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Elution of the oestrogen receptor is achieved by DES (Coffer 
and King, 1980, 1981) at either 5° or 25-30°C (Sica and Bresciani, 
1979; Greene et al., 1980; Puca et al., 1980). Warming to 30*C has 
been found to reduce the time necessary for E2 to reach equilibrium 
binding with receptor, without significantly altering the binding 
affinity (Sica et al., 1973, 1980; Greene et al., 1980; Sica et al., 
1981; Lubahn et al., 1985). Eluting the oestrogen receptor using E2 
had the disadvantage of eluting other proteins which have low 
affinity for E2 but not for DES. This could be avoided by adequate 
washing with TEDKq Bresciani et al. (1971) reported that, with
respect to E2, the 8.6S and 4.5S oestrogen receptor both have an 
affinity 1.5 to 2.9 times higher for DES. Attempts to increase 
receptor yield by the use of buffers containing sodium thiocyanate 
were not very successful but adding 10% dimethylformamide into the 
mixture helped to increase the yield significantly (Table 3).
4.2.3 SDS-PAGE of the Affinity Eluate
The major endogenous band seen in the aliquot from the E2 
eluate pool was presumed to represent the oestrogen receptor as 
verified below. The presumptive oestrogen receptor band first 
becomes evident when E2 binding affinity is initially detected in 
the eluate. A molecular weight estimation based on the migration of 
protein standards versus their molecular masses provided a value for 
this band of approximately 65,000. This was just smaller than 
bovine serum albumin at 67,000.
Purification to homogeneity is indicated by the presence of a 
single band on SDS-denatured gel electrophoresis at the same 
position as reported by others (Sica et al., 1973; Sica and 
Bresciani, 1979; Sakai and Gorski, 1984b) for classic mammalian 
oestrogen receptors in which the major species found were
65,000-70,000. A higher molecular weight species of 89,000, 
molybdate stabilized oestrogen receptor of calf uterus, had also 
been reported recently by Atrache et al. (1985). These authors did 
not rule out the fact that a non-steroid binding protein molecule
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might be present. A similarity in size of cytosolic and nuclear 
uterine receptors has also been indicated by others (Erdos and 
Fries, 1974; Erdos and Fries, 1979; Katzenellenbogen et al., 1983). 
Calf, pig, mouse and rat uterine receptors all had been reported by 
Lubahn et al. (1985) to have similar binding affinities and, along 
with the human receptors, had the same maximum molecular weight on 
SDS-PAGE of 70,000. In smaller amounts in all cases, they found a 
"50,000" band was visible and, even more faintly, a "30,000" band 
was also seen. The relationship of the smaller bands to the 70,000 
molecular weight band was not clear but probably represents common 
endogenous proteolytic activity occurring prior to the preparation 
of cytosol. This size heterogeneity was also reported by others 
(Katzenellenbogen et al., 1983; Van Oobree et al., 1983). Rabbit 
uterine oestrogen receptor, purified on a DES-agarose affinity 
column by Van Oosbree et al. possessed a 70,000 and a 50,000 
molecular weight protein (Van Oosbree et al., 1983). Katzenellen­
bogen et al. (1983), by an affinity-labelling technique using 
tamoxifen aziridine, have demonstrated two similar sized bands in 
cytosol from rat uterus. Studies using gel exclusion chromatography 
in 6M guanidine-HCl yielded molecular weight estimates of
53,000-55,000 (Erdos and Fries, 1974; Erdos and Fries, 1979).
Although O.IM of ^p-mercaptoethanol was included in the elution
buffer, the concentration might not be sufficient to bring a
complete cleavage of the disulphide bonds.
The 50,000 and 30,000 molecular weight species of oestrogen 
receptor could represent active forms of the receptor either
antigenically similar or smaller forms that are formed by cleavage 
from a larger precursor. The 30,000 molecular weight is the smallest 
size of receptor that is large enough to retain sufficient E2 
binding capacity so that it can be efficiently retained by the
affinity column throughout the vigorous washing conditions (Lubahn
et al., 1985). This hypothesis is supported by other reports where 
oestrogen receptors that have deliberately cleaved with endogenous 
proteases and examined by sedimentation and gel filtration analysis
(Sica et al., 1976; Miller et al., 1981). However no such smaller
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binding species were evident in this study, due to either the
inability of such forms to bind to the affinity column, the 
stability of the receptor which occurred in the presence of Ca^* 
thus avoiding proteolysis or, too small a quantity to be detected on 
the gel. However, the reason for the existence of these receptor 
species reported by others is not clear. It could be: 1) The
presence of subunits of more than one receptor of similar size; (2)
microheterogeneity of a single subunit; or (3) postsynthetic 
modification such as phosphorylation. Reports in the literature 
suggest that the receptor is phosphorylated (Migliaccio et al.,
1982) and that dephosphorylation may cause some loss in E2 binding 
(Auricchio et al., 1982; Auricchio et al., 1984).
Although there is growing support for the proposal that 
untransformed receptors are oligomeric proteins in vitro, questions 
concerning identity or dissimilarity of the polypeptide chains 
remains unresolved. Nonsteroid-binding components of molecular
weight 58,000 and 13,000 have been proposed by Murayama et al. 
(1980) for the 8S oestrogen receptor. Separate reports indicate 
that, in untransformed 85 progesterone receptor complexes from chick 
oviduct, the A and B receptor subunits are associated with a 90,000 
molecular weight component which does not bind hormone (Dougherty et 
al., 1984). A hetero-oligemeric structure composed of molecular 
weight 90,000, 41,000, 40,000 and 24,000 units has been suggested
for the unactivated glucocorticoid receptor (Grandies et al., 1984).
The 85 oestrogen receptor has a molecular weight of 240,000 
for a purified receptor under nondenaturing conditions, and the 
apparent molecular weight of 65,000 for the SDS-dissociated unit 
appears consistent with a tetrameric model proposed separately by 
Raaka and Samuels (1983) and Sherman et al. (1983). The isolation 
described in this thesis using SDS-PAGE also gave a 65,000 molecular 
weight protein again supporting the tetramer model.
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4.2.3.1 Identification of the Band as Oestrogen Receptor
The 65,000 molecular weight protein band on SDS-polyacrylamide 
gels was identified as oestrogen receptor by two criteria. First, 
the 65,000 molecular weight protein becomes evident only when the 
receptor was detected during the elution of the affinity column. 
The other contaminant proteins present with the 65,000-dalton band 
were all observed earlier in the wash fractions and displayed no E2 
binding activity. Secondly, preloading of the receptor with E2 
prior to passing it through the affinity column prevented the 
receptor from binding. Thus the 65,000 molecular weight band was 
prevented from binding to the column and was not observed in the E2 
eluted fractions.
This 65,000 molecular weight protein of SDS denatured oestrogen 
receptor showed a single peak with a sedimentation coefficient of 
about 4S. Results from earlier experiments (section 3.1) proved the 
presence of nondenatured receptor of 240,000 molecular weight 
protein. While there is uncertainty concerning the molecular weight 
of the native cytosol receptor, these results are in good agreement 
with studies by other groups (Puca et al., 1971, 1972, Sica et al., 
1973 and Sica and Bresciani, 1979) who calculated that nondenatured 
receptor has a molecular weight of 240,000 and sedimented at 8S 
while SDS denatured protein has a molecular weight of 64,500 with a 
sedimentation values of 45. Thus the results indicate that the human 
uterus oestrogen receptor subunit is one and carries a single 
hormone binding site. It appears that the native state in cytosol, 
several subunits are associated to form a larger quaternary 
structure, but the number of interacting subunit cannot be specified 
which could be four as seen through the size of the nondenatured 
molecular weight protein.
4.3 RECOGNITION PATTERN OF ANTI-RECEPTOR ANTISERA
Using ELISA, the immunoglobulins from the sera of the rabbit 
immunized with human uterine receptor shown to cross react with
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oestrogen receptor from all sources tested including cytosol 
receptor from ZR-75-1 cells, human, mouse and rat uterus and ER+ 
human breast cancer, suggesting the conservation of a common 
antigenic determinant in oestrogen receptor across a variety of 
species.
4.4 SPECIFICITY OF THE IgG-ER
4.4.1 Sucrose-density Gradient
Oestrogen receptor sediments at 8S in low ionic strength 
sucrose gradients (O.OIM KCl) and at 4S in high ionic strength 
sucrose gradients (0.4M KCl) (Gorski et al., 1968). Anti-receptor 
antibody interaction was also studied using the (^H]E2 as a marker 
both for double-antibody precipitation and SDG.
The antibody raised against oestrogen receptor showed two interes­
ting properties. First, it reacted with E2-receptor complex without in­
terfering with the ability of the receptor protein to bind or retain the 
hormone, so the labelled steroid can be employed as an indicator of 
antibody receptor interaction. Second, the antibody reacts with 
oestrogen receptor to produce non-precipitating immune complexes 
presumed to consist of one molecule of immunoglobulin associated 
with each receptor protein molecule. Thus, antibody-receptor 
interaction can be conveniently studied and quantified by the shift 
observed in the sedimentation peak of a [^gjEg-receptor complex when 
subjected to ultracentrifugation in a sucrose density gradient in 
the presence of immunoglobulin from an immunized animal, compared 
with that from a control animal (IgG-N). The shift in the 
sedimentation values had been employed as indicator for 
antibody-antigen reaction by many authors (Greene et al., 1979, Raam 
et al., 1981, Coffer and King, 1981; Holt et al., 1983; Giambiagi et 
al., 1984). The increase in size of the shift (48 to 85 in high 
salt, and 88 to 108 in low salt) which is equivalent to an increase 
of about 25,000 molecular weight is good confirmation that antibody 
interacts with oestrogen receptor at a 1:1 ratio. The same
195
observation was also reported by others (Moncharmont et al., 1982, 
Moncharmont and Parikh (1983), Moncharmont et al., 1984).
4.4.2 Reactivity of IgG-ER with Different Steroid-binding Proteins
Results of screening studies for cross-reaction of IgG-ER with 
other steroid-binding proteins indicated no reaction with rat 
uterine cytosol progesterone receptor and rat ventral prostate
dihydrotestosterone receptor. The antisera also did not react with
free [%]E2 label. The IgG-ER antibodies cross-react with
cytoplasmic oestrogen receptor derived from oestrogen-sensitive 
target tissue but not to progesterone receptor or androgen receptor.
As IgG-ER did not react with rat progesterone receptor or
dihydrotestosterone receptor from rat prostate, this confirms that 
different steroid hormone receptors lack immunochemical similarity 
(Greene et al., 1979, Coffer and King, 1981).
4.4.3 Immunoprécipitation: Double antibody method
The IgG from the serum of a rabbit immunized with purified 
receptor contained antibodies to the receptor protein was further 
characterized by double antibody precipitation. Comparing IgG-ER 
with IgG-N, a significant amount [about 60% (Figure 23)] of human 
myométrial cytosol [^H]E2-receptor complex was precipitated by the 
antiserum. Greene et al. (1977), using antiserum to oestrogen 
receptor, also raised in rabbit, reported similar observation but 
their method of antigen purification was from the nuclei of calf 
uterine tissue.
4.4.4 Immobilized IgG-ER on Sepharose
The ability of the immobilised IgG to bind to oestrogen 
receptor in a saturable manner revealed two facts. The binding of 
antibody to oestrogen receptor is concentration dependent and the 
oestrogen receptor that bound to the resin could be eluted and 
characterised. The eluted protein was analysed on native PAGE and
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found to have 240,000 molecular weight. The molecular weight falls 
into the range that had been reported by Sica et al. (1976); Puca et 
al. (1972); Moncharmont et al. (1982, 1984). The same protein were 
run on SDS-PAGE gave a molecular weight of 65,000 (Sica and 
Bresciani, 1979; Moncharmont et al., 1984), suggesting that the 
aggregate seen on PAGE could be a homo-tetramer.
4.4.5 Detection of Antigen by Antibody Binding on Blots
The method allows detection of antibody specificity for its 
protein antigen by autoradiography and is simple and precise. The 
immobilized proteins were detectable by immunological procedures. 
All additional binding capacity on the nitrocellulose was blocked 
with excess protein; then a specific antibody was bound and finally, 
a second antibody directed against the first antibody was added. 
The second antibody was radioactively labelled with [^25i], xhe 
specific protein was then detected by autoradiography. It has the 
advantage of detecting as little as 100 pg of protein. It has been 
found that oestrogen receptor transferred to nitrocellulose sheets 
remained there without being exchanged over several hours.
The electrophoretic blotting technique described here produces 
replica of proteins separated on PAGE. A quantitative transfer was 
obtained with proteins from gels containing oestrogen receptor. 
Still there remains the possibility that certain classes of protein 
do not bind to nitrocellulose. To check this, the gel left after 
transfer was silver nitrate stained and found to be clear.
4.5 IMMÜNOCYTOCHEMISTRY
Before the immunocytochemical experiments were carried out 
careful measures had been taken to obtain optimal conditions.
4.5.1 ZR-75-1 Cells
The growth medium of the cell-line was changed to fresh medium
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without E2 6 days before each experiment. This long pretreatment of 
the cells with charcoal treated heat-inactivated calf serum and, 
hence E2 free medium is required to completely remove E 2 from these 
cells. However, more than six days was not recommended, since the 
cells grow very slowly and might cease to grow altogether, as 
observed by Allegra and Lippman (1980). They also observed an 
obvious decrease in cell adhesiveness in oestrogen deprived cells 
and detached cells are easily seen in the medium.
4.5.2 Fixatives
ZR-75-1 cells were used. They were removed from the growth 
medium and immediately fixed in: (1) acetone (100%), (2)
methanol:acetone (1:1) and (3) ethanol (100%). The best results 
were obtained with 100% acetone which gave a clear background and 
comparable intensity. Fixation with alcohol did give receptor 
localisation but with less intensity and slightly higher background.
Allowing the tissue to air dry (30-60min) before fixation, had no 
appreciable effect on the intensity of specific staining. However, 
the length of time that tissue or cells were in fixative had an 
important effect on the ability of the antibodies to locate the 
oestrogen receptor. Prolonged fixation did affect the specific 
staining for oestrogen receptor. Fixation with methanol:acetone for 
longer than 30min led to a progressive loss of specific staining. 
The same was true with 100% acetone and 100% alchohol.
Unfixed tissues or cells was not suitable for oestrogen 
receptor localization as there was progressive loss of specific 
oestrogen receptor staining when the cells were incubated in PBS 
prior to application of immunostaining. Greene et al. (1984) 
reported that it was due to the escaping of the oestrogen receptor 
into the washing buffer. This could also be due to the oestrogen 
receptor not being fixed on to the slides as there was loss of cells 
together with the absence of staining. The cells should be 
adequately fixed e.g. using paraformaldehyde which causes 
perforations in the cell membrane (Ewijk et al., 1984) which allow
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the antibodies to penetrate the cells. In addition, the unfixed 
tissue was observed to have more nonspecific background staining 
than fixed tissues even though some non-specific binding could be 
avoided by preabsorbing the antiserum with 1% BSA overnight at 4®C.
The stability of the receptor probably depends on storage 
temperature. Temperature seems to have no effect on the specific 
staining if the fixed cells, frozen sections or FNAs were kept at 
0-30*C for a few hours and then subjected immediately to 
immunostaining. Also, if the fixed cells and tissues are kept at 
-20* or -70°C for more than 24h there was some preservation of the 
specific staining, but storage for I week or more gave noticeably 
weaker staining intensity and after 1 month of storage, specific 
staining was usually not detectable by this method.
4.5.3 Immunocytochemical Methods
A number of histologic methods for localizing oestrogen 
receptor in tissue sections have been reported. These methods depend 
on immunocytochemical localization of putative receptor-bound 
steroid (Kurzon and Sternberger, 1978; Pertschuk et al., 1978; 
Farley et al., 1982). None of these methods has yet been validated 
as capable of detecting specific receptor proteins (Castaneda and 
Liao, 1975; Chamness et al., 1980). In fact, a comparative study of 
patients with breast carcinoma showed the absence of any correlation 
between histochemical methods and biochemically determined steroid 
receptor levels or clinical response (McCarty et al., 1982). 
Besides, a valid histochemical technique for the localization of 
oestrogen-binding proteins would be desirable since it could offer 
the attractive possibility of studying steroid hormone-receptor 
interactions at the individual cell level, and possibly the 
heterogeneity of the oestrogen receptor distribution between cells 
thus adding significantly to the elucidation of the basic mechanism 
of steroid hormone action.
The presence of cytoplasmic and nuclear oestrogen receptor in
199
oestrogen responsive tissues and human mammary carcinoma cell-lines 
could be detected by using the immunocytochemical technique. An 
effective and most economical way of studying the oestrogen receptor 
localization and translocation phenomenon would involve the use of 
histochemical methods. One such histochemical method has been 
described by Nenci et al. (1976, 1980). These authors studied Eg 
kinetics in breast cancer cells by incubating the cells at different 
temperatures in E2 and detecting the intracellular localization of 
the hormone by using rabbit anti-oestradiol antibody and 
fluorescein-labelled goat anti-rabbit immunoglobulins. The authors' 
claimed that their experimental results demonstrated receptor 
kinetics rather than the steroid kinetics. This brought criticisms 
of the method published. The points of criticism have been 
summarized by Chamness et al. (1980) who emphasized that the hormone 
binding methods cannot distinguish steroid binding of Type I 
receptors from that of Type II receptors.
4.5.4 Specificity of Antibody
An important criterion is that the specificity of the 
antiserum be restricted to the hormone receptor under study and that 
there is no interaction of the antibodies with other proteins or 
hormones.
The aim of the experiments was to present immunochemical and 
cytological evidence for the presence of oestrogen receptor in the 
target cells using anti-receptor antibody. The presence of any 
nonsecific staining could be eliminated by preabsorption with BSA 
(0.1%) overnight at 4*0 or Ih at 37*0. Application of these 
antibodies to immunocytochemistry required a clear demonstration 
that they recognised receptor in E2 responsive cells and tissue 
sections. Oompetition studies were set up. Oestrogen receptor 
protein, found in cytosol of breast cancer tissue (500-1000fmol/mg 
protein) and used as the diluent, was found to be capable of 
preventing the antibodies from binding to their respective antigenic 
determinants in the E2 target cells (Figure 33a). However, other
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cytosolic components present in receptor-depleted cytosol were 
unable to compete effectively for the antibodies (Figure 33b). These 
competition studies provide strong support for the presumption that 
the antibodies were recognising tissue oestrogen receptor. The 
chances of nonspecificity was very small since the immunocy­
tochemical reaction was obtained in this work after only a short 
exposure to 100-fold diluted antiserum. This suggests the presence 
of antibodies of high specificity for the corresponding antigens.
The specificity of the anti-receptor antiserum that was used in 
this study has been investigated by biochemical and immunochemical 
methods. Evidence had been presented that the antiserum does not 
react with E2 (Figure 33c), or cellular proteins other than 
oestrogen receptor. The following results obtained in this study 
utilizing cells from an E2 target organ such as myometrium or 
endometrium from both human and rat further substantiate the 
restricted specificity of the antiserum to oestrogen receptor.
(a) The antibodies recognise a protein which translocates in res­
ponse to E2 and DES (Figure 32a,b,c,d and 31c). Translocation 
of the protein from the cytoplasm to the nuclear compartment of 
cells incubated not only with E2 but also with DES ruled out 
the possibility that the antiserum detected the hormone and not 
the receptor. A complete translocation of the protein from the 
cytoplasmic to the nuclear compartment testified that the 
antigenic sites recognized belonged to the Type I oestrogen 
receptor which, unlike Type II, is known to translocate under 
these conditions (Muldoon,1980).
(b) The anti-receptor antiserum recognised cytoplasmic oestrogen 
receptor with unoccupied steroid binding sites in the human 
ZR-75-1 cells as evidenced by the presence of fluorescence in 
the cells exposed to 37*C in a E2 free medium (Figure 34a,b). 
This is also further evidence that the antibody recognise 
oestrogen receptor, rather than E2«
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(c) The antibodies also react with oestrogen-occupied cytoplasmic 
receptors (cells which had been incubated with E2 or DES). The 
antiserum interacts efficiently with oestrogen receptor 
saturated with E2 or DES. No difference in the intensity of 
fluorescence was observed when compared to the cells from E2 
free medium.
(d) The antibodies cross-react with the nuclear form of receptor 
even when they are bound to the acceptor sites in the 
chromatin. In the ligand incubated cells, an absence of 
cytoplasmic fluorescence, unaccompanied by an emergence of 
nuclear fluorescence, would be expected if the antibodies 
failed to recognize nuclear forms of the receptors. This was 
not observed in this study. Fluorescence was clearly seen to 
be transferred from the cytoplasm to the nuclear compartment.
The antiserum raised in rabbit against the human uterine 
receptor preparation was apparently monospecific when applied to 
uterus of rat origin, but this cannot definitively rule out 
contaminant antibodies reacting with unknown proteins in very low 
concentration, as discussed previously.
The subcellular distribution of the receptor was of great 
interest. The presence of the receptor in the cytoplasm itself was 
an interesting result, since the biochemical methods deal in fact 
with 'cytosol', that is only an experimentally defined cytosoluble 
fraction of tissue extract. The shift in the receptor subcellular 
distribution in favour of the nucleus, after E2 administration, 
agrees with the understanding of steroid hormone receptor 
translocation. The in vitro translocation studies revealed the 
Specificity of the antiserum and the fact that oestrogen receptor 
present was of Type I, because of its ability to translocate to the 
nucleus. Frozen sections, either fixed prior to storage at -70*C or 
immediately fixed following sectioning, showed mostly cytoplasmic 
with occasional nuclear staining. The mechanism of oestrogen 
receptor action in target cells, as originally proposed (Gorski et
202
âl.j 1968; Jensen et al., 1968) proposed that cytoplasmic oestrogen 
receptor became activated following the binding of E2, and was
translocated to the nucleus. Oestrogen receptor present in the
soluble fraction of a cell extract is assumed to be cytoplasmic 
(low-salt extracts).
The phenotype (8S, AS and 5S) of the receptor could not be 
deduced from these experiments. However the 'nuclear type' receptor, 
through large numbers of studies, could be classified as either 5S 
or 45. Raam et al. (1982) reported rabbit antibodies to oestrogen
receptor that recognized the 45 rather than the 55 form in the
nuclei of MCF-7 cells.
4.5.5 In Vitro Translocation Studies
In addition to the specificity characteristics of the anti-ER 
antiserum, several interesting facts related to the oestrogen 
receptor translocation emerged from this study:
(1) Binding of the hormone is perhaps an essential prerequisite for 
the transformation of cytoplasmic receptors into the nuclear 
form in normal uterine cells. This conclusion is drawn from 
the fact that the immunofluorescence was exclusively 
cytoplasmic in the cells grown in E2 free medium while nuclear 
fluorescence was observed only in cells incubated with E2 or 
DE5. Such results were obtained in most of the cell 
population.
(2) Binding of the hormone perhaps increases the binding affinity 
of the oestrogen receptor to the acceptor sites in the nucleus. 
This was seen in the ZR-75-1 cells where immunofluorescence was 
in the nucleus only after incubating the cells with E2 and DES.
(3) One nanomolar concentrations of ligand was effective in indu­
cing transformation and allowed complete translocation of 
cytoplasmic oestrogen receptor to the nuclei to take place.
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(4) One hour incubation with the hormone at 37*0 appeared to be 
sufficient for complete translocation of oestrogen receptor 
into the nuclei for the normal myométrial cells and breast 
cancer cell-line. Incubating at 22*0 resulted in incomplete 
translocation, with the cells retaining residual fluorescence 
in the cytoplasm at the end of the experiment. Since the 
translocation of these cells was complete at 37*0 this 
indicates that the partial translocation initially observed was 
not due to abnormalities in oestrogen receptor nor to the 
antiserum detecting cytoplasmic proteins other than oestrogen 
receptor. The data obtained by Eckert and Katzenellenbogen 
(1982) for MOF-7 cells using radiolabelled E2 also indicated 
completion of oestrogen receptor translocation to the nucleus 
within an hour.
(5) The pattern of distribution of oestrogen receptor obtained with 
anti-ER antisera, consisting of oestrogen receptor hormone 
complex formation in the cytoplasm, binding to the nuclear 
membranes and/or chromatin, and the eventual translocation and 
retention in the nucleoli-like spots in the chromatin are 
analogous to the observation of Raam et al. (1983) who studied 
the intracellular oestrogen receptor movement using anti­
oestrogen receptor antibodies.
The in vitro translocation studies could also extend our 
knowledge of the specific acceptor sites where the nuclear binding 
occurred. Increasing the translocation time to 2h (Raam et al., 
1983), tended to reveal distinct spots localised in the nuclear 
compartment rather than on the general surface of the nuclei. This 
finding could support the specific acceptor sites hypothesis (Raam 
et al., 1982) for ER-DNA interaction. The fact that cryostat 
sections can be used for such studies is very useful.
However these studies were not consistent with the findings of 
Greene's group (Greene et al. 1984; McClellan et al 1984; Press and 
Greene, 1984; Press et al., 1984; King et al., 1985) who developed
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monoclonal antibodies to oestrogen receptor and found the location 
of the receptor was mostly in the nuclei. They suggested the 
presence of the cytoplasmic oestrogen receptor in the tissue extract 
was merely an artifact of extraction whereby the weakly bound 
nuclear receptor became soluble in low salt buffer during 
homogenization.
The findings from this study fit some of the information in 
the two-step model. When it was originally postulated there was no 
direct proof. The mechanism of action in target cells was 
hypothesized to consist of a number of steps including (a) diffusion 
of E2 into a target cell, (b) high-affinity, specific binding of E2 
to cytoplasmic oestrogen receptor, (c) activation of the 
oestradiol-receptor complex, (d) translocation of the activated 
complex to the nucleus, (e) binding to nuclear chromatin and (f) 
induction of specific RNAs (Gorski et al., 1968; Jensen et al., 
1968). This model would predict that the majority of the receptor 
should be cytoplasmic, under conditions in which E2 levels are low, 
and nuclear when receptor is saturated by high levels of E2 The 
obvious explanation for migration to the nucleus is that only the 
oestradiol-receptor complex can bind to DNA in a physiologically 
significant manner (Yamamoto and Alberts 1972). The results obtained 
in this study are consistent with the proposed model except that 
even in the absence of E2 some oestrogen receptor could still be 
detected in the nucleus. Results obtained by Raam et al. (1982, 
1983) and Morel et al. (1981) also working with rabbit antibodies 
against oestrogen receptor, and Morel et al., (1984) with antibodies 
against progesterone receptor, followed the model very closely, and 
as did those of Greene and Jensen (1982) using monoclonal antibodies 
to oestrogen receptor. Later, King and Greene (1984), also working 
with monoclonal to oestrogen receptor and Welshons et al. (1984) 
independently discovered purely nuclear localization of oestrogen 
receptor. However, King and Greene (1984), King et al. (1985), and 
McClellan et al. (1984) used fixatives such as glutaraldehyde and 
paraformaldehyde which are known to cause crosslinking of proteins 
by interaction with free amino groups (Hopwood, 1972; Collins and 
Goldsmith, 1981). This was adjusted for optimum preservation of
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chromatin (McClellan et al.,(1984). While Morel et al. (1981), Raam 
et al. (1983), Tamura et al. (1984) and also the present study used 
fixatives which conserved cytoplasmic protein without any particular 
emphasis on the preservation of chromatin. Various possibilities 
stated below cannot be ruled out. The cytoplasmic oestrogen receptor 
detected by the rabbit antibody in this study could be related to 
oestrogen receptor newly synthesized, which is believed to occur in 
the cytoplasm. Another possibility is the presence of the degraded 
form of oestrogen receptor which is still capable of binding Eg but 
such a molecule would be unlikely to translocate. They could be 
lower molecular weight proteolytic fragments (Thibodeau et al.,
1983) which are generated during the purification of antigen. This 
is unlikely since the gel of affinity eluate demonstrated only one 
band at 65,000 molecular weight. Another important factor is the 
effect of fixatives. Fixation with acetone or alcohol might cause 
the lability of protein to take place since Brandtzaeg (1981) 
observed a loss of cytoplasmic proteins from cells fixed with 
ethanol. This could result in the distribution of 'loosely 
associated nuclear bound receptor' (King et al., 1985) in the 
cytoplasm in the absence of ligand. The presence of ligand might 
increase the binding affinity for its sites in the nucleus thus not 
detecting any cytoplasmic receptor. Another possibility could be the 
property of the oestrogen receptor itself which could be activated 
spontaneously even in the absence of other stimuli, such as elevated 
temperature (20°C), increased salt concentration (0.4M KCl), or 
added steroid, all of which have been necessary for the activation 
of other steroid receptors (Thibodeau et al., 1983).
In conclusion, with the help of biochemical techniques, nuclear 
translocation of cytoplasmic receptor has been demonstrated in 
oestrogen responsive cells. Like the biochemically measured 
receptors, the antigenic determinants, detected immunohistochemi- 
cally with the rabbit antiserum, can also be fully translocated. 
Utilizing anti-ER antiserum, failure to detect any proteins other 
than oestrogen receptor in the target cells by immunofluorescent 
procedure was consistent with the antiserum containing only
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antibodies directed against oestrogen receptor.
Intracellular movement of the receptor protein can be studied 
in vitro using antibodies directed against steroid receptors, 
especially if the antibody population contains a mixture of 
antibodies that recognize receptors in both hormone-occupied or
unoccupied forms, and the receptors bound to the nuclear chromatin.
Polyclonal antibodies directed against cytoplasmic oestrogen 
receptor are excellent tools for investigating the action of
oestrogens and antioestrogens in hormone-responsive cells and for 
understanding the abnormalities associated with the translocation 
process in malignancy. The methodology described can easily be 
adapted to study the effect of progestins on oestrogen receptor
synthesis. In addition, the heterogeneity of oestrogen receptor
distribution that cannot be examined by using radiolabelled hormones 
can also be investigated by using the immunohistochemical method 
described.
4.6 OESTROGEN RECEPTOR QUANTITATION OF FNA SAMPLES
The measurement of oestrogen receptor has been generally
accepted as clinically valuable in selecting patients for hormone 
therapy. It has been known that the likelihood of a successful
response to endocrine therapy is increased at least tenfold in ER+ 
breast cancer patients (McGuire et al., 1975b). Small quantity
samples such as in the form of FNAs can be easily obtained from
out-patient clinics. Another important aspect of FNAs was in 
providing information regarding both the prognosis and the 
likelihood of response to endocrine therapy before surgery. This 
pre-operative knowledge helps the surgeons in selecting both the 
extent of surgery and the type adjuvant therapy.
The biochemical assay has the disadvantage that a drug such as 
tamoxifen may interfere. Further the biochemical assay gives only 
an average value for receptor concentration and has no ability to
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answer the essential question concerning the proportion of tumour 
cells relative to total cell content (fat, stroma etc.) and the 
proportion of ER+ and ER- cells in the biopsy.
Present methods for the determination of steroid hormone 
receptors depend on the radioactive steroid as a marker for the 
receptor protein and have several inherent disadvantages. Some of 
the receptors in the tumour may be bound to endogenous hormone and 
remain undetected unless some type of exchange assay is also carried 
out. The binding of steroid to receptor, though strong, is 
non-covalent, so the radioactive marker is subjected to displacement 
by dissociation, by exposure to heavy metal ions, or by degradation 
of the rather labile receptor protein during storage and processing 
of the tumour specimen. In fact, it is believed that deterioration 
of the receptor during sample manipulation may be one reason why 
clinical response to endocrine therapy is occasionally seen with 
apparently ER- breast cancers. The two analytical procedures most 
commonly used for separating the receptor-bound steroid from the 
excess unbound hormone (SDGA and DCC with Scatchard plot) are costly 
in terms of time and/or instrumentation and usually require a tumour 
specimen larger than is available with metastatic cancers. Due to 
these reasons many biochemical bioassays had been developed. Among 
these bioassays are iso-electric focussing or selective retention of 
oestrogen receptor on DE-81 cellulose paper (Barbonel et al., 1977) 
or small Sephadex columns (Barnes et al., 1977). Isoelectric 
focussing had been tried on FNAs and shown to correlate well with 
the biochemical technique (Silfversward et al., 1980) but the 
limitation still lies in its inability to fully analyse the given 
sample for heterogeneity.
Until recently only autoradiography, using [3h ] ligands with 
high specific activity, has been used to visualize steroid-binding 
cell subpopulations at physiological concentrations (10“  ^ to 10”^^M) 
of hormone. However, autoradiography requires the preparation of 
4pm frozen sections and long exposure times at low temperatures. 
These drawbacks make this technique inappropriate for widespread 
clinical use. The use of steroid hormones conjugated with
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fluorescent molecules has been reported to detect other types of 
receptor (Type II). This lower binding affinity could also be due 
to the size of the steroid ligand with the bulky fluorophore 
resulting in a large structural perturbation that reduces the 
affinity for the receptor drastically (Lee et al., 1977; McCarty et 
al., 1977; Chamness et al., 1980; Pertschuk et al., 1981). Attempts 
to use these agents at higher concentrations raises the possibility 
that sites other than the receptor are being detected (Chamness et 
al., 1980; McCarty et al,, 1981; Pertschuk et al., 1981).
4.6.1 Tissue Heterogeneity
One of the limitations of current receptor assays that would 
not be overcome by an immunobead assay, DCC (titration assay) or 
SDGA (sedimentation analysis) is the inability to assess tissue 
heterogeneity. If a breast biopsy contains ER+ tumour, but the 
amount of tumour tissue is very small, then the DCC assay will yield 
low or negative values. There are ample examples of the lack of
quantitative agreement among assays carried out on different
portions of the same large breast cancer. A great deal of effort 
has been devoted to the development of methods for the visualization 
of ER+ cells within a heterogeneous cell population. Successful
measurement of receptor at the cellular level requires at least 2
criteria: (a) the molecule used as a label must interact with the
receptor with high affinity and high specificity; and (b) the method 
of detection must be extremely sensitive. In the latter case, the 
sensitivity of the detection device and the detectability of the tag 
(for instance, its specific activity for autoradiography or its 
fluorescence emission for fluorescence microscopy) are complementary 
factors. With the availability of the specific antibody prepared 
against human myometrium receptor, specific and also sensitive 
methods for immunocytochemical assay of receptor became feasible.
Recent studies by cytochemical and fluorescence methods have 
indicated that most breast tumours are composed of ER+ and ER- cells 
(Pearson et al., 1978). Cellular heterogeneity is a particularly 
important issue in the case of human breast tumours, where it has
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been used to explain the varied clinical response to hormone therapy 
in ER+ cases (Silfversward et al., 1980). Furthermore, it is 
thought that a proper knowledge of the cellular heterogeneity of a 
tumour would be useful in selecting an appropriate combined therapy.
4.6.2 Biochemical Versus Anti-ER Antibody Assay (IF-antibody Assay)
It is very important to realise that the quantity of oestrogen 
receptor measured by biochemical assay can be directly related to 
the intensity of IF only if the tumours are homogenously positive 
with an equal amount of oestrogen receptor in all the tumour cells. 
Conversely, samples with both high and low ER+ cells may show little 
quantitative correlation between IF and biochemical values An 
antibody assay of 7 ER+ and 1 ER- (biochemical classification) 
tumours revealed complete qualitative agreement but little 
relationship between quantity of oestrogen receptor and IF intensity 
presumably due to a lack of homogeneity in oestrogen receptor 
content of the tumour cells. An analysis of IF data on the ER+ 
tumours revealed that 83% of tumours with >400fmol of oestrogen 
receptor were homogeneous i.e. contained only IF(+) cells in 
category B and C in the multiple areas of the slide examined. A 
distinct trend towards greater heterogeneity, not only in tumour 
cellularity, but also in antigen status of the tumour cells was 
observed in tumours containing from 50-399 fmol/mg of oestrogen 
receptor. The majority of these tumours contain a mixture of IF(+) 
and IF(-) cells. It is also evident that IF(-) cells made up more 
than 50% of the tumour when oestrogen receptor content was less than 
59 fmol/mg protein.
Biochemical and IF antibody technique agreed qualitatively on 
20 out of 21 ER+ tumour which had an adequate quantity of tumour 
cells. With the biochemically ER- tumours, 2 out of 26 patients were 
found positive by the antibody. Of these, one patient found positive 
by IF antibody technique had the biochemical assay done on a tru-cut 
sample i.e. much less tissue than normally required. The other
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patient was premenopausal and her tumour was very heterogeneous in 
its staining pattern. Some cells exhibited extensive nuclear 
staining giving an overall significant IF value although many others 
were negative (Figure 41c). However, the data indicate a high 
correlation between the biochemical and immunohistochemical methods 
qualitatively.
Interestingly patients with breast tumour clinically ER- i.e. 
ERc positive and ERn negative was found to be negative by this assay. 
The distribution of IF(-) cells seem to be homogeneous in the smear 
inspected. One example from a patient having such tumour is shown in 
Figure 40a. This finding could offer an explanation as to why the 
group of patients does not show a response to endocrine therapy.
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CONCLUSION
The procedure for purification of human myométrial oestrogen 
receptor involved the application of affinity chromatography 
employing E2“Succ-Alb-Sepharose 4B, and elution with DES. For 
antibody raising, the amount of receptor injected is very small, 
only between 10-30pg compared to SOOpg used by Greene et al. (1979) 
to immunize a single rabbit and 700pg of the purified protein to 
immunize a goat.
Experimental data have been gathered to check the specificity 
of the antibodies towards oestrogen receptor. The presence of 
anti-oestradiol antibodies has been excluded since there is no 
sedimenting radioactive immune complex seen when [%]E2 is reacted 
with IgG-ER. Similarly when [%]E2 is added to the Sepharose 
immobilized IgG-ER, the latter does not bind [% ] E 2« IgG-ER induces 
a shift in the sedimentation coefficient of the oestrogen receptor 
from 4S to 8S (high salt); and 8S to lOS (low salt). The IgG-ER has 
no effect on the sedimentation rate of [%] DHT receptor or [^H] 
progesterone receptor. The selective binding to E2 target tissues 
together with the demonstration of translocation is added proof of 
anti-receptor activity. Lastly, the evidence shown by the 
immunoblot experiments clearly indicates that the antibodies 
recognise a protein of 65,000 molecular weight.
The antibodies have been used as probes for detecting and 
localising oestrogen receptor in the target cells. An 
immunofluorescent technique using anti-receptor antibody has been 
applied to FNAs from human breast cancer. This technique shows a 
good correlation with the results of the DCC assay. It offers the 
additional possibility of detecting receptor-positive cells in 
heterogenous tumours, which cannot be shown conclusively by the DCC 
technique. As more highly purified preparations of antibody become 
available, it should be possible to use them, in kit form, to 
identify oestrogen receptor in FNAs in routine breast cancer 
clinics.
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A PROPOSED MODEL FOR STEROID HORMONE ACTION
The mechanism for oestrogen action is still debatable. Thus it 
is difficult to propose a model which is not subject to critism. 
Since part of the result obtained in this study fits the two-step 
mechanism model for oestrogen receptor, this classical model is 
still preserved. It is merely the case that the location of the 
receptor must be changed. In the classical model it was established 
that empty receptor had little or no affinity for the nucleus thus 
residing in the cytoplasm alone, while the most recent findings 
reported that oestrogen receptor resides in the nucleus alone. 
Interestingly the present study using immunofluorescence technique 
and antibody to oestrogen receptor, showed that both empty and 
filled receptors are residing in the cytoplasm as well as in the 
nucleus which includes nuclear membrane, chromatin and nuclear 
matrix. A model is then proposed.
Steroid diffuses into the cell down a concentration gradient. 
Once into the cell, the steroid comes into contact with the 
oestrogen receptor. The receptor-hormone complex is then formed. 
The binding of the steroid to the receptor causes activation which 
results in an increase in affinity towards the chromatin. The 
binding kinetics of the activated receptor to specific sites in the 
chromatin may be helped by non-histone chromosomal protein.
Another possibility is the fixatives artifact. However, 
artifacts brought about by fixation cannot be ruled out. The empty 
receptor might be residing loosely in the nuclear component. Thus 
with fixatives like alcohol or acetone, the empty receptor is easily 
detached and distributed in the cytoplasm.
How the receptor is released from the nucleus is not known. It 
could be through dephosphorylation or the presence of specific 
proteases which have a high Km for the receptor.
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